Serial magnetic resonance spectroscopy imaging in the acute stroke and the relationship with diffusion and perfusion parameters by Cvoro, Vera
Serial Magnetic Resonance Spectroscopy Imaging in the







The aim of this thesis is to investigate the changes in brain metabolite concentration
in the acute stroke across the whole of the diffusion lesion and their relationship
with the parameters that measure diffusion and perfusion. 51 patients with cortical
strokes of mean (+SD) age 75 ±15 years, and mean NIHSS 11 ±8 were imaged within
24 hours of onset, mean of 11 ± 7 hours for the first, and 5 ±1, 12 ±2, 31 ±2, and 95 ±6
days for each of the subsequent scans. Follow-up scanning was not possible in all
cases. From the 51 initial patients, 26 (51%) were scanned up to 1 month and 23
(45%) at 3 months. All patients had structural T2 imaging, diffusion weighted (DWI)
imaging, perfusion weighted (PWI) imaging and spectroscopy (MRS) as well as full
initial clinical assessment and functional outcome at 3 months (Rankin score, Barthel
index and extended Nothingam ADL scale).
(1) Distribution of the metabolites within 24 h of stroke onset (region of interest
(ROI) and MRS grid analysis). The metabolites were measured in the diffusion
lesion classified according to its appearance on visual inspection (grid analysis).
NAA differentiated 'definitely' from 'possibly abnormal', and 'possibly abnormal'
from 'mismatch' (both comparisons p<0.01) voxels, but not 'mismatch' from
'normal' voxels. Lactate was highest in 'definitely abnormal', and progressively
lower in 'possibly abnormal', 'mismatch', then 'normal' voxels (all differences
p<0.01). There was no correlation between NAA and ADC or PWI values, but high
lactate correlated with low ADC (Spearman q=-0.41, p=0.02) and prolonged MTT
(Spearman q=0.42, p=0.02). The ROI analysis showed similar correlations.
Conclusion: ADC and MTT indicate the presence of ischemia (lactate) but not
cumulative total neuronal damage (NAA) in acute ischemic stroke, suggesting that
caution is required if using ADC and PWI parameters to differentiate salvageable
from non-salvageable tissue.
(2) Choline and creatine are not reliable denominators for calculating metabolite
ratios in acute ischemic stroke. Choline and creatine concentrations were measured
by MR S in 51 patients at 5 times up to 3 months after stroke. Choline and creatine
levels changed significantly in the ischemic region. Choline was significantly
reduced during the first 2 weeks after stroke onset (P=0.034). Creatine was
significantly reduced during the whole period of the study (P=0.011). Choline and
creatine concentrations are not reliable denominators for metabolite ratios in acute
stroke because their levels vary significantly in ischemic brain regions.
(3) Changes in NAA and lactate over 3 months in the ischaemic lesion. NAA was
significantly reduced from admission in definitely and possibly abnormal (p=0.01)
compared to contralateral normal voxels, reaching a nadir by 2 weeks and
remaining reduced at 3 months. Lactate was significantly increased in definitely and
possibly abnormal voxels (p=0.01) during the first 5 days, falling to normal at 2
weeks, rising again later in these voxels.
(4) Correlation with functional outcome. In the ROI analysis there was no
association between any of the metabolites and the NIHSS score. There was no
correlation between the metabolites, ADC, MTT or CBF and three month Rankin
score. However, the clinical parameter of NIHSS (measured at baseline) was
associated with the three month Rankin score (Spearman's p= 0.665, p=0.0001), in
keeping with the known strong association between stroke severity and functional
outcome.
Declaration
I composed this thesis and made substantial contribution to the work presented.
I performed the literature review which formed the basis of chapter 1.1 saw around
300 patients of which I recruited 60 in to the study. I was present during all of the
MRI scans and decided on the position of the spectroscopy slice. I also performed all
the transcranial Doppler examinations. There were over 100 follow up scans and I
organised all the follow up visits and took patients myself in the taxi between the
rehabilitation hospitals and the MRI scanner. I collected all the data and entered it in
to the database. I performed all the statistical analysis except for multiple time
points where I had to seek an expert help of the statistician Dr Francesca Chapel. I
analysed all the spectroscopy data but did not set up the algorithms, which was
done by Professor Ian Marshall and practically implemented by Karolina
Wartolowska. I checked all the spectra manually, entered all the data in to the
programme for the analysis and drew around all the spectroscopy regions of
interests.
Professor Wardlaw performed all the coding for the infarct swelling and supervised
scientists Dr M. Bastin, Dr P. Armitage, Dr C.S.Rivers and Dr Trevor Carpenter who
analysed diffusion and perfusion images. Professor Wardlaw and Dr C.S.Rivers
drew around all DWI regions of interests.
All of the work contributing to the thesis was undertaken whilst I was in post of a
Clinical Research Registrar at the Western General Hospital in Edinburgh. Clinical
fellowship was funded by the Stroke Association.
Work from chapters 4 and 6 have been presented as platform and poster
presentations at the national and international conferences (The European stroke
conference 2004, 2006 and 2007, The World Stroke Congress 2004, British
Association of Stroke Physicians meeting 2005, The UK Stroke Forum 2006 and The
British Geriatric Society Annual Meeting 2004.
Also, the data from chapters 4 and 5 has been published in peer reviewed journals:
1) Choline and Creatine are not Reliable Denominators for Calculating Metabolite Ratios in
Acute Ischaemic Stroke; Stroke 2008; 39: 2467-2469;
2) Changes in NAA and lactate following ischemic stroke: A serial MR spectroscopic
imaging study; Neurology 2008; 71:1993-1999;
3) Association Between Diffusion and Perfusion Parameters, N-Acetyl Aspartate, and
Lactate in Acute Ischaemic Stroke; Stroke 2009; 40: 767-772;
4) MR Diffusion and Perfusion Parameters: Relationship to Metabolites in Acute Ischaemic
Stroke; JNNP 2010; 81:185-91.
This thesis has not been submitted in candidature for any other degree,
postgraduate diploma or professional qualification.
Acknowledgements
I would like to thank all of the patients who agreed to participate in this study. It
was a demanding study for the patients as most of them attended several times for
lengthy MRI scans.
I have been welcomed and received support from the staff at the Division of Clinical
Neurosciences at the Western General Hospital in Edinburgh. Professor M Dennis,
Dr S. Keir, Professor C.Warlow, Dr C Sudlow and professor Sandercock were all
great teachers and helped with any clinical queries I had about the patients. Mrs
Vera Soosay designed my database. Mrs Brenda Thomas helped with advice and
design of the search strategy for the systematic review.
The radiographers of the SHEFC Brain Imaging Research Centre - Mrs Annette
Blane, Mrs Evelyn Cowie, and Miss Lorna Cunningham were most helpful in
scanning patients. Dr Anne Rowat provided support in helping to identify suitable
patients, performed monitoring of the patients whilst in the scanner and helped
with setting up pump and the contrast for perfusion imaging.
I also have to thank my colleagues from NHS Fife department of Geriatric Medicine
who have had lots of patience and allowed me the time off from the department for
writing.
Special thanks goes to my supervisor, Professor Joanna Wardlaw who will remain
constant source of inspiration. I thank her for all the support and encouragement
that she provided over all these years.
Dedication: This thesis is dedicated to my parents Vukosava and Cedomir, my
husband Zoran and son Sasha for their patience, love and support during all this
time.
Glossary of terms
ADC Apparent diffusion coefficient
CBF Cerebral blood flow
CBV Cerebral blood volume
CMRO2 cerebral metabolic rate of oxygen
CNL Contralateral normal tissue
CPP Cerebral perfusion pressure
CSI Chemical shift imaging
CSF Cerebrospinal fluid
DAL Definitely abnormal tissue
DTI Diffusion tensor imaging
DWI Diffusion weighted imaging
IN Ipsilateral normal tissue
MRS Magnetic resonance spectroscopy
MRI Magnetic resonance imaging
MTT Mean transit time
OEF Oxygen extraction fraction
PAL Possibly abnormal tissue
PET Positron emission tomography
PWI Perfusion weighted imaging
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Preface
The magnetic resonance imaging (MRI) made it possible to study brain
pathophysiology in humans in vivo, rather then being dependent on laboratory
experiments. Initially, our insight in to the development, evolution and the
mechanisms of damage in cerebral ischaemia was very much based on animal
studies. The development of MRI and spectroscopy (MRS) made it possible to have
longitudinal studies of the patients and study disease progression in individuals
and groups over time. The development of diffusion weighted imaging (DWI)
enabled early detection of the ischaemic lesion which is clearly delineated (Moseley
et al., 1995). The ability to have repeated measurements has allowed us to study the
natural disease course, but also to observe the effect of treatments. Many MRI
sequences have been developed to provide information on morphology, diffusion
and perfusion state and the metabolic condition of the ischaemic tissue (Fisher et al.,
1995).
The concept of ischaemic penumbra has been developed in the late seventies and
eighties (Astrup et al., 1981). The penumbra (from the Latin paene "almost, nearly"
and umbra "shadow") is considered to be hypoperfused tissue where neurons are
functionally silent but retain structural integrity and are potentially salvageable if
blood flow can be restored quickly. Permanently damaged tissue would not be
salvaged by restoration of blood flow. It is hoped that these tissues could be
distinguished in patients by using imaging techniques. For example, the mismatch
between magnetic resonance (MR) diffusion-weighted (DWI) and perfusion (PWI)
imaging has often been regarded as synonymous with penumbra. The more
"penumbra" was imaged it became clear that there is a lack of standardisation of the
definition of penumbra as well lack of standardisation of the measurements (such as
perfusion) that contribute to the penumbra (Bandera et al., 2006; Davis et al., 2008;
Kane et al., 2007b; Kidwell et al., 2003a). Proton MR spectroscopy (MRS) has been
available for many years but its use in acute stroke was limited by long acquisition
times. MRS can now be performed within minutes, making it feasible in the clinical
setting (Karaszewski et al., 2006; Stengel et al., 2004).
N-acetyl aspartate (NAA), found in intact neurones, is reduced in acute ischaemia
(Labelle et al., 2001;Saunders et al., 1995). The precise function of NAA is not clearly
1
understood. NAA is present in sufficient quantity in the human brain to provide a
clear measurable signal on MRS, and loss of NAA indicates neuronal death
(Monsein LH et al., 2008; Demougeot et al., 2004; Tsai and Coyle 1995). The reduction
in NAA also correlated closely with histological evidence of neuronal loss in
ischaemia models (Sager et al., 2000; Sager et al., 1995). Lactate, produced
predominantly by anaerobic metabolism, rises sharply in acute ischemic tissue, and
in the acute stage is a marker of ischaemia (Lanfermann et al., 1995; Lemesle et al.,
2000; Parsons et al., 2000). Spectroscopy could potentially help to determine the
association between diffusion and perfusion levels and salvageable versus non-
salvageable tissue.
The aim of this thesis was two told; firstly, to evaluate if proton MRS, by identifying
neuronal death (reduced NAA) and ischemia (raised lactate), could help clarify the
relationship between DWI and PWI parameters and tissue damage in acute ischemic
stroke. If ADC or PWI directly indicate neuronal damage, then ADC and PWI
values should correlate closely with NAA; if they mainly indicate ischemia, then
ADC and PWI values should correlate closely with lactate rather than NAA;
secondly, the aim was to examine temporal variation of NAA and lactate within the
ischaemic stroke lesion over the period of three months and correlate radiological
appearances of the ischaemic lesion with the functional outcome at three months.
Chapter 1 explores the concept of stroke, its incidence, anatomical and pathological
basis for stroke and pathophysiological findings as known to date. It also examines
different MRI techniques and their use in stroke imaging.
Chapter 2 is a systematic review of the literature of MR spectroscopy studies in
stroke patients with particular attention to the studies that compared DWI and PI
with spectroscopy.
The recruitment of acutely ill patients into any MR imaging study poses many
challenges. This is partly due to limited access to MRI facilities but also these
patients are often acutely ill and not tolerant of long MRI scans. For this study,
patients were prospectively recruited over the period of 24 months. The recruitment
methods, imaging details and types of data analysis are all described in the methods
Chapter 3. Two approaches were used to evaluate the acute ischemic lesion -
'region of interest', drawing around the whole lesion and 'voxel based approach',
across the whole slice of the brain therefore including the lesion and surrounding
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tissue. The analysis to determine the relationship between spectroscopy, diffusion,
and perfusion values is presented in Chapter 4.
Patients were followed up for 3 months and at regular intervals. The longitudinal
changes in spectroscopy data are presented in Chapter 5.
The relationship between imaging parameters and functional outcome is presented
in Chapter 6.
Finally, the summary of the findings of this study is presented in the conclusion.
In summary, there are number of MR methods available to explore characteristics of
the ischaemic stroke lesion in vivo and the techniques are becoming faster and
easier to use in a clinical setting. This study uses MR spectroscopy to try and
correlate the metabolic changes of the acute ischaemic stroke lesion with diffusion
and perfusion parameters at the onset of stroke and also looks at the trends of the




Stroke is defined by the World Health Organisation as the clinical syndrome of
rapid onset of focal (or global, as in subarachnoid haemorrhage) cerebral deficit,
lasting more then 24 hours or leading to death, with no apparent cause other then
the vascular one. It is not a new disease, but certainly one that has been ignored by
health professionals and officials for decades, partly because little has been known
about what exactly happens with the tissue when it infarcts and as a consequence
"no cure" has been available. The last two decades have changed considerably our
knowledge of stroke disease although attitudes may take longer!
The first record of what we would describe a stroke today dates back to Hippocrates
(5th century BC), who used term 'apoplexy' to describe the sudden cataclysmic event
involving paralysis of the body (Clarke 1963).
In the last few decades, stroke has started to receive deserved attention from health
professionals and officials and although the incidence of stroke is falling in UK and
Scotland (Figure 1), it still remains the third largest cause of death (after coronary
heart disease and cancer) and the largest cause of disability.
Stroke incidence varies around the world between 300/100 000 and 500/100 000 for
ages between 45 and 84 (Sudlow and Warlow 1997).
There are three pathological types of stroke: Ischaemic, which accounts for around
80% in white population, primary intracerebral haemorrhage (around 15%) and
subarachnoid haemorrhage (about 5%) (Warlow CP et al., 2008). In order to
distinguish between types of stroke, imaging of the brain is essential. The type of
imaging used will depend on the timing of imaging from the onset of symptoms
and the availability. Computed tomography (CT) is widely available and reliable
within the first week of stroke for differentiating between ischaemic and
haemorrhagic event. Magnetic resonance imaging (MRI), except in the first few
hours of the haemorrhagic stoke, is the method that is more sensitive to ischaemic
stroke and can identify ischaemic stoke early with the very sensitive diffusion
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weighted imaging (DWI) sequence but it is not so readily available to a majority of
stroke patients.
This chapter will explore what is known to happen when blood vessel occludes, the
use of MRI in imaging in ischaemic stroke and value of various sequences in the
assessment of the progression of the stroke lesion.
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1.2 The anatomical and pathological bases of stroke
1.2.1 The blood supply
The brain receives blood from two sources: the internal carotid arteries and the
basilar artery. The internal carotid artery (ICA) is a branch of the common carotid
artery after its bifurcation in the neck, which on the right arises from the
brahiocephalic trunk and on the left from the aortic arch. Each ICA enters the
subarachnoid space by piercing the roof of the cavernous sinus. In the subarachnoid
space it gives off ophthalmic, posterior communicating and anterior choroidal
arteries before dividing in to two major cerebral arteries, the anterior and middle
cerebral arteries. The right and left vertebral arteries, after arising from the
subclavian arteries and passing through foramen magnum at the base of the skull
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come together at the level of the pons on the ventral surface of the brainstem to form
the basilar artery (BA). Vertebral artery prior to forming BA gives of its biggest
branch, posterior inferior cerebellar arteriey. From the basilar arise paired anterior
inferior cerebellar arteries, superior cerebellar arteries, perforating arteries to the
brainstem and it ends by dividing in to the posterior cerebral arteries.
The basilar artery joins the blood supply from the internal carotids in an arterial ring
at the base of the brain (in the vicinity of the hypothalamus and cerebral peduncles)
called the circle of Willis. The posterior cerebral arteries arise at this confluence, as
do two small bridging arteries, the anterior and posterior communicating arteries to
complete the circle of Willis. Variations of the circle of Willis are common. Post
mortem studies report variations as high as 54.8% (Kapoor et al., 2008). Variations of
the anterior and posterior half of the circle of Willis vary between the studies but
overall there seems to be predominance of the posterior variations. The frequency of
variations will also depend if the studies were conducted on normal brains or in
patients with brain disorders. When comparing patients who had infarct with
controls, an abnormally small posterior communicating artery was the commonest
anomaly observed and was found in greater frequency in the infarct group. The
incidence in the control group was 39 % and in the infarct group 59 % (Battacharji et
al., 1967;Kapoor et al.,2008).
The main reported variations of the circle of Willis include absence, hypoplasticity,
duplication, triplication or persistence of embryonic pattern.
The territories supplied by each artery vary. Therefore, when the stroke lesion is
found on neuroimaging, it may not be possible to establish the affected vessel
without further imaging of the vasculature.
6








































. , Left vertebral artery
Anterior spinal artery
Reproduced from Waxman S.G.: correlative neuroanatomy (Waxtnan S.G 2000)
The anterior cerebral artery (ACA) passes above the optic chiasm over the medial
surface of the cerebral hemisphere and it forms an arch around the genu of the
corpus callosum. It supplies anterior frontal lobes and the medial aspect of the
cerebral hemispheres. Right and left ACAs are connected by the anterior
communicating artery (ACoA), which is an important route of collateral blood
supply in case of the occlusion of an internal carotid.
The middle cerebral artery (MCA) supplies the majority of the cerebral cortex (around
70%). It is divided anatomically into several regions: the first part (segment Ml)
passes along the Sylvian fissure after giving off multiple small penetrating arteries
with virtually no collateral circulation (lenticulo-striate arteries) that supply the
basal ganglia; the second segment (M2) runs through the insular cortex and then
branches further to supply the frontal lobe, parietal temporal lobes and the mid
region of the optic radiation (M3-M5) (Hacke W et al., 1989).
The posterior cerebral artery (PCA) winds around the brainstem to supply the
splenium of the corpus callosum and the cortex of the occipital and temporal lobes.
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It gives off branches to the midbrain and a posterior choroidal artery to the choroid
plexus of the lateral ventricle. The central branches called thalamoperforating and
thalamogeniculate, supply the thalamus, subthalamic nucleus and optic radiation.
Figure3. Diagram of the vascular territories as depicted in four axial sections. ACA: anterior
cerebral artery, MCA: middle cerebral artery, PCA: posterior cerebral artery, LSA:
lenticulostriate arteries, PP: posterior perforators, SCA: superior cerebellar artery, PICA:
posterior inferior cerebellar artery, BP: basilar perforators.
Reproduced from Cinnamon 1995 (Cinnamon et al., 1995)
From all cortical branches, deep penetrating arteries pass through the gray matter
and penetrate the white matter to a depth of 3-4 cm, where they supply the core of
the hemisphere's white matter. These vessels intercommunicate very little, and thus
constitute many independent small systems - terminal arteries. This is in contrast to
the surface arteries supplying the cortical gray matter that anastomose to form a
continuous network of tiny arteries covering the perimeters or border zones
between the core (central) territories of the three major cerebral arteries. In addition,
there is a great variability of the size of the arteries and exact zones that they supply,
found in vivo and post mortem studies (Hendrikse et al., 2004;van der Zwan A. et
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al., 1992;van der Zwan A. et al., 1993;van Laar et al., 2006). The biggest contributor to
the variability seems to be the circle of Willis. Anatomical variation in the circle of
Willis causes flow variations in the territories of ICA and posterior circulation(van
Laar et al.,2006).
This very simple overview of the anatomy of the cerebral arterial blood flow shows
the complexity of the cerebral circulation in health. In cerebrovascular disease,
especially where there is gradual narrowing of the arteries leading to an occlusion, it
becomes even more complex with the development of collateral circulation (van
Laar et al., 2007). Although imaging can tell us the location and the size of the lesion,
it is not always possible to be certain of the vascular territories involved as they are
quite variable between individuals.
1.2.2 The pathology of ischaemic stroke
In this section I will discuss ischaemic stroke only, as it is the type studied in this
thesis.
About 50% of all ischaemic strokes are caused by the thrombotic or embolic
complications of atheroma, a disorder of large and medium sized arteries. 25% are
due to intracranial small vessel disease causing lacunar infarction and 20% are due
to embolism from the heart. Remaining 5% are due to rarities (Bamford et al., 1991).
The formation, progression, and consequences of atheroma
Atheroma begins as intimal streaks in childhood (Strong 1999), and over many years
circulating monocyte derived macrophages adhere to and invade the arterial wall
resulting in cytokine production and T-lymphocyte activation. Intra and later
extracellular lipids are deposited, particularly in macrophages which are then
described as foam cells. Arterial smooth muscle cells migrate in to the lesion and
proliferate causing fibrosis and formation of fibrolipid plaque. These plaques spread
around and along arterial wall, the arterial wall thickens, the vessel dilates and the
lumen narrows and the artery becomes stiffer and tortuous. Atheromatous plaque
promotes platelet adhesion, activation and aggregation which initiates blood
coagulation and thrombus formation (Fuster et al., 1996; Libby 2009). As a result of
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this process the lumen may obstruct or thrombus may embolise (in whole or a part)
to obstruct a distal intracranial artery.
Figure 4: The growth, progression, and complications of atheromatous plaques: (a) early
deposition of lipid in the artery wall as a fatty streak; (b) further build-up offibrous and lipid
material; (c) necrosis, inflammatory cell infiltrate, calcification and new vessel formation,





Reproduced from Warloio C 2008 (Warlow C et al., 2008)
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Intracranial small vessel disease
This is not the topic of this thesis but it is mentioned here for completeness. Small
vessels can be affected by a number of the pathologies such as amyloid angiopathy,
vasculitis, atheroma near the origin of the deep perforating arteries but much more
common is hyaline arteriosclerosis. This is almost universal in the small vessels of
the aged brain but sometime seen in young patients without any of the classical risk
factors (Lammie 2000). In addition to hypertension and diabetes mellitus,
breakdown of blood brain barrier with incorporation of plasma proteins in to the
vessel wall may be an important factor in development of the disease. Smooth
muscle cells in the wall are replaced with collagen which reduces distensibility of
the vessel but does not necessarily affect the lumen. More acute change is described
by the term "fibrinoid vessel wall necrosis", as for example in accelerated
hypertension. Unfortunately, there is very little post mortem evidence about the
changes in these vessels as these patients usually have smaller strokes and survive.
However, it is widely accepted but not uniformly that lacunar infarction has
different pathology and is seldom a result of embolisation from the proximal sites.
Further research is needed to determine whether abnormal blood-brain barrier
might predate development of lacunar disease (Wardlaw et al., 2009; Wardlaw et al.,
2008) and the mechanism of development of the lacunar infarction.
Embolism from the heart
Embolism can come directly from the heart or from the venous circulation through
the heart to the brain (paradoxical embolism). The size and characteristics of the
emboli vary. The most substantial threat is from non-rheumatic and rheumatic atrial
fibrillation, infective endocarditis, prosthetic heart valves, recent myocardial
infarction, dilated cardyomyopathy, intracardiac tumours and rheumatic mitral
stenosis. Altered blood flow in atrial fibrillation (AF) may lead to stasis and
formation of a cardiac thrombus. The left atrial appendage is the most common site
for thrombus formation in patients with AF. A small thrombus from the left atrium
can embolize to the brain and occlude a major intracranial artery thus causing a
large stroke.
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1.3 The pathophysiological changes in ischemic stroke
Injury from ischemic stroke is the result of a complex series of cellular metabolic
events that occur rapidly after the interruption of nutrient blood flow to a region of
the brain. The duration, severity, and location of focal cerebral ischemia determine
the extent of brain function and thus the severity of stroke. In this section I will talk
about the cerebral metabolism in health and mechanisms that lead to cell death.
1.3.1 Cerebral metabolism in health
Energy production and demand
The human brain has high metabolic demand for energy and, unlike other organs
uses glucose as its sole substrate for energy metabolism (about 75-100 mg/min, or
125 g/day). It is metabolised entirely via the glycolytic sequence and tricarboxylic
acid cycle where glucose is metabolised to pyruvate. During this process, the
oxidised form of nicotinamide-adenine dinucleotide (NAD+) is reduced (NADH).
Pyruvate is then oxidised in the mitochondria to carbon dioxide and water and
maximum energy yield is 36 moles of ATP. Neurones require a constant supply of
ATP to maintain their integrity and to keep the major intracellular cation, potassium
ions, within the cell, and the major extracellular cations, sodium and calcium,
outside the cell. In the absence of oxygen, the anaerobic pathway takes over which
produces 2 moles of ATP and in addition lactic acid which accumulates within and
outside cells. The cells become acidified and mitochondria lose their ability to
sequester calcium and as a consequence intracellular calcium rises (Kristian and
Siesjo 1998; Siesjo et al., 1996). As the brain is unable to store energy, it requires a
constant supply of oxygen and glucose to maintain its functional and structural
integrity.
Cerebral blood flow
Global cerebral blood flow (CBF), reflecting both gray and white matter per unit of
brain in a healthy young adult, is about 50-55 ml/100 g of brain per minute. These
values are higher in those younger then 20 years of age and lower in those over 60
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years of age (Leenders et al., 1990). The brain is only 2% total body weight and
therefore has disproportionately high total CBF for it's weight of 800 ml/min which
is 15-20% of total cardiac output. At this level of blood flow, the whole brain oxygen
consumption, expressed as cerebral metabolic rate of oxygen (CMR02), is about 3.3-
3.5 ml/ lOOg of brain per minute, or 45 ml of oxygen per minute, which makes it 20%
of the total body oxygen consumption at rest. The fraction of oxygen extracted from
blood (OEF) is fairly constant and coupled with CBF, cerebral blood volume,
CMR02 and cerebral metabolic rate of glucose (Leenders et al., 1990). In health CBF
is a good measure of OEF, but if CBF reduces the OEF increases to maintain CMR02
Cerebral autoregulation
Cerebral blood flow is maintained at a constant level despite changes in cerebral
perfusion pressure under normal conditions (mean systemic arterial pressure within
60-160 mmHg). This relationship is human autoregulation. The relationship
between the CBF and cerebral perfusion pressure (CPP) can be expressed as
CBF=CPP/CVR (cerebrovascular resistance). The CPP represents a difference
between arterial pressure forcing blood into the cerebral circulation and the venous
back pressure. Usually, CVR is negligible and CPP equals arterial pressure.
Maintaining flow with changes in pressure is achieved by altering vascular
resistance (by dilatation or constriction of intracerebral and pial arterioles). Other
influences on CBF are systemic arterial oxygen content, carbon dioxide tension, local
pH and the degree of local functional activation of neurones (Paczynski R. et al.,
1995). If the capacity to autoregulate is lost, the CBF becomes directly dependent on
systemic arterial pressure and even very small reductions in arterial pressure can
cause significant reductions in cerebral perfusion (Powers 1993).
1.3.2 The consequences of arterial occlusion
Acute cerebral ischaemia usually begins with occlusion of the artery (occasionally
vein), but can also happen as a consequence of a low flow (less common on its own).
When there is a sudden occlusion of the artery, blood pressure and cerebral blood
flow fall, distally to the site of the occlusion, and an area supplied becomes
ischaemic. Occlusion of the artery rarely completely abolishes supply of oxygen and
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glucose to the affected area due to existence of collateral channels which partly
maintain blood flow in the ischaemic territory and in some cases can produce areas
of relatively increased CBF so called "luxury perfusion."
The site of ischaemia is also important to cell survival. Neurones are most sensitive
to ischaemia followed by oligodendroglia, astrocytes and endothelial cells. Even
among neurons there are different sensitivities and those in hippocampus are
thought to be most sensitive with neocortex being least sensitive.
The duration of ischaemia will determine the fate of the tissue. This can be thought
of in terms of three main types of the tissue which are: tissue that is destined to die
(infarct core), tissue that will survive, and the tissue that may die or survive
(penumbra).
Critical thresholds of blood flow
Models of focal cerebral ischaemia have identified critical flow thresholds for certain
cell functions. The development of infarction is critically dependent on blood flow
(Astrup et al.,1981).
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Initially, small reductions in CPP and CBF (<50 ml/100g/min) are compensated by
regional vasodilatation to maintain CBF. With continued reduction in CPP (<45
ml/lOOg/min) and dilatation of all vessels to capacity, OEF and glucose extraction
are increased to maintain a normal CMROz and cerebral metabolic rate of glucose
(Powers 1991). Protein synthesis becomes inhibited. This is a state of "misery
perfusion" and the tissue is at risk (Baron 1999). The gold standard method of
studying this process in vivo is by a positron emission topography (PET) which is
the quantitative imaging technique that allows to obtain maps of the main
physiological variables involved in tissue ischaemia, perfusion and oxygen
conssumption. (Baronl999).
Further ischaemia (<35 ml/lOOg/min) causes inhibition of mitochondrial
metabolism and activates inefficient anaerobic glycolysis with elevation of lactate
levels and extra and intracellular acidosis. The energy dependant functions of the
cell membrane fail allowing intracellular potassium (K ) to leak out and allowing
extracellular sodium (Na+) and water to enter cells causing cytotoxic oedema.
Calcium (Ca++) also moves in to the cells causing mitochondrial failure and
compromises the ability of cell membrane to control ion fluxes (Kristian and
Siesjol998). When CBF reduces to below 20 ml/lOOg/min, electrical failure begins
to occur. Compensatory mechanisms temporarily sacrifice electrophysiological
activity to preserve cell viability, and suppression is seen on electroencephalogram
with evoked potentials attenuated. At this point, a focal neurological deficit will be
present (Fisher M 1999). The OEF is maximal and CMR02 begins to fall. With
further reduction in blood fallow, the electrical activity now fails, evoked potentials
are lost, the EEG flattens, and finally becomes isoelectric. With reduction of CBF to
15 ml/100 g/min, membrane failure occurs, leading to cytotoxic oedema, calcium
enters the cells leading to failure of mitochondria. The critical threshold for the
beginning of irreversible cell damage is a CBF of about 10 ml/100 g/min.
Duration of ischaemia
There are two main factors that determine tissue outcome, the severity of flow
reduction and its duration (Heiss and Rosner 1983) (Figure 6). The CBF threshold
for membrane failure (infarction) depends on the time elapsed since vessel
occlusion. The tissue with CBF 15 ml/lOOg/min may withstand three hours of
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occlusion, but tissue with CBF 10 ml / lOOg/min may withstand only two hours. The
data from PET studies indicate that substantial penumbra is present within six
hours of onset (around 90%), but falls to around 50% within nine hours. There is still
evidence of intact penumbra at 18 hours in about 30% (Marchal et al., 1996). The
data from thrombolytic trials of desmoteplase between 3 to 9 hours in patients with
a diffusion perfusion mismatch (Hacke et al., 2005), in addition to data from PET
studies (Baronl999;Baron 2001), suggests that the window for a therapeutic
intervention may be longer then the currently accepted 4.5 hours (Hacke et al., 2008).
However, the data on tissue survival in relation to duration of ischaemia is still
limited.
Figure 6. Combined effect of residual cerebral blood flow (CBF) and duration of ischaemia on
reversibility on neuronal dysfunction during focal cerebral ischaemia.
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Penumbra
The ischaemic penumbra can be defined as severely ischaemic, functionally
impaired tissue but still surviving. It is at risk of infarction but it can be saved and
recover if reperfused before permanent damage occurs. In threshold terms it means
that cells falling between suppression of electrical activity and the next threshold
when cells start breaking down are in the penumbra (Keith W Muir et al, 2006) .
Penumbra has been the target of acute stroke therapy and "Time is brain" is very
important concept to remember when treating acute stroke patients. Penumbral
tissue needs to be distinguished from the ischemic core (tissue that is already
irreversibly injured even if blood flow is re-established) and from tissue
experiencing benign oligemia, in which the mild reductions in tissue perfusion do
not actually place the tissue at risk Figure 7.
Figure 7. The ischaemic penumbra (Baron 1999). Idealised diagram of the baboon's brain
showing the topography of the ischaemic core, the pneumbra, and the oligaemia, following
occlusion of the MCA.
Oligemia
Reproduced from Baron 1999 (Baronl999)
The duration of the penumbra in humans varies, probably substantially from person
to person depending on a variety of factors, including location of the vessel
occlusion, degree of collateral blood flow, intrinsic susceptibility to ischemia of
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hypoperfused tissues (grey versus white matter), and other patient-specific factors.
Therapeutic strategies in acute stroke are based on the concept of arresting the
transition of the penumbral region into infarction, thereby limiting ultimate infarct
size and improving neurological and functional outcome (Fisher 1997). It is thought
that direct visualization of the location and extent of the penumbra could greatly
improve our ability to determine which patients may benefit from therapy and
allow treatment decisions to be based on individualised pathophysiology rather
than arbitrary chronological time thresholds.
Although the time varies, it is certain that if no reperfusion occurs, the area that
defines the core of the lesion increases with time until it reaches penumbral
threshold, at which point the entire penumbra has been recruited Figure8.
Figure 8. Idealised diagram of the baboon's brain showing the time course of infarct growth
at the expense of the pneumbra, from the situation immediately following MCA occlusion
(top left), to 3 h later (bottom right). The oligaemia is not a risk of infarction.
Reproduced from Baron 1999 (Baronl999b)
Imaging of the ischaemic penumbra
The main methods of imaging the ischaemic penumbra in vivo are by positron
emission tomography (PET), MRI, CT perfusion and single photon emission
tomography (SPECT). PET is able to differentiate between normal, penumbral and
infarcted tissue in the acute stages of ischaemic stroke. It is often referred to as a
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gold standard as it uses validated thresholds but because of its logistic and practical
limitations, its clinical role in acute stroke is limited.
MRI is more widely available and the mismatch between magnetic resonance (MR)
diffusion-weighted (DWI) and perfusion (PWI) imaging has often been regarded as
synonymous with penumbra (PWI> DWI is associated with subsequent infarct
enlargement). This is an oversimplification and it is recognised that mismatch
region will also include tissue with benign oligaemia and that some of the DWI
infarct core may in fact be salvageable (Kidwell et al., 2003,). This is discussed later
in the section on MRI imaging.
There are no studies that used MR spectroscopy in the assessment of the penumbra.
CT perfusion is a relatively new technique and not fully validated but it may be able
to delineate between infarcted and penumbral tissue. It provides CBF, CBV and
MTT and it is not best for visualising posterior fossa. SPECT is cheap and relatively
available but provides perfusion only and has limited spatial resolution.
At the present moment all potential penumbral imaging methods have drawbacks
for use in the acute setting and/or question about how accurately they can identify
tissue at risk.
1.4 Magnetic resonance imaging
1.4.1 Basic principles of MRI
The physics underlying MR imaging is extremely complex and beyond the scope of
this thesis. What follows is therefore a summary of basic principles.
Magnetic resonance imaging (MRI) is based on the principles of nuclear magnetic
resonance. The term "nuclear" has been dropped from the description of medical
MR techniques because of its association with radiation and radioactivity.
Hydrogen nuclei (protons) have magnetic properties, called nuclear spin. They
behave like tiny rotating magnets, represented by vectors in Figure 9a. The sum of
all the tiny magnetic fields of each spin is called net magnetization. Normally, the
direction of these vectors is randomly distributed. Thus, the sum of all the spins
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gives a null net magnetization. Within a large external magnetic field (called B0),
nuclear spins align with the external field as in Figure 9b. Some of the spins align
with the field (parallel) and some align against the field (anti-parallel).
Figure 9 a) In the absence of a strong magnetic field, hydrogen nuclei are randomly aligned
b) When the strong magnetic field, B0, is applied, the hydrogen nuclei align with B0 and
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(Reproduced from Basic Principles of MRI http: / /www.cs.sfu with permission from Blair
Mackiewich)
Protons wobble (or precess) about the axis of the B0 field so as to describe a cone.
This is called precession. Spinning protons are like "spinning tops," spinning about
their axis. The resonance frequency, called Larmor frequency (co0) or precessional
frequency, is proportional to the main magnetic field strength. The magnetic vector
of spinning protons can be broken down into two orthogonal components: a
longitudinal or Z component, and a transverse component, lying on the XY plane.
Precession corresponds to rotation of the transverse component about the
longitudinal axis. Within the B0 magnetic field, there are more spins aligned with
the field (parallel - low energy state) than spins aligned against the field (anti-
parallel - high energy state). Due to this slight excess of parallel spins, net
magnetization (macroscopic magnetization) has a longitudinal component (along
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the Z axis) aligned with B0. As spins do not rotate in phase, the sum of all the
microscopic transverse magnetizations tend to zero so that there is no net transverse
macroscopic magnetization.
Exchange of energy between two systems at a specific frequency is called resonance.
Magnetic resonance corresponds to the energetic interaction between spins and
electromagnetic radiofrequency (RF). When a RF pulse is applied, the net
magnetization vector tips down during excitation but the microscopic spin
magnetization vectors do not. Modifications of the energy state and phase of spins
depend on intensity, waveform, and duration of RF pulse.
Figure 10. a) The RF pulse causes the net magnetic moment of the nuclei to tilt away from
B0 b) When the RF pulse stops, the nuclei return to equilibrium such that magnetic moment
is again parallel to B0. During realignment, the nuclei lose energy and a measurable RF
signal
a) b)
(Reproduced from Basic Principles of MRI http:/ / www.cs.sfu with permission from Blair
Mackiewich)
Once the RF signal is removed, the nuclei realign themselves such that their net
magnetic moment is again parallel with B0. This return to equilibrium is referred to
as relaxation. During relaxation, the nuclei lose energy by emitting their own RF
signal (see Figure 10 b). This signal is referred to as the free-induction decay (FID)
response signal. The FID response signal is measured by a conductive field coil
placed around the object being imaged. This measurement is processed or
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reconstructed to obtain 3D grey-scale MR images. To produce a 3D image, the FID
resonance signal must be encoded for each dimension. The encoding in the axial
direction, the direction of B0, is accomplished by adding a gradient magnetic field to
B0 This gradient causes the Larmor frequency to change linearly in the axial
direction. Thus, an axial slice can be selected by choosing the frequency of RF pulse
to correspond to the Larmor frequency of that slice. The 2D spatial reconstruction in
each axial slice is accomplished using frequency and phase encoding.
The voxel intensity of a given tissue type (i.e. white matter vs grey matter) depends
on the proton density of the tissue; the higher the proton density, the stronger the
FID response signal. MR image contrast also depends on two other tissue-specific
parameters: a) the longitudinal relaxation time, Tl, and b) the transverse relaxation
time, T2. Tl characterizes the rate at which the longitudinal component of the
magnetization vector returns to equilibrium (i.e. realign itself with B0), while T2
characterizes the rate at which the magnetization vector decays in the transverse
plane for a given tissue type. When MR images are acquired, the RF pulse is
repeated at a predetermined rate. The period of the RF pulse sequence is the
repetition time TR. The FID response signals can be measured at various times
within the TR interval. The time between which the RF pulse is applied and the
response signal is measured is the echo delay time TE. By adjusting TR and TE the
acquired MR image can be made to contrast different tissue types.
In clinical MRI, hydrogen is the most frequently imaged nucleus due to its great
abundance in biological tissues. Other nuclei such as 13C, 19F, 3[P, 23Na have a net
nuclear spin and can potentially also be imaged using MR, albeit with vastly
reduced spatial resolution. However, they are much less abundant than hydrogen in
biological tissues and require a dedicated RF chain, tuned to their resonance
frequency.
1.4.2 Structural MR imaging sequences
A routine MR brain imaging sequence of a stroke patient consists of a combination
of a Tl weighted midline sagital view of the brain, a T2 axial image, a fluid
attenuated inversion recovery (FLAIR) axial image, a gradient echo (or T2*) axial
image and diffusion weighted (DWI) axial image covering the whole brain
(DeLaPaz RL and Mohr JP 1998;Wardlaw JM 2008). The exact sequence performed
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depends on the preference of the neuroradiologist. The images obtained with these
routine sequences provide information about the structure of the brain. T2* gradient
echo is sensitive to the presence of blood in acute and chronic haemorrhage
(DeLaPaz RL and Mohr JP1998;Patel et al., 1996;Wardlaw JM2008) or in more
chronic small petechial minor haemorrhages (Keir 2002).
The FLAIR images are T2-weighted with the CSF signal suppressed. This means the
lesions near the brain surface stand out more clearly. It appears to detect ischaemic
abnormalities better then T2 weighted imaging (Lansberg et al., 2000;0ppenheim et
al., 2000) and shows small cortical and periventricular infarcts well. However, it
cannot distinguish between acute and subacute infarcts and may miss posterior
fossa lesions. It can also be oversensitive especially for asymptomatic white matter
lesions (Wardlaw JM2008;Oppenheim et al.,2000). Diffusion and perfusion imaging
will be discussed in more detail as it is a major part of the imaging protocol.
1.4.3 Diffusion weighted imaging
Diffusion weighted imaging (DWI) is the most sensitive way to image acute infarcts.
Diffusion-weighted imaging sequences now are incorporated into most MR imaging
protocols and are essential component of an acute stroke evaluation (Schaefer et al.,
2000).
Basic physics of DWI
Diffusion explores the micromovements of water molecules. It is often thought of as
a redistribution of molecules from a region of high concentration to a region of low
concentration. However, in MRI, the "random walk model" is more suitable because
it describes the effects of diffusion in the absence of any concentration gradient
(Figure 11). Because of random thermal motions (Brownian motion), water
molecules in a pure sample change position and direction of movement in a random
fashion. This process is called isotropic diffusion. In biological systems, water
diffusion is not truly random because diffusion is restricted by natural barriers such
as cell membranes, protein molecules and fibres. When the observation time is very
short, most molecules do not have enough time to reach the barriers; therefore, they
behave as if they are diffusing freely. If the observation time increases, the restricted
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molecule will strike the boundaries in its motion, and therefore its displacement will
deviate from its behaviour in a free medium. Diffusion is a three-dimensional
process, and the molecular mobility in different directions may be affected by the
presence of natural barriers that limit free diffusion. This spatial dependency is
called anisotropic diffusion (Schaefer et al.,2000;Moseley et al., 1991). For example,
water diffuses readily up and down white matter tracts, but diffusion perpendicular
to the fibre is restricted by axonal membranes and the myelin sheath (Baird and
Warach 1998) Figure 12..
Figure 11. Schematic representation of a diffusion process described as "random walk." Four
particles (different colour), all begin at the same origin but follow different chaotic paths.
Diffusion - Random Walk
Displacement of 4 particles starting
at the same origin
Reproduced from C. Beaulieu(Beaidieu 2002)
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Figure 12. Exemples of isotropic diffusion and anisotropic diffusion
A. Isotropic Diffusion B. Anisotropic Diffusion
(A) Water molecules in the brain are constantly moving (i.e., in Brozvnian motion). When motion is
unconstrained, as in the large fluid-filled spaces deep in the brain (i.e., the ventricles, as illustrated in
the MR image on the left), diffusion is isotropic, which means that motion occurs equally and
randomly in all directions. (B) When motion is constrained, as in white-matter tracts (illustrated on
the right), diffusion is anisotropic, meaning that motion is oriented more in one direction than another
(e.g., along the y axis rather than along the x axis).
Reproduced from M. Rosenbloom (http://pubs.niaaa.nih.gov/publications)
The principles of DW imaging
The overall principle of diffusion measurement is that the spatial location of each
water molecule is tagged such that any net movement of a water molecule during
the observed period results in signal loss (darkening of the images). This is achieved
by a pair of very strong pulsed magnetic field gradients (diffusion gradients) to each
side of a 180° pulse, which are added to a spin-echo sequence (typically T2-
weighted). The first of these diffusion gradients (the dephasing gradient) causes the
spinning protons to fall out of phase with one another whilst the second diffusion
gradient (the rephasing gradient), rephases the protons completely with one
another. If there has been no movement of the water molecules between the
application of the two diffusion gradients, and a T2-weighted image would result as
if the pair of diffusion gradients had not been added. When there is movement of
water, the protons are not brought back completely into phase by the second
diffusion gradient. The further the water has moved, the more out of phase it will
be, and the more signal attenuation (signal loss or image darkening) will occur.
Regions of fast diffusion (CSF) appear darker then normal brain tissue because
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movement of water results in signal loss (Baird and Warachl998). Normal brain will
appear darker then the regions of hyperacute injury which have restricted diffusion.
The amount of signal loss in DWI is related to the magnitude of the molecular
translation (i.e., net diffusion) and to the strength of the diffusion weighting, given
by the b-value. The b value is specific for the particular pulse sequence used to
measure diffusion and is a function of the diffusion gradient strength, the duration
of the diffusion gradient pulse and the time of the diffusion measurement (the time
between the beginning of the two diffusion gradients).The higher the b-factor the
greater the diffusion weighting.
The diffusion description needs to account for the spatial dimension (axial, sagittal,
or coronal) that the diffusion is measured in. In practice, the so-called trace of the
diffusion tensor can be measured by averaging images obtained with diffusion
gradients applied in three orthogonal planes (x, y, and z) to give average diffusion
coefficient (Ulug et al., 1997;Warach et al., 1995). Average diffusion coefficient is not
dependent on the orientation of the subject with respect to the magnetic field
gradient axes and provides a good approximation to the mean of the diffusion
tensor (Ulug et al.,1997). The earliest DWI studies were limiting due to very slow
acquisition time (used spin-echo type sequences) (Warach et al., 1992). With the
implementation of echoplanar imaging (EPI) much faster acquisition of DWI images
was possible. The effects of bulk motion were minimized and DWI became practical
for the acute stroke setting (Warach et al.,1995). The advantages of DWI using EPI
are: (1) the acquisition is very rapid (on the order of tens of milliseconds) so that
multiple slices from a whole brain can be imaged in a few seconds, (ii) the effect of
head motion leading to poor image quality can be reduced to a minimum, and (iii)
studies of multiple different diffusion properties are possible. Limitations of EPI of
the brain are strong chemical shift artefacts making precise fat suppression
techniques obligatory, and strong susceptibility artifacts that cause image
distortions, particularly in the posterior fossa and at the margins (inferior frontal
and anterior temporal lobes)(Warach et al.,1995).
Apparent diffusion coefficient
The rate of diffusion can be quantified and is expressed as apparent diffusion
coefficient (ADC). For the calculation of the ADC, at least two b values are required,
(typically b = 0 no diffusion weighting and 1000 s/mm2). The accuracy of the ADC
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calculation is directly related to the range and number of b values used for the
measurement, and the signal-to-noise ratio of the T2-weighted EPI acquisition. ADC
removes T2 effect and is useful mostly in cases of lesion with a T2 hyperintensity
appearing as a hyperintensity on DWI (differentiates between T2-shine-through and
diffusion restriction).
The abnormality on ADC is the inverse of its appearance on DWI. Therefore, CSF
that has unrestricted water movement is bright whilst the lesion with low diffusivity
is dark.
Anisotropic diffusion
The ADC in certain regions of the brain appears to depend on the direction of the
applied diffusion gradient (Moseley et al., 1990a) implying that ADC is directionally
dependent. Beailieu and Allen performed a number of experiments in the 1990s to
determine the origin of diffusion anisotropy. By the process of elimination they
were able to rule out the effects of susceptibility induced gradients (Beaulieu and
Allen 1996), axonal cytoskeleton (Beaulieu and Allen 1994a;Moseley et al.,1990a)
and fast axonal transport (Beaulieu and Allen 1994b;Moseley et al.,1990a). They
concluded that the main determinant of anisotropy in nervous tissue is the presence
of intact cell membranes and that myelination serves to modulate anisotropy
(Beaulieu2002).
Diffusion Tensor Imaging (DTI)
Water molecule diffusion is a three-dimensional process. In order to acquire more
detailed information about anisotropic diffusion properties of the tissue, simple
DWI is not sufficient. While ADC maps reveal the tendency of water molecules to
diffuse within a voxel, directional variation is also required to image 3D anisotropic
diffusion. By sampling 6 or more diffusion directions and establishing a relationship
between the acquired data and applied diffusion gradients in the pulse sequence,
the directional variation in the tendency of water molecules to diffuse within a voxel
can be imaged.lt describes the diffusion along each direction and interactions
between the directions providing important information about tissue connectivity.
However, complex maths is required to determine the diffusion tensor for each
voxel in the brain, and this analysis is beyond the scope of this thesis.
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DWI in ischaemia
Acute stroke restricts supply of glucose and oxygen and eventually results in failure
of cell membrane pumps and influx of sodium and water into the cell (see
Pathophysiology section earlier in this chapter). Water enters the cells from
extracellular space where it can diffuse freely, to intracellular space where its
movement is restricted (Beauchamp, Jr. et al., 1999). It is generally accepted that high
signal on DWI (low ADC) is due to excess intracellular water accumulation, or
cytotoxic edema, with an overall decreased rate of water molecular diffusion within
the affected tissue (Albers 1998;Beauchamp, Jr. et al.,1999;Fisher et al.,1995).
Figure 13. Slice from the brainstem ofdiffusion image and corresponding ADC lesion.
Although there is an "agreement" that decrease in ADC in ischemic stroke reflect
early cytotoxic oedema, the exact mechanism is not known. Various other
mechanisms have been proposed such as decreased extracellular space (Hasegawa
et al., 1996) or restricted intracellular diffusion (Neil et al., 1996).
The time course of ADC/DW lesion
DWI is capable of detecting cerebral ischaemia very early, within minutes in animal
models (Moseley et al., 1990b), and within first hour in human ischaemia (Yoneda et
al., 1999). In acute stroke studies, ADC values decrease after stroke onset, then
normalise before becoming high in the chronic phase. The decrease can be very
rapid after stroke, and can reach minimum value within 1.5 hours (Kucinski et al.,
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2002). A decrease in ADC always precedes the development of infarction but not all
low ADC lesions will necessarily go on to infarct. So, the diffusion lesson appears to
be heterogeneous and includes reversibly and irreversibly damaged tissue
(Guadagno et al., 2004;Kidwell et ah, 2000;Kidwell et al.,2003;Rivers and Wardlaw
2005;Rivers et ah, 2006b). A DWI lesion can be found in some patients with a
transient ischaemic attack (Ay et ah, 2002) whilst others with a clinical stroke may
never develop a DWI lesion (Ay et ah, 1999).
In animal models, the ADC value falls as neuronal and glial swelling develops, and
then either remains low in persistent occlusion models until dead cells of all types
are lysed, or rises in transient ischemia models due primarily to resolution of glial
swelling (Rivers and Wardlaw2005). Indeed histological comparisons suggest that
the ADC is a better marker of glial cell status than of neuronal viability, with the
DWI signal ("whiteness") being a better marker of neuronal death than the ADC
(Rivers and Wardlaw2005;Rivers et al.,2006b). So far, no consensus has been reached
on the threshold of cerebral perfusion that results in a diffusion abnormality
(Bandera et al.,2006;Fiehler 2003).
1.4.4 Perfusion weighted imaging (PWI)
Perfusion MRI provides a relative and/or "absolute" measurement of the
parameters of cerebral microvascularisation: regional blood volume, mean transit
time and regional blood flow. Two types of MR perfusion imaging have found
applicability to be used clinical practice and research; 1) susceptibility-based
techniques that use either paramagnetic contrast agents such as those containing
gadolinium (contrast agent bolus tracking) also called (dynamic susceptibility
contrast [DSC] imaging), or endogenous changes in deoxyhemoglobin, which is an
intrinsic paramagnetic molecule (blood oxygen level dependent [BOLD]); and 2)
arterial spin labelling techniques.
In the ASL method, water proton spins in the extracranial blood are saturated and
inverted electromagnetically, and these labelled protons mix with extravascular
water in the brain. The imaging before and after spin inversion detects the
difference in tissue magnetization, which is proportional to local perfusion. The
method has a relatively low signal-to-noise ratio, requiring long imaging times as
compensation, but may provide quantifiable data. This is an experimental method
with few data regarding its utilization in acute or chronic ischaemia.
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DSC imaging relies on the intravenous administration of an MR contrast agent.
Gadolinium based contrast is injected fast into arm (usually through a pump) and
rapid imaging performed immediately before and 1.5 minutes after the injection to
capture the first pass of the contrast agent. This imaging is typically susceptibility
based and depends on T2* effects. This may be T2 weighted instead, but the signal is
not as strong. The passage of an intravascular MR contrast agent through the brain
capillaries causes a transient loss of signal because of the T2* effects of the contrast
agent. The concentration difference between intravascular and extravascular
contrast agent (for intact blood brain barrier) leads to local magnetic field gradient,
which in turn results in a decrease of T2* signal. The signal decrease in brain tissue
is dependent on perfused cerebral volume and the signal drop in gray matter
exceeds that of white matter which in turns appear more hyperintense compared to
gray matter (Figure 14). In ischaemic tissue, only a small amount of contrast agent
passess throught the capillaries, the signal intensity during bolus maximum passage
is even brighter then normally perfused white matter.
The dynamic contrast-enhanced MR perfusion imaging technique involves tracking
of the tissue signal changes caused by susceptibility (T2*) effects to create a
hemodynamic time-signal intensity curve. The time course of the (relative) contrast
agent concentration is calculated using: the relative concentration of the contrast
agent in the region of interest or the voxel (C (t)), the signal intensity (S (t)), and the
mean signal intensity (S 0) before the bolus appears within the region of interest.
Figure 14 Signal-time course in normally perfused gray and white matter: The signal drop of
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In the concentration time curve the first pass of the bolus appears after the pre
contrast baseline. After the first pass, the concentration does not return to zero, but
remains increased. This effect is due to contrast agent molecules remaining within
the capillary network and second pass effects. One way to avoid these effects is to fit
a gamma-variate function to the measured values of contrast agent concentration
(Belliveau et al., 1991).
Semiquantitative parameters
From the concentration time curve several parameters can be calculated. These
physiological parameters are used to diagnose and /or monitor pathophysiological
processes. These parameters are: cerebral blood volume (CBV) which is defined as
an area under concentration/time curve; mean transit time (MTT) defined as first
moment of concentration/time curve; the time between contrast agent injection and
arrival of the first contrast agent within the region of interest (TTA) also called bolus
arrival time (BAT), the time between contrast agent injection and the maximum
contrast agent concentration within the region of interest (TTP), maximum
concentration value C max; first moment "balancing point" of curve along the time
axis (FWHM) "full width half maximum"; and cerebral blood flow (CBF) which is
calculated from the knowledge of CBV and MTT as CBV/MTT , Figure 15.
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Figure 15. Contrast-time curve showing the different parameters used to estimate perfusion.
FWHM first moment "balancing point" of curve along the time axis; Cmax (also known as
peak height), FTP (also known as Tmax after deconvolution), and BAT bolus arrival time.
AUC indicates area under the curve.
Time (s)
Reproduced from Kane I et al. 2007(Kane et al, 2007a)
Qualitative parameters
In order to obtain quantitative values, the knowledge about the arterial input
function (AIF) is required. In DSC imaging with EPI sequences there are usually
several slices where major feeding blood vessels can be visualised. The AIF can be
measured in both internal carotid arteries (ICA) and middle cerebral arteries
(MCA). For practical reasons, the MCA measurements are used most frequently as
image data mostly contain these arteries. The voxels that represent the AIF must
meet certain criteria; the maximum signal drop is larger, the TTA is shorter and the
MTT is lower then the normal brain tissue (Figure 16). With the knowledge of the
AIF and the concentration time curve within the tissue, quantitative ("absolute")
values of the perfusion parameters can be calculated by deconvolution (Calamante
et al., 2002; Ostergaard et al., 1996b; Ostergaard et al., 1996a). Quantitative CBF can
be calculated as a height, CBV as the area under the deconvoluted concentration
time curve and MTT as a CBV/CBF (Calamante et al.,2002; Ostergaard et al.,1996b;
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Ostergaard et al.,1996a). The deconvolution required to produce the quantitative
perfusion measurement can be performed in several different ways but the one
most frequently used in clinical and research studies is singular value
decomposition (SVD)(Ostergaard et ah,1996b; Ostergaard et al.,1996a).
Figure 16. Signal time curves determined in normal tissue and in the feeding arteries (AIF).
The signal drop in the arteries is much larger than in tissue.
time (s)
Reproduced from von Kummer R(von Kummer R and Back T2006)
Use of perfusion in diagnosis of ischaemic stroke
Perfusion imaging is used in stroke, both in clinical practice and research. There is a
potential for perfusion imaging to identify tissue, not visible by other means, which
may go on to infarct without any intervention. Many studies have looked at the
changes in perfusion parameters after the acute stroke and the territory that is
supplied by the occluded artery can be defined by the changes in MTT, TTP and
CBF. Both MTT and TTP are prolonged significantly due to the decline in CBF (Thijs
et al., 2002).
The study of 46 patients has compared semi quantitative CBF and MTT and DWI
lesion size and final T2 infarct volume at least one month after the stroke who did
not receive thrombolysis (Rivers et al., 2006a). The baseline DWI and semi
quantitative CBF lesion sizes were not significantly different from final T2 weighted
lesion volume, but semi quantitative MTT lesion was significantly larger. The
correlation with final T2 weighted volume was strongest for DWI, followed by semi
quantitative CBF and weakest for semi quantitative MTT baseline lesion volumes.
The results of this study are in agreement with previous studies indicating that MTT
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lesions overestimate tissue at risk, and CBF provides a closer estimate of final infarct
extent.
Different centres use different ways of analysing perfusion data. Kane at al. assessed
ten different perfusion processing methods (Kane et al., 2007a), and showed that
different PWI parameters produce very different estimates of abnormal perfusion in
the same data from the same patient and therefore, very different estimates of the
volume of "tissue at risk." This study showed that relative perfusion parameters
performed as well as quantitative ones. Some parameters (mainly representing MTT
measures) were correlated with clinical scores, others were correlated with final
infarct size, and only arrival time of the contrast (BAT or TTA) was correlated with
both. If perfusion is to be used in the selection process of patients that are to be
treated then a consensus is required on which perfusion measurement and
processing methods should be used.
In addition to problems with use of different processing methods, many studies of
perfusion imaging have tried to identify a threshold beyond which the tissue is not
salvageable but so far there does not appear to be an MR perfusion threshold that
reliably distinguishes between dead and salvageable tissue (Bandera et al.,2006).
Diffusion perfusion mismatch
In the very early stage of ischaemia, the volume of hypoperfused tissue often
exceeds the volume of ischaemic core, where tissue injury is irreversible. The core
can roughly be delineated by the DWI (Moseley et al.,1990b;Schellinger et al., 2001),
and this has led to the concept of the "diffusion - perfusion mismatch." This concept
has become synonymous with the "penumbra" (see 1.3.2), reversibly damaged but
potentially salvageable tissue if perfusion to the brain is restored. Knowledge of the
extent of this salvageable brain would be useful to guide the choice of acute stroke
treatment, such as thrombolysis (Hjort et al., 2005). The concept of diffusion
perfusion mismatch may be oversimplification of the complex process taking place
when blood vessel occludes complicated further by the uncertainties about how to
extract perfusion data.
Initial natural history studies supported this simple diffusion perfusion mismatch
model by demonstrating that if early reperfusion of the perfusion lesion occurs,
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growth of the acute DWI lesion is inhibited (Barber et al., 1998). The duration and
extent of the penumbra in humans varies substantially from person to person
depending on a variety of factors, including location of the vessel occlusion, degree
of collateral blood flow supply, intrinsic susceptibility to ischemia of tissues
hypoperfused (eg, gray versus white matter), and other patient-specific factors.
Direct visualisation of the tissue at risk would greatly benefit the decision making
process which then could be based on the pathophysiological processes rather then
arbitrary chronological time windows (Thrombolytic treatment in stroke was until
recently licensed up to three hours from onset of symptoms (NINDS 1995), but there
is also evidence that it is effective up to 4.5 hours (Hacke et al.,2008) and the licence
has been extendeds).
Number of studies found presence of diffusion perfusion mismatch up to 24 hours
following stroke (Baird et al., 1997;Beaulieu et al., 1999;Darby et al., 1999;Neumann-
Haefelin et al., 1999;Parsons et al., 2001;Schellinger et al., 2000;Sorensen et al., 1999).
The volume and presence of mismatch tissue decreases with time, at least 50% of
patients have significant tissue at risk after 24 hours from onset of stroke. There
have been number of studies of DWI and PWI suggesting that mismatch does
predict infarct growth by demonstrating that thrombolysis "rescues" mismatch
tissue from infarction (Jansen et al., 1999;Kidwell et al.,2000;Parsons et al.,
2002;Schellinger et al.,2000).
However, there are number of challenges to the above described "simple" mismatch
concept. The diffusion lesion is not uniform (Guadagno et al., 2004;Nicoli et al.,
2003), diffusion lesion (parts of it or whole) is reversible (Chalela et al., 2002;Fiehler
et al., 2002;Kidwell et al.,2000;Lutsep et al., 2001;Uno et al., 2000), and perfusion
imaging exaggerates the areas of truly ischaemic tissue and includes the area of
benign oligaemia (Kidwell et al.,2003a). The model for the salvageable tissue
proposed by Kidwell (Kidwell et al.,2003a) is shown in Figure 17
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Figure 17. Modified view ofMRI-defined ischemic penumbra in which the penumbra equals
not only regions of diffusion-perfusion mismatch but also a portion of the diffusion
abnormality itself
■ Benign Oligemia Core
■ Perfusion Abnormality Penumbra
■ Diffusion Abnormality
Figure reproduced from Kidiuell, C. S. et al.(Kidwell et al. ,2003a)
How good is the evidence that mismatch predicts patients with different outcome or
who might benefit more from the same treatment as those without mismatch?
Systematic review by Kane (Kane et al.,2007b) that looked at mismatch for
thrombolysis found that of the methodologically sound studies (total sample size
641 patients), less then half provided the data on outcome. The studies used
different mismatch definitions and different perfusion methods. Mismatch (v no
mismatch) without thrombolysis was associated with a non-significant twofold
increase in the odds of infarct expansion (OR 2.2), which did not change with
thrombolysis (OR 2.0). Half of the patients without mismatch also had infarct
growth (with or without thrombolysis). No data were available on functional
outcome. From these data it cannot be reliably concluded whether thrombolysis
changes infarct growth. The mismatch hypothesis was tested in a prospective trial of
the echoplanar imaging thrombolysis evaluation trial (EPITHET) which did not
confirm lower infarct growth with thrombolysis in mismatch patients but this
changed when baseline lesions of less than 5 mL were excluded. More importantly,
the functional outcome was the same between the patients that received the
thrombolysis and those that did not.
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It is possible that mismatch in the future could be used for extending time window
for thrombolythic treatment in stroke as there is evidence as discussed earlier that
the tissue can survive up to 24 hours. At the same time, there is a need for
standardising the mismatch definition before it is more widely used in a clinical
practice as well perfusion processing method.
1.4.5 Magnetic Resonance Spectroscopy and Chemical Shift Imaging in
stroke
What is MR spectroscopy?
Magnetic resonance spectroscopy (MRS) detects signals from water soluble
metabolites and can demonstrate metabolic changes in ischaemic tissue in
vivo(Beauchamp, Jr. et ah, 1999). MRS can be performed on all nuclei with a spin and
depending on the chosen nucleus, different compounds can be detected. The most
frequently used nucleus in MRS is hydrogen (proton, 'H) which is abundant in the
body. Other nuclei used in MRS are 3IP, 13C, 15N, I9F, and 23Na. Of these, 3IP has also
been used in stroke studies in the evaluation of sources of metabolic energy in the
brain, giving insights into the energetic pathways, including, for example ATP and
phosphocreatine (PCr). 13C, 15N are at low natural abundance and must be
administered as labelled compounds and therefore have not been studied as much.
At the strength of the magnetic field used in clinical practice only 'H nuclei shows
sufficient sensitivity to be detectable in small volumes within reasonable acquisition
time. To be able to acquire signals representing metabolic compounds of interest,
the brain water resonance which is the main signal source in 'H-MRS and exceeds
the metabolite signal by approximately 104, has to be suppressed. Special water
suppression pulses are added to saturate water signal.
MRS techniques
There are two imaging methods of proton magnetic resonance spectroscopy




In SVS, the signal is received from a volume limited to a single voxel. This
acquisition itself is fairly fast (1 to 3 minutes) and a spectrum is easily obtained, but
there are three steps to this method. First, suppression of the water signal; the most
commonly used method to suppress the water peak is CHESS (CHEmical Shift
Selective). CHESS consists in applying three couples (90° RF pulses + dephasing
gradients), one in each spatial direction. The bandwidth of these RF pulses is
narrow and centered on the resonance frequency of the water peak in order to
saturate the water signal and preserve the signal from the other metabolites. The
second step is a selection of the voxel of interest which is done by a succession of
three selective radiofrequency pulses (accompanied by gradients) in the three
directions in space. These pulses determine three orthogonal planes whose
intersection corresponds to the volume studied. Only the signal of this voxel will be
recorded, by selecting only the echo resulting from the series of three
radiofrequency pulses. Two types of sequence are available; PRESS - Point-
RESolved Spectroscopy and STEAM - STimulated Echo Acquisition Mode (Frahm et
ah, 1989).
In the STEAM the three voxel-selection RF pulses have flip angles of 90°. The
stimulated echo is recorded from the cumulated effect of the three pulses, thus
corresponding to the signal from the only voxel of interest. The TE of the stimulated
echo corresponds to double the time interval between the first two pulses. The delay
between the second and third RF pulses is the mix time TM. This technique is
particularly adapted to short TE spectral acquisitions.
In the PRESS method, the RF pulses have flip angles of 90° - 180° - 180°. The signal
emitted by the voxel of interest is thus a spin echo. The amplitude of this spin echo
is two times greater than the stimulated echo obtained by STEAM. The PRESS
technique thus offers a better signal-to-noise ratio than STEAM. It can be used with
short TE (15 - 20 ms) or long TE (135 - 270 ms)( Figure 18).
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Figure 18. Single-voxel pulse sequences: (a) schematic illustration of three orthogonal slice
selective pulses. The size and position of the voxel is controlled by the frequency and
bandwidth of the slice selective pulses, as well as by the amplitude of the associated slice
selective field gradients, (b) STEAM and (c) PRESS. Simplified diagrams are presented









Figure reproduced from P. Barker, Fundamentals of MR spectroscopy in Clinical MR Imaging
(Gillard J H et al, 2004)
SVS was frequently used in clinical practice as it is quick to perform, widely
available, can be done at short TE and are relatively easy to interpret. However it
does have limitations, the most significant one being the lack of ability to determine
spatial heterogeneity of spectral patterns and also the fact that only a small number
of brain regions can be covered within the constraints of clinical examination. For
the example of the single voxel spectra see Figure 19.
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Figure 19. Single voxel within a T2 image of the brain slice and examples of spectra from
normal and stroke tissue (long TE).
Multivoxel magnetic resonance spectroscopy (MRSI,CSI)
MRSI was developed in an attempt to overcome the problems of SVS. The data is
recorded for a group of voxels. The first attempt was by using phase encoding
gradient in one direction (Petroff et al, 1992) but this was not enough to show the
detail required. The technique was then developed in to two dimensional (2D) by
using phase - encoding gradient in two directions (Duyn et al., 1993) and then by
using full three-dimensional (3D)encoding (Nelson et al., 1999).
As in single voxel spectroscopy due to small concentration of brain metabolites in
comparison to protons in the water, as well as presence of pericranial fat it is
essential to perform water and lipid suppression. The most common method of
water suppression is to pre-saturate the water signal using frequency selective, 90°
pulses - chemical shift selective water suppression (CHESS) pulses (Haase et al.,
1985) prior to localization of pulse sequence Figure 20. Good suppression can be
achieved by using a combination of more then one pulse and correct flip angle.
Lipid signal can be suppressed by using STEAM or PRESS localization to avoid
exciting lipid containing regions (see above SVS), but there is also an option of using
outer volume suppression (OVS) to pre-saturate lipid signal (Duyn et al.,1993). An
inversion pulse can also be used to suppress lipid signal by using the difference in
T1 between metabolites and lipids. Using short inversion time will selectively null
the lipid signal.
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Figure 20. Schematic illustration of pulse sequence for multi- slice MRSI with CHESS
water suppression and outer volume saturation hands for lipid suppression (Duyn et
al.,1993)(for clarity, not all crusher gradients are illustrated). A slice selective spin-echo
sequence is used, with interleaved acquisition (in this example) or four slices within one TR
period. (b)The orientation and locations of the eight OVS pulses are schematically illustrated
on sagittal and axial views; an octagonal pattern is prescribed in order to saturated as much
peri-cranial lipid as possible while signal from grain is un-perturbed. Ideally, sharp profile,
high bandwidth pulses (to minimize chemical shift effects) should be used for OVS.
Figure reproduced from P. Barker, Fundamentals of MR spectroscopy in Clinical MR Imaging
(Gillard / H et al.,2004)
MRSI is based on a repetition of STEAM or PRESS type sequences to which is added
spatial phase encoding. Signal processing uses Fourier transformation and requires
data correction. The results appear in the form of parametric images (metabolite
maps) or a matrix of the spectra of the region studied.
-TR-
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Figure 21.Brain slice with the CSI grid covering the whole slice. On the right is an example













Another essential variable in the acquisition of proton magnetic resonance
spectroscopy is the choice of echo time. With short echo times (less than 30
milliseconds), the magnetic resonance spectrum detects larger numbers of
metabolites, but it is more likely that peaks will superimpose over each other,
causing difficulty in spectroscopic curve interpretation. Macromolecules also cause
a complex baseline. Short echo times are indicated for the study of metabolic and
diffuse diseases. By using long echo times (more than 135 milliseconds), smaller
numbers of metabolites are detected, but with better definition of peaks and better
reproducibility. Long echo times are more used in focal brain lesions.
Spectroscopic signal recording does not use a frequency encoding readout gradient,
as the frequency is used to constitute the spectrum (rather than the position).
Protons in different molecules resonate at slightly different frequencies because the
local electron cloud affects the magnetic field experienced by the proton. A Fourier
transform is applied to the signal to separate (or resolve) the chemical shifts of
different metabolites. Resonant frequencies are expressed in parts per million (ppm)
relative to a reference frequency, and the scale reads from right to left. In a proton
spectrum at 1.5 T, the metabolites are spread out over a range of approximately 300
Hz (5 ppm).
42
It takes considerably longer to acquire data for MRSI than the single voxel, but with
continuous improvement in the software the acquisition time has reduced
significantly (Stengel et al., 2004).
Quality of spectra and technical requirements
In spectroscopy, MR signals correspond to biochemical compounds investigated
and these are presented as peaks (also called resonances); MR spectra is with long
and short TE is illustrated in Figure 22. Obtaining good quality spectra is not easy
and certain technical requirements need to be fulfilled. Shim procedures represent
one of the major challenges in clinical MRS, as the separation of resonances requires
a field homogeneity exceeding standards known from conventional MRI. A
heterogeneous magnetic field leads to resonance frequency dispersion, spreading
out the peaks or even causing them to disappear into the background noise. Prior to
any MRS acquisition, the magnetic field is homogenized (shimming) in the region of
interest. The bigger the region, the harder it is to homogenize the magnetic field
throughout. Close to bone, calcifications, hemorrhagic zones or air filled cavities,
spectroscopic quality will be poorer due to disruption in the field caused by the
differences in magnetic susceptibility compared to soft tissue. The precession
frequency of the water must be optimized to adequately suppress the water peak,
using selective frequency pulses and dephasing gradients. The other problem with
MRS concerns the weak signal-to-noise ratio. This entails multiplying the number of
measurements and limits spatial resolution. Spectrum quality is evaluated
according to two main criteria: signal-to-noise ratio (height of metabolite peaks in
relation to background noise) and spectral resolution (peak width, which
determines whether the different metabolites can be separated).
Spectral resolution will depend on the homogeneity of the magnetic field B0 and on
digital resolution, i.e. the precision with which the signal is sampled, determined
according to sampling time and the total number of points measured.
Evaluation of metabolite concentration
The accuracy of the metabolite concentration depends on the approach used for data
quantification. Generally, the spectrum is evaluated by measuring the area under
the metabolite signal peak. This can be done by numerical integration of metabolite
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peaks or by using sophisticated tools which perform a nonlinear fit of the entire
spectrum. Depending on the tool, it can be done off line (Naressi et al., 2001) or
online on the scanner console (Provencher 1993). All methods report signal
intensities that are proportional to the metabolite concentrations in the studied
volume of interest. Conversion of these hardware specific units to absolute
concentrations is not simple and requires a set of correction factors which are
dependant on the pulse sequence used, hardware parameters like signal
amplification and coil loading, relaxation times (Tl, T2) of the metabolites as well as
fraction of gray, white matter and CSF in the volume of interest (VOI). Hardware
parameters can be corrected for by using either "phantom replacement method"
(Michaelis et al., 1993)or scaling relative to the water signal (Barker et al., 1993).
The absolute concentration method is rather cumbersome and not practical for
clinical use. The semi quantitative method is much easier to use in the acute setting
and the correction for hardware sensitivity can easily be applied.
Also of note is that spectroscopic data are prone to artifacts. If the data are
visualised as metabolite maps it is important to be aware of the method used to
calculate the maps; are they based on a simple integration of marked metabolite
specific regions or on fitting of the spectra. It is also important to be aware of the
processing steps involved such as baseline correction or frequency correction before
final signal analysis. All these will affect metabolite concentration but cannot be
properly evaluated just by looking at the metabolite map. Careful inspection of the
entire spectrum is required in order to exclude artifacts, which may have caused
apparent concentration change. Lactate metabolite maps are prone to contamination
by lipids (from skull base, vault, and orbits) which can be misleadingly interpreted
as lactate. If the spectra are carefully analysed, lactate can be distinguished from
lipids by its unique doublet signal (two peaks of identical intensity separated by 7.4
Hz) which may be inverted at an ECHO time of 144ms.
The 1H MRS spectrum
The metabolites that can be measured in the brain give rise to different measurable
peaks. A change in the resonance intensity of these peaks represents a change in the
concentration of the compound.
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During the acquisition with long TE the only measurable metabolites are N acetyl
aspartate (NAA), creatine (Cr)/phosphocreatin (PCr) and choline (Cho) in normal
brain. Lactate is measured during anaerobic metabolism. The acquisition with
shorter TE reduces the effect of signal loss due to T2 relaxation and therefore
provides spectra with increased signal to noise. In the normal brain, it detects
resonances from metabolites with complex MR spectra such as myo-inositol,
glutamate, glutamine, and lipids. In addition it also detects succinate, acetate, amino
acids acetoacetate, acetone, manitol and ethanol which are not usually detected in
the normal brain. The problem with short TE is that in addition to providing more
information on metabolites it also includes a broad background signal consisting of
low concentration metabolites and macromolecules and lipids with short T2
relaxation times. This complex picture therefore increases the difficulty of accurate
peak area estimation.
Figure 22.Proton spectra of the human brain recorded at both (a,b) long (TE 272) and c)
short (TE 35ms) TEs, in the long TE spectra from a patient with an acute right middle
cerebral artery (MCA) stroke, the normal spectrum (a) from the left hemisphere shows signs
from Choline (Cho), Cretine (Cr) and N-acetyl aspartate (NAA). In the short TE spectrum
of normal frontal WM (c), in addition to NAA, Crand Cho, signals can be detected from
myo-inositol (ml), Glutamate and Glutamine (Glx), and lipids, (a) and (b) are from a multi-
slice MR spectroscopic imaging (MRSI) data set(normal voxel size 0.8cm3), while (c) is




ppm 4.0 3.0 2.0 1.0
Figure reproduced from P. Barker, Fundamentals of MR spectroscopy in Clinical MR Imaging
(Gillard ] H et al.,2004)
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For the purpose of this thesis I will discuss the metabolites measured in this study at
long TE: NAA, Choline, Creatine and lactate.
N acetyl aspartate (NAA)
NAA is found in very high concentrations in the human brain and gives powerful
signal when examined with water suppressed proton magnetic resonance
spectroscopy (H MRS). The methyl group of NAA resonates at 2.01 ppm producing
a large sharp peak. It is second only to glutamate in terms of free amino acid
concentrations. The "NAA" signal includes smaller contributions from other
acetylated compounds, such as from the neuron-specific dipeptide, N-
acetylaspartylglutamate (NAAG)(Caramanos et al., 2005), N- acetylneuraminic acid
(Varho et al., 1999), and underlying coupled resonances of glutamate and glutamine.
NAA was initially described by Tallan (Tallan et al., 1956;Tallan 1957) but to date,
the precise function of NAA is still debated. Various roles have been assigned to
NAA in the function of the brain; from being a source of acetyl groups for lipid
synthesis, a storage form of acetyl-CoA or aspartate, a breakdown product of
NAAG, a regulator of protein synthesis, "molecular water pump" or an osmolyte
(Barker 2001). However, NAA is often thought of as a "marker of intact neurons" in
the literature on brain imaging in stroke. Immunocytochemical techniques suggest
that NAA is mostly localised in the neurons, axons and dendrites of the central
nervous system (Simmons et al., 1991). Levels of NAA are reduced or absent in a
number of diseases that cause neuronal and or axonal loss such as multiple sclerosis
(DeStefano N. et al., 2001), tumour (Goebell et al., 2006) or stroke (Saunders et al.,
1995,'Wild et al., 2000). NAA's place as a neuronal marker is not completely certain
yet. There are reports of NAA being detected in other types of cells such as
oligodendrocyte type II astrocyte progenitor cells in rats (Urenjak et al., 1993), but
these cells represent only a small proportion of human glial cells (Wolswijk et al.,
1991). Also, NAA was identified in mast cells and oligodendroglial preparations
(Bhakoo and Pearce 2000) but this work so far has been in vitro and not reproduced
in vivo. For now, NAA seems to be the best available marker of neuronal integrity
available that can be measured non-invasively.
NAA changes in ischaemic stroke have been discussed in the systematic review
(chapter 2) and in the results chapters 4, 5, and 6.
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Choline (Cho)
The choline signal resonates at 3.24 ppm and arises from several compounds:
glycerophosphocholine, phosphocholine, and a small amount of free choline which
is involved in membrane synthesis and degradation. It is often thought of as a
marker of membrane damage. In stroke, early studies reported no significant
changes in choline concentrations in the ischemic lesion (Fenstermacher and
Narayana 1990), but other studies found either an increase (Graham et al.,
1992;Sappey-Marinier et al., 1992) or a decrease in choline levels (Duijn et al.,
1992;Lanfermann et al., 1995)in stroke lesions. Changes in choline levels have been
also reported in other pathological processes such as multiple sclerosis where levels
are increased during active disease (Davie et al., 1993)as well as diabetic ketoacidosis
(Kreis and Ross 1992), and hepatic encephalopathy where levels are decreased
(Kreis et al., 1992).
Creatine
This is a composite signal coming from the two main compounds involved in
energy metabolism, creatine and phosphocreatine. Both compounds have signals
that resonate at 3.94 ppm (methylene singlet) and 3.03 ppm (methyl singlet). It is
impossible to distinguish between the two on MRSI and therefore total
creatine /phosphocreatine signal is measured by MRSI. In events such as ischemia,
creatine concentration varies with the anaerobic tissue conditions and there is a
general decrease in the concentration of creatine in the ischemic lesion (Duijn et
al.,1992;Lanfermann et al.,1995). Creatine levels also vary in other brain disorders
most of them related to enzyme deficiencies leading to either lack of production or
defective transport to the brain (Bizzi et al., 2002). Creatine is present in both
neurons and glial cells (Urenjak et al.,1993;Wolswijk et al.,1991).
Lactate
Lactate signal resonates at 1.33 ppm as a doublet. Lactate is not "usually" present in
normal human brain. It is produced as a result of anaerobic metabolism, as the end
product of glycolysis. When the glycolytic rate exceeds the tissue's capacity to
catabolise it or remove it from the blood stream, the concentration of lactate will
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rise. Increased lactate has been observed in acute (Gideon et al., 1992;Graham et al.,
1993;Munoz Maniega et al., 2008) and chronic stroke (Munoz Maniega et
al.,2008;Saunders et al.,1995) as well as other conditions such as brain tumours.
Small amounts of lactate can be detected in the cerebrospinal fluid (CSF) of normal
ageing brain(Sijens et al., 2001). Changes in lactate in acute stroke are further
discussed in the systematic review chapter and the results chapters.
Pathophysiological processes visualised by MRSI
Early ischaemic changes can be visualised by using MR diffusion and perfusion
imaging but neither of these methods are able to record pathophysiological
processes that happen between reduction in blood flow and cell swelling. MRS,
however can offer some insight in to pathophysiological events in that critical
period following arterial occlusion.
The cascades of events after the arterial occlusion are described earlier in this
chapter. Oxygen depletion will induce anaerobic glycolysis, which in turn will cause
lactate production, leading to lactate accumulation especially in the presence of
hypoperfusion. Lactate accumulation and persisting lack of glucose and oxygen
supply will lead to drop in ATP and pH, both of which can be measured by 31 P
MRS. Drop in ATP will lead to failure of Na+-K+ ATPase activity and influx of Na+
ions which can be monitored by 23Na MRS (Hilal et al., 1983). Influx of Na will lead
to development of cytotoxic oedema which can be visualised by DWI. Once
neuronal death ensues, monitoring of NAA as a neuronal marker can provide
information on viable neurons. There is a considerable overlap between these stages
that can be measured by MRSI Figure 23. Whilst it is relatively easy to include
HMRS into acute stroke protocol that is not the case for 31P which requires further
equipment. 23Na MRS has not been studied in humans.
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Figure adapted from von Kummer R (von Kummer R and Back T2006)
Application of MRSI in clinical practise
Although H MRSI is relatively fast technique in comparison to 31P spectroscopy, it is
still not "fast enough" for a routine use in clinical practice especially in the acutely
ill stroke patients. The acquisition time of the MRSI spectra can be as fast as 6
minutes (Stengel et alv2004), but it still requires significant time for the data
processing and would not facilitate immediate decision making in the treatment of
acute stroke. Magnetic resonance spectroscopy in stroke is further discussed in the
systematic review chapter 2.
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Chapter 2: Spectroscopy in the last 20 years - literature
review
In the previous chapter I have described the anatomy and pathophysiological
processes relevant to the patients in this study. I have also described all of the
imaging sequences used to study this population.
In this chapter, I will discuss the evidence and findings from spectroscopic imaging
in human stroke, especially in relation to diffusion and perfusion imaging.
2.1 Background
Recent advances in neuroimaging and development of new techniques, such as
diffusion and perfusion imaging, have raised hopes of quickly and accurately
identifying tissue at risk in the acute ischaemic stroke. This, in turn, would help
identify patients who would benefit the most from the acute stroke treatments.
However, no consistent perfusion threshold has so far distinguished dead from
salvageable tissue reliably.
Proton magnetic resonance spectroscopy (MRS) is a non-invasive in-vivo method
which is used to visualise metabolic abnormalities in the brain. MRS can potentially
lead to better understanding of the pathophysiology of the ischaemic stroke, which
helps us target potentially dangerous treatments more appropriately, thus reducing
the risk of side effects. MRS has evolved from being a very slow method, covering
only a limited area of the brain with often poor signal to noise ratio (and therefore
not practical to be used in the every day clinical practice), to a much more efficient
technique (data can be acquired within six minutes) which covers one or more slices
of brain. This increases the chances of performing spectroscopic imaging in acutely
ill stroke patients (although not always possible) and has the potential to help us
unravel the metabolic changes in acute stroke which might increase detection of
dead versus at risk tissue.
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2.2 Aim and methods
One of the aims of this review is to determine whether the data published so far is
sufficient to establish the role of MRS technique in every day clinical practice. In
addition, it examines what information there is on the levels and the distribution of
metabolites in the acute stroke and their temporal evolution, as well as the
relationship of metabolite levels with blood flow, diffusion imaging (DWI) and final
outcome.
2.2.1 Methods
The review was conducted according to the methods used by the Cochrane
Database of Systematic Reviews.
Search strategy
An electronic search of all published records of MR Spectroscopy in stroke was
preformed using the electronic databases MEDLINE and EMBASE from 1980 to
2009. Reference lists of the relevant articles were also checked manually (see
Appendix 1 for the search strategy).
Selection criteria
All prospective and retrospective studies that had well defined population group
with ischaemic stroke were included. Other types of stroke were excluded. Only
original articles were selected. Case reports and studies that appeared only in
abstract form were excluded. All patients had Proton magnetic resonance
spectroscopy (HMRS) in addition to any other imaging (data on phosphorus (P),
sodium (Na) and carbon (C) spectroscopy was not collected). Only data on humans
with stroke were included.
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Data extracted:
• Main purpose of the study
• Stroke severity / subtype
• How the diagnosis of stroke was made and by whom
• Time from onset / diagnosis to scanning was recorded and any follow up that
has been arranged. If no arranged follow up, then timing of any follow up
was noted and its range
• Outcome data if available
• Relationship of MRS findings to clinical outcome (short or long term)
• Relationship of MRS to other imaging modalities such as DWI/ PI
• Metabolites measured and change in metabolite concentration if followed up
• Image analysis (whether the reader was blinded to clinical data and other
imaging modalities).
For each trial, the number of patients was recorded including their age and sex.
Quality score (based on type of the study, blinding to image analysis and final otitcome,
systematic follow up, who made the diagnosis, validated spectroscopy technique and
description ofpatient population) was applied to each paper. (Appendix 2)
The studies selected for the review were subdivided according to the time from
onset to the imaging. The times were specified as follows; Acute stroke (within 24
hours of onset), subacute stage (mean time less then one week but included patients
within first 24 hours from the onset of symptoms), subacute stage (mean time
around one week but did not include the patients within first 24 hours of onset) and
the chronic stage (included patients with strokes older then 1 month).
The studies that investigated the time course of metabolites were subdivided in to
those that followed the patients up from onset to three months and those that
followed them up longer (up to 17 months). In addition studies were also divided in
to those that investigated the core of the lesion and the area around it, also studies
that compared the metabolites to the blood flow and diffusion imaging and the final
outcome. The rationale for this subdivision of the studies in this way was due to




The initial search identified 2985 articles using systematic search strategy. After
excluding animal studies, reviews, case reports, studies that did not measure
metabolites within the stroke lesion and non-English language publications, there
were 39 original papers (761 patients) included. Some of the patients were possibly
included twice (separate publications by the same author analysing data in a
different way) therefore the actual number of unique patients is fewer (Graham et
al., 1995).
2.2.3 Studies quality
Only two studies met all the quality criteria (Parsons et al., 2002f;Wardlaw et al.,
1998). Another six studies met at least 5/7 criteria (Federico et al., 1996; Federico et
al., 1998; Lemesle et al., 2000; Liu et al., 2003; Parsons et al., 2000; Pereira et al., 1999).
Only one study was retrospective (Graham et al.,1995). Flowever, due to different
study designs, not all the quality criteria were necessarily applicable to all the
studies. Design of the studies varied enormously. Initial studies were usually very
small or even case reports, mostly concentrating on the feasibility of the technique in
the acute setting, but also reporting the findings of MRS. Some of the larger studies
looked at the possibility of predicting the outcome by using metabolites, either with
or without combining other MR sequences. Several studies used different ways of
measuring blood flow and only eight studies, in addition to conventional MR
imaging, also used DWI sequence. I have reported all the data available on N Acetyl
aspartate (NAA) and lactate and their relation to the acute lesion as shown on T2 or
DWI, blood flow and outcome.
2.3 N-Acetyl Aspartate (NAA)
It is widely accepted that NAA is a marker of intact neurons (see Chapterl) as
suggested by the balance of evidence. When the tissue NAA content is reduced it is
suggestive of neuronal or axonal loss. Therefore, in stroke, NAA can be used as a
surrogate marker for neuronal function and integrity and, if temporal
measurements available, a degree of stroke progression and severity. All studies
64
that measured NAA were categorised according to timing and then the time course
if available was reviewed.
2.3.1 NAA levels within the stroke lesion
Although quite a few studies investigated "acute" stroke, timing of the scans from
the onset of symptoms were widely varied. Only seven studies included patients
before 24 hours. Significant number of studies included patients from the onset up
to a week in the acute stroke group.
2.3.2 NAA within 24 hours
Seven studies (73 patients in total) measured the metabolites in patients within 24
hours (Felber et al., 1992; Gillard et al., 1996; Labelle et al., 2001; Liu et al.,2003; Nicoli
et al., 2003; Parsons et al.,2000; Stengel et al., 2004). The studies had different aims;
using metabolites to estimate prognosis (Parsons et al.,2000), to diagnose acute and
chronic stroke (Felber et al.,1992), exploratory (Barker et al., 1994; Gillard et al.,1996;
Stengel et al.,2004), examining pathophysiological processes in acute stroke (Liu et
al.,2003;Labelle et al.,2001) and comparison to other imaging (Nicoli et al.,2003). Half
of the studies measured metabolites from a single voxel placed within the lesion and
the other half used a CSI technique (Tablel). Also, most studies (six of them) used a
ratio to express the concentration of NAA with denominators including: choline (2),
creatine (1), contralateral normal (2), sum of metabolites in the acute lesion (1) and
one used absolute metabolite (Table 1). The prognostic study did not comment on
the ratio of NAA to Choline but only looked at its prognostic value and neither did
comparative study, but expressed the result as a correlation, therefore no actual
metabolite values were reported. Interestingly, two studies that use the ratio to
contralateral side report exactly the same reduction in NAA in the stroke lesion with
a ratio of 6.3. All studies agreed that NAA was reduced within the lesion as
visualised on T2 and DWI, in the first 24 hours measured either by the ratio or
absolute values.
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2.3.3 NAA within the lesion in the first week from stroke
Fourteen studies measured metabolites in the patients from onset (within hours) up
to maximum of 1 week (Federico et al.,1996; Federico et ah,1998; Gideon et ah, 1992;
Gideon et ah, 1994; Graham et ah, 1993; Floukin et ah, 1993; Lauriero et ah, 1996;
Lemesle et al.,2000; Pereira et al.,1999; Rumpel et ah, 2001; Saunders et ah, 1995;
Stengel et al.,2004; Wardlaw et al.,1998; Wild et ah, 2000). Although some of these
studies measured NAA within 24 hours of onset of symptoms, it was not possible to
group them in to the category of <24 hours as all the data was analysed together
including the patients at later times.
The aims of the studies were different; assessing contribution of metabolites to
estimate prognosis (5), measuring the longitudinal changes in metabolites (4),
comparative to other imaging parameters (4) and the feasibility of the technique (1).
For the method of acquiring spectroscopy data and the way the results were
expressed see Table 2. All of the studies show reduction of NAA within the lesion.
Two studies did not report actual values but commented on NAA reduction and
reported the association with outcome. Twelve studies reported numerical values,
eight as a ratio and four as an absolute value. The four studies that used ratio of
NAA to contralateral side had the results ranging from 0.42 - 0.51. It is difficult to
compare this to the other ratios that were done to a different standard (eg water),
choline and/or creatine (see Table 2). The studies that reported absolute values
(although they may not be necessarily comparable) range from 2.8-8.9 (for the units
see Table 2). These levels of NAA appear lower then the studies that reported the
NAA level within 24 hours from the onset of symptoms although the methods used
to quantify the NAA may have differed. All studies commented that the reduction






































































































































2.3.4 NAA within the lesion in the first two weeks from stroke
Five of the studies measured NAA from onset up to 2 weeks, including a total of 89
patients (one patient was scanned at 19 days) (Graham et al., 1992; Graham et
al.,1995; Graham et al., 2001; Marshall and Sellar 1994; Mathews et ah, 1995). The
studies had different aims and the majority were single voxel spectroscopy
acuisition (see table 3). The three studies that reported actual values were expressed
as a ratio to the contralateral side. The values ranged from 0.21-0.62. The bottom
value of the range is smaller then the previous category, but overall the values are
quite similar.The other two studies measured NAA value in absolute units, but only

















































2.3.5 NAA within the lesion from one day to six weeks
Only three studies measured metabolites between one day and 42 days (Demougeot
et ah, 2002; Fenstermacher and Narayana 1990; Lanfermann et at., 1995). None of the
three studies included patients within 24 hours. The studies had a similar aim,
mostly exploring the ischaemic lesion with spectroscopy (Table 4). Two studies used
CSI method for data acquisition and one of the studies was single voxel. Two
studies reported the ratio of NAA either to contralateral side or to choline. However
one study did not report numerical value but reduction in NAA within the lesion, as
defined on T2 weighted MRI. The values of NAA (ratio to contralateral side) were
from 0.2 - 0.73 in the large and small infarcts respectively. The range of these values
is similar to the previous category that measured NAA up to two weeks. In the


































2.3.6 NAA within the lesion in the chronic stage (mean of one to fifteen
months)
Chronic stage for the purpose of grouping the data was defined from one month
onward. Only six studies included patients at the chronic stage (Duijn et al., 1992;
Felber et al.,1992; Kamada et al., 1997b; Ford et al., 1992; Kamada et al., 1997a;
Sappey-Marinier et al., 1992). Some of the studies at the chronic stage are part of
evaluation of metabolite change over time, but the actual values of the metabolites
in the chronic stage will also be discussed in this section.
Four studies included patients over a year since the onset of stroke (Table 5). They
show that NAA is present within the lesion, but reduced compared to the
contralateral side. Only one study had patients with a completely absent NAA. All
studies reported the result as a ratio but only three used a ratio to the contralateral
side. The ranges of values were from 0.23-0.63. It is not possible to analyse the data



































































2.3.7 NAA outside the MRI visible lesion
A number of studies had a specific aim to investigate the distribution of metabolites
in the core of the lesion, as defined on T2 or DWI, and around it whilst others noted
the varied distribution as part of a different aim (see Table 6). All together, seven
studies investigated metabolites across the stroke lesion and around it (Gideon et
al.,1992; Wild et al.,2000; Gillard et al.,1996; Stengel et al.,2004; Labelle et al.,2001;
Demougeot et al.,2002; Kamada et al.,1997b).
The majority of the patients were recruited within 24 hours, two studies having the
mean time of 1.8 and 7.9 days and one study with more chronic strokes of a mean of
29.2 days. All together there were 83 patients in the studies. Only two studies used
diffusion weighted imaging for visualising the lesion (Labelle et al.,2001; Stengel et
al.,2004). Both studies recruited patients within 24 hours but in both studies the
NAA levels were similar within and outside the DWI lesion.
Five studies found only minimal reduction in NAA outside the T2 lesion. Only one
study by Demougeot (that included patients at the considerably later time point)
showed more significant reduction outside the T2 abnormality compared to
contralateral normal tissue (but still significantly higher then within the T2 core
lesion). The study by Kamada that also included more chronic patients gave no
numerical data but commented that NAA outside the lesion was slightly reduced.
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2.3.8 Time course of NAA
Out of 37 studies of MRS in stroke, 19 looked at the time course of metabolites,
either as primary or secondary aim. Only a few studies had predetermined time
follow up points, but frequently did not manage to recruit in all pre set time points.
Often, the metabolites reported were from different patients scanned at different
time points.
The studies were grouped in to those with short and intermediate follow up (mainly
up to a month and 3 months), and long term (up to a year or longer). I have
excluded one study from this discussion at the outset, as the data on NAA was not
presented in the right format due to different aim of the study (Parsons et al.,2000).
Time course of NAA from onset to three months
Nine studies (114 patients) followed the NAA from onset up to three months
(Lanfermann et al.,1995; Gideon et al.,1992; Houkin et al.,1993; Graham et al.,1993;
Saunders et al.,1995; Wardlaw et al.,1998; Liu et al.,2003; Labelle et al.,2001;
Fenstermacher and Narayanal990). One study only followed the patients up for 10
days (Rumpel et al.,2001).
All of the studies show initial reduction in NAA. There seemed to be at least two
temporal patterns. Although the timing of the second scan is varied, it seems that
the majority of the reduction in NAA happened after the first 24 to 52 hours, and
then a further reduction occurred up to a week. One study that scanned patients
frequently in the first week noted reduction in the first two days, but then further
reduction on day three and four. A similar pattern is seen in one study that followed
the patients up for 10 days only. None of the studies showed recovery of NAA up to
a month, and in one study that followed patients up to three months, there was a
partial recovery of NAA in 2/7 patients. Extrapolating slightly from the data, it is
possible that NAA falls markedly after hyperacute phase, 24-48 hours. It then
continues to fall up to a week but at a slower rate.
The second pattern is more varied and shows all three possible variations with
increase, decrease and no change in the level of NAA; in one study the initial scan
was performed within the first four days, but it is not clear if the subsequent
78
measurements were taken at 5-10 days or 10-31 days. Finally, one study showed
partial recovery of NAA in the period of three weeks to two months (see Table 7).
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Long term temporal variation of NAA
Ten studies measured metabolites from the acute or subacute stage right through to
the chronic stage (from three months to over a year, and in some cases several years)
(Federico et al.,1996; Federico et ah,1998; Felber et ah,1992; Ford et ah,1992; Gideon
et al.,1994; Graham et al.,1992; Graham et al.,2001; Lauriero et al.,1996; Rutgers et al.,
2000; Walker et al., 2004). All 10 studies confirmed the variability of NAA and
several possible patterns; levels staying the same as in subacute stage, further
declining or in some cases increasing as well as increasing and declining again. Five
out of 10 studies concluded that the levels stay the same as in subacute stage; three
studies show gradual increase and recovery after three months. Two studies
described both trends with some patients continuing to decline and others partially
recovering. Only one patient showed temporary increase and then decline in NAA.
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2.3.9 NAA and lesion size
All the studies that measured lesion size (either DWI or T2) found correlation
between reduced levels of NAA and increasing lesion size.
NAA in relation to final outcome and comparison to other imaging will be
discussed together with lactate in section 2.4.
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2.4 Lactate
Lactate is not "usually" present in normal human brain but there is some evidence
that small amounts can be detected in the ageing brain (Sijens et al., 2001), and in the
cerebrospinal fluid (CSF) of normal subjects.
It is generally accepted that lactate is produced as a result of anaerobic glycolysis.
The concentration of lactate rises when the production exceeds the tissue capacity to
catabolise it or remove it from the blood stream. Lactate has been demonstrated by
HMRS at the various stages of brain ischaemia, early and late. Removal of lactate
depends on number of factors such as tissue perfusion, the permeability of the
blood brain barrier and the diffusion of the metabolites through the damaged tissue.
Various studies recorded lactate at different stages of ischaemia and also looked in
to the predictive value of lactate in the stroke.
2.4.1 Lactate within acute stroke lesion within 24 hours of onset
Eight studies, including 95 patients in total, measured lactate within the lesion in the
first 24 hours from onset (Felber et al.,1992; Gillard et al.,1996; Labelle et al.,2001; Liu
et al.,2003; Nicoli et al.,2003; Parsons et al.,2000; Parsons et al., 2002a; Stengel et
al.,2004). For the type of measurement and result reporting see Table 9. All 95
patients had lactate present at this stage.
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2.4.2 Lactate within the lesion in the first week from stroke
Eleven studies with a total of 224 patients measured lactate from onset (within
hours) up to maximum of 1 week (Federico et al.,1996; Federico et al., 1998; Gideon
et al.,1992; Gideon et al.,1994; Graham et al.,1993; Houkin et al.,1993; Lauriero et
al.,1996; Lemesle et al.,2000; Pereira et al.,1999;Rumpel et al.,2001; Saunders et
al.,1995; Stengel et al.,2004; Wardlaw et al.,1998; Wild et al.,2000). Although some of
these studies mesured lactate within 24 hours of onset of symptoms, as before, it
was not possible to group them in to the category of <24 hours hours as all the data
was analysed together including the patients at later times.
The aims of the studies were different; assessing contribution of metabolites to
estimate prognosis (5), measuring the longitudinal changes in metabolites (4),
comparative to other imaging parameters (2). For the method of acquiring
spectroscopy data and the way the results were expressed see Table 10.
In most patients lactate was present; but not all and lactate levels varied widely.
Five studies did not report the results as a numerical value. The studies that
expressed the result as a ratio used different denominators and cannot be compared.
Only a couple of studies used absolute values and ranged from 16.6-24.3. Some of
the studies looked at the outcome in relation to lactate (to be discussed later).
Houkin found lactate increased immediately and the maximum level of lactate was
reached in 48 hours. Also, in another study by Federico, seven out of 26 patients did
not have lactate present (three of them were scanned on days one and three and the
others on days five and seven).
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2.4.3 Lactate within the lesion in the first two weeks from stroke
Five studies measured lactate from onset up to 2 weeks, including a total of 89
patients (one patient was scanned at 19 days) (Graham et al.,1992; Graham et
alv1995; Graham et al.,2001; Marshall and Sellarl994; Mathews et alv1995). The
studies had different aims and the majority were single voxel spectroscopy
acquisition (see Table 11).
The lactate was absent in four patients. Two studies reported the result as a ratio to
NAA and the values were very similar at 1.26 and 1.3. The absolute values were 7.5
and 12 and also reported only in two studies. These overall seem to be smaller then
the values of lactate in the first week from stroke.
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2.4.4 Lactate within the lesion from one day to six weeks
Only three studies measured lactate between one day and 42 days (Demougeot et
al.,2002; Fenstermacher and Narayanal990; Lanfermann et al.,1995). None of the
three studies included patients within 24 hours. The studies had a similar aim,
mostly exploring the ischaemic lesion with spectroscopy (Table 12). Two studies
used CSI method for data acquisition and one of the studies was single voxel. Two
studies reported the ratio of lactate to contralateral choline. The ratio ranged from
0.54 in a small lesion to 1.31 in the large lesion and up to 1.7 in the second study.
One study did not report numerical value but presence of lactate within the lesion
as defined on T2 weighted MRI in 50% of the patients.
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2.4.5 Lactate in the chronic stage
As mentioned with NAA, chronic stage for the purpose of grouping the data was
defined from one month onward. Only six studies included patients at the chronic
stage (Duijn et al.,1992; Felber et al.,1992; Ford et ah, 1992; Kamada et al., 1997b;
Kamada et al.,1997a; Sappey-Marinier et al.,1992). The aims of the studies and the
type of MRS are presented in Table 13. The studies included a total of 60 patients.
Four studies included patients over a year since the onset of stroke. Only four
patients did not have lactate present in the chronic stage from only one study.
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2.4.6 Lactate outside visible lesion on MRI
Five studies measured lactate outside the visible lesion on MRI (as seen on diffusion
or T2)(Demougeot et al.,2002; Gillard et al.,1996; Kamada et al.,1997b; Labelle et
al.,2001; Stengel et al.,2004) (see Table 14). All of the studies showed higher levels of
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2.4.7 Time course of lactate
As with NAA, a number of studies investigated time course of lactate. To facilitate
the data interrogation, the studies were split into two groups: those that measured
metabolites up to three months and those that took measurements over the longer
period.
In the first group there were 12 studies that measured lactate (Fenstermacher and
Narayanal990; Gideon et ah,1992; Graham et alv1993; Houkin et al.,1993; Labelle et
al.,2001; Lanfermann et al.,1995; Lauriero et al.,1996; Liu et al.,2003; Parsons et al.,
2002a; Saunders et al.,1995;Wardlaw et al.,1998). Further details about these studies
can be found in table 10. In total, 167 patients were followed up for temporal
variaton of lactate. It is not clear how many patients did not have lactate at follow
up measurement (at least 9). Where lactate was present at the initial measurement,
levels decreased gradually, but there is no clear indication of the rate of reduction. It
appears that at some point between 10 -30, days lactate levels fall to a very low level,
but stay detectable at that level thereafter.
Eight studies measured lactate in the period longer then three months (Federico et
al.,1996; Federico et al.,1998; Felber et al.,1992; Ford et al.,1992; Gideon et al.,1992;
Gideon et al.,1994; Graham et al.,2001; Rutgers et al.,2000). In total, the studies
included 123 patients, but one study that scanned patients in the first six months,
rather then acutely, contributed 50 patients. 23 of these patients did not have any
lactate detected at the follow up. Overall, the trend was of gradual decline and
presence of low level lactate at the later stages. There was no indication of any
factors that might be associated with persistance of lactate (eg appearance of lesion,
age of patient, evidence of ongoing inflamation) although the number of patients
was probably too few to give meaningful result.
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3.1 Comparison of metabolites to blood flow imaging
Eleven studies assessed the adequacy of the blood flow in the lesion in some way
(Gideon et al., 1992; Gideon et alv1994; Gillard et al.,1996; Graham et al.,1995;
Henriksen et al., 1992; Houkin et al.,1993; Kamada et al.,1997a; Lauriero et al.,1996;
Lemesle et al.,2000; Liu et al.,2003; Wardlaw et al.,1998). The methods varied from
formal angiography being most invasive, MR angiography (MRA), SPECT and
trans cranial Doppler ultrasound (TCD). The reason for measurement were varied,
from investigating the aetiology of stroke, finding an occluded vessel to actually
looking at the relationship between blood flow and metabolites.
Hoewer 5/11 studies gave no data on the blood flow measurements. In studies that
did present the blood flow measurement data, SPECT was the most frequently used
imaging method (five studies), followed by MR relative cerebral blood flow (rCBF)
(two studies) and MR angiography (two studies) and finally, one study measured
the blood flow with TCD and one study performed carotid Dopplers ultrasound.
All three studies that reported SPECT results showed reduction of blood flow in the
acute phase (day one), slight increase at day seven, and hyperemia at subacute
stage. One study quantified blood flow as 51% day one, 94% day seven and 125%
day 14 -28 (Gideon et al.,1992). Only one of the three studies measured the blood
flow with SPECT beyond a month. This study showed reduction of blood flow
similar to the acute level when measured from 7-17 months from onset.
Lauriero tried to correlate metabolites with blood flow and showed a correlation
between rCBF and NAA at < 3 days from onset (Spearman r=0.73), but this was lost
in the hyperemic stage. Chronic (up to three months) rCBF reduction also correlated
with NAA level. The other two studies did not specifically look at the metabolites
and blood flow. In both studies NAA levels fell and lactate was increased in the
acute stage whilst rCBF was reduced. In one of the studies, in the hyperemic stage,
NAA remained low; in the other, one half continued to reduce whilst the other half
had a degree of recovery in NAA level. The lactate was elevated in the acute stage
but then either dissapeared in the hyperemic stage or stayed present in a few
patients at a reduced level.
Only two other studies reported relationship between rCBF and rCBV and
metabolites. Henriksen showed an inverse relationship between lactate and rCBF in
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the third week, whilst Liu showed a similar pattern as with SPECT, with reduced
rCBV being low at the acute stage, and reaching peak values at the early chronic
stage. NAA did not follow the same pattern; after a reduction in the acute stage,
there was a complete loss after four days. There were also differences between
territorial and watershed infarcts. The above described pattern was followed in
territorial infarcts, whilst watershed infarcts had consistently high rCBV, with NAA
present at one month and lactate levels generaly lower than in territorial infarcts.
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3.2 Relationship of metabolites to diffusion imaging
Only eight studies measured metabolites within the diffusion weighted (DWI)
lesion or apparent diffusion coefficient (ADC) lesion (Labelle et al.,2001; Liu et
al.,2003; Nicoli et al.,2003; Parsons et ah,2000; Parsons et al., 2002; Rumpel et ah,2001;
Stengel et ah,2004; Walker et ah,2004). Only three studies investigated the
correlation between ADC levels and metabolites. Rumpel found close correlation
between ADC and creatine and two different patterns of reduction in NAA, but did
not correlate NAA or lactate with ADC. Labelle found no correlation between
metabolites and ADC, either acutely or in the chronic stage. Finally Nicoli, who
investigated the ADC lesion, looked at the ratio of lactate and NAA to the sum of
metabolites (sum) and found significant correlation between NAA/sum and
lact/ sum and ADC. However, the number of patients in this study was tiny (see
Table 18).
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3.3 Relationship of metabolites to the lesion volume
Thirteen studies in total measured lesion volume but only eight commented on their
relationship with metabolites in any way (Federico et al.,1996; Graham et alv1993;
Graham et al.,1995; Lemesle et al.,2000; Parsons et al.,2000; Pereira et al.,1999;
Wardlaw et al.,1998) (see Table 19). Three of the stuides correlated lactate with a
larger infarcts but there was no influence on outcome. Two studies corelated
reduction in NAA with larger infarct volume. Three of the stuides did not correlate
NAA or lactate with infarct size but discussed reduction in NAA and increase in
infarct size as a predicor of poor outcome see Table 19.
A further five studies measured lesion volume but gave no correlation with
metabolites (Duijn et al.,1992; Gideon et al.,1992; Lanfermann et al.,1995; Liu et
al.,2003; Parsons et al., 2002; Stengel et al.,2004). The study by Parsons had a rather
different aim and he looked at the progression of the mismatch area whilst Liu
compared volumes of watershed and territorial infarctions and their progression
with time
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3.4 Relationship to the final clinical outcome
Thirteen studies in total looked at the correlation between metabolites and clinical
outcome including a total of 322 patients (Federico et al.,1996; Federico et al.,1998;
Ford et al.,1992; Gideon et al.,1994; Graham et ah,1993; Graham et al.,1995; Kamada
et al.,1997b; Lemesle et ah,2000; Parsons et al.,2000; Parsons et al., 2002; Pendlebury
et al., 1999; Pereira et al.,1999; Wardlaw et al.,1998).
Six studies found that better preserved NAA was associated with better functional
outcome but no association between lactate and clinical outcome(see Table 20).
Three studies found that elevated lactate correlated with functional outcome but not
NAA (see Table 20). One study found that both NAA and lactate correlated with
outcome. In one of the studies, lactate did not correlate with clinical outcome but
did correlate with the lesion volume. Two studies found no correlation between any
of the metabolites and clinical outcome (see Table 20).
It is important to note that none of the studies recruited patients within 24 hours of
onset. The majority of studies recruited patients within a week of stroke onset
(Federico et al.,1996; Federico et al.,1998; Gideon et al.,1994; Graham et al.,1993;
Graham et al.,2001; Lemesle et al.,2000; Pereira et al.,1999; Wardlaw et al.,1998), two
studies recruited within a month (Graham et al.,1995; Parsons et al.,2000), and two
recruited patients over a month since the stroke onset (Ford et al.,1992; Kamada et
al.,1997a; Pendlebury et al.,1999).
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4.1 Discussion and conclusions
"Ifyou wish to converse with me, defineyour terms." Voltaire
4.1.1 Methodological aspects of the studies included in the literature
overview
Almost all studies are small and use different definitions, different spectroscopy
methods (acquisition and analysis) and different timing of scans, making it difficult
to draw firm conclusions. Future studies need to be very clear in their definitions,
analysis methods and bias by avoiding use of choline or creatine as denominators
because they change in acute stroke(Munoz et al., 2008).
An important source of variability between the studies was the time from onset to
scanning and lack of structured follow up, even in the studes that set out to
investigate temporal variation of the metabolites. There are several reasons for it.
Firstly, one has to take in to consideration technical difficulties of performing an
MRI on acutely ill stroke patients. Stroke is a heterogenous disorder and very
severe stroke patients, especially ones with aphasia, are unlikely to tolerate
prolonged time in the scanner (or even a short time). Doing spectroscopy tended to
add on at least 10-15 minutes on to the routine protocol, even with single voxel
spectroscopy. It is only in recent years that sequences have become faster, as well as
processing; Stengel reported completing a CSI examination in six minutes (Stengel
et al.,2004). In addition, it is very difficult to perform physiological monitoring in
the scanner and sometimes it is necessary to do so in such acutely ill patients.
Significant number of patients desaturate in the MR scanner (Rowat et al., 2002). If
no history from the patient is available (or collateral history), occasionally Xray of
the orbits is necessary for safe scanning. MRI scanners are often not available out of
hours, and therefore significantly reduce the number of patients scanned.
All these factors play a role in the ability to scan patients, especially in the
hyperacute and acute stage. Therefore, it is not supprising that only seven studies
out of 39 included patients within 24 hours of onset (n=73).
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Timing of the follow up of the patients also varied. Again, this is multifactorial. One
of the reasons is heterogeneity of the stroke and not all patients will be well at the
given time for a follow up. Also, MR scanning is not an easy procedure to tolerate
and many patients cannot tolerate repeated exams (Melendez and McCrank 1993).
Several studies reported results as part of temporal variation, having scanned
different patients at different time points. Although this provides some data on
temporal variation, it does not take in to account the individual variation between
patients.
Data collection and results reporting
All studies used validated MRS techniques in terms of data collection and analysis
of the spectra (but not of the derived metabolites). However, MRS has significantly
developed since the mid- to late 1980s, when the first studies were performed.
Originally it was a single voxel technique, but with time it developed into a
multivoxel MRS, covering a whole slice of the brain and providing a metabolic map
that can be superimposed in the structural image. Most studies used single voxel
data collection; some of them were multivoxel, whilst some used a combination of
the two.
An important cause of variability between the studies comes with the way the
metabolite results were reported. The 39 studies presented above used the following
approaches to present the data: the ratio to choline, the ratio to creatine, the ratio to
an internal standard, the ratio to water, the ratio to the contralateral side, the ratio to
the sum of all metabolites in the lesion and various absolute values either expressed
as mmoles or arbitrary units validated by an internal standard. One has to be careful
when interpreting such data; especially those presented as ratios to choline and
creatine. The choline and creatine levels change in the acute stroke and therefore the
potential ambiguity could be introduced into the ratios by the variation of these
metabolites. This ambiguity should be carefully considered when interpreting the
results (Munoz et al.,2008).
In addition, one of the important weaknesses of all spectroscopy studies is a partial
volume effect. When imaging a focal lesions or particular brain areas, they often
have an irregular shape that does not neatly fit in to a rectangle or a square. The
partial volume effect happens either due to contributions from surrounding tissue
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or because only a part of the region of interest is covered. Most studies have
commented on the possible ways they dealt with the problem but it could not be
completely eliminated. The majority of studies commented that they excluded the
voxels contaminated by the cerebrospinal fluid (CSF).
4.1.2 The metabolite levels in the acute stroke and temporal variations
All spectroscopy studies of human stroke agree on one point; that there is a decrease
in NAA level within the stroke lesion. There is no definite agreement on the timing
and the rate of decrease, but that is likely to be multifactorial and dependent on
other factors such as blood flow, size of the lesion and clinical severity. In general,
the NAA decline seems to occur rapidly in the first 48 hours and then continues to
decline at the slower rate thereafter.
The size of the lesion in all studies (where measured) correlated with the
metabolites (Graham et al.,1993;Graham et al.,1995;Lemesle et al.,2000;Wardlaw et
al.,1998). However, this is not a uniform agreement, as Lemesle et al. found NAA to
be associated with lesion size and outcome, but two other studies found high lactate
but not NAA to be associated with a large lesion and one study found both lactate
and NAA to have a correlation with the lesion size.
It is interesting to point out the differences in the distribution of the NAA across the
lesion, where the lesion and surrounding area were studied with DWI and T2
imaging. In the studies that used DWI, there is no significant decrease in NAA
levels between the core and outside of the lesion, whilst in T2 lesion there is a slight
decrease in the levels of NAA within the lesion centre compared to outside of the
lesion. Studies that used DWI had slightly shorter time from onset to imaging
(<24h), whilst ones that used T2 scanned patients up to 3 days (Table 5). This may
indicate that NAA levels may be preserved up to 24 hours in the lesion as well as
the surrounding area but, as times moves on and the lesion is visible on the T2, the
levels change. We do know from previous studies of DWI , SPECT and MRS that
DWI lesion is heterogeneous at the acute stage (Guadagno et al., 2004;Guadagno et
al., 2005;Nicoli et al.,2003). Lactate was highest in the centre and present in lower
levels, immediately outside the lesion as delineated on both DWI and T2.
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Unfortunately, only a couple of studies that measured blood flow investigated the
correlation with metabolites. The blood flow measurements follow the pattern of
reduced blood flow in the acute stage with a gradual increase to normal levels and
then hyperaemia in the subacute stage. One study repeated measurements at the
chronic stage and showed them to be similar to the acute stage. Lauriero et al. found
a positive correlation between NAA and rCBF in the acute and chronic stage, but
not in the hyperaemic phase (Table 12). None of the studies examined lactate in
relation to rCBF.
Temporal variation of metabolites
At least half of the studies investigated temporal variation of the metabolites. All the
difficulties with the timing of the follow up studies were discussed earlier. Also, the
number of patients that were followed up was rather small. The largest study that
looked at the temporal variation of metabolites did not follow up the same patients
but scanned different patients at different times from onset.
From the studies included in the review, a NAA level continue to fall further after
the acute stage; most rapidly up to three days and then continues to fall at a slower
rate up to one to two weeks. A similar pattern has been demonstrated in an animal
ischemia model with an initial rapid decrease of NAA following induction of
ischemia, then a further slower decline or persistent absence (Fliguchi et al.,
1996;Monsein et al., 1993) . These changes in NAA correlated closely with
histological evidence of neuronal death (Sager et al., 1995;Sager et al., 2000). In
addition to neuronal loss, a few other explanations of reduced levels of NAA were
offered. The accumulation of oedema in the ischaemic lesion could "dilute" the
NAA and account for some of the apparent reduction in NAA (Bruhn et al.,
1989;Dzialowski et al., 2004). It was also suggested that NAA is degraded by an
enzyme in the first few days after injury (Bruhn et al.,1989). At the subacute stage of
injury, there is some uncertainty about whether any residual NAA detected
spectroscopically represents a few still viable neurons, neuronal debris, infiltrating
microglia, or possibly migrating neural stem cells (Demougeot et al., 2004). NAA
seems to be at it's nadir in the period of one to two weeks from the onset of
symptoms. From the data presented, there is very little recovery of NAA up to a
month. After a month the time course of NAA is more variable. The levels may stay
the same as in a subacute stage, decline further or in some cases increase, but very
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rarely reach normal level again. However, these data are derived from very few
patients.
The time course of a lesion lactate is different from that of NAA. The level is highest
initially and it seems to stay high for up to two weeks. At some point between two
to four weeks, its level drops significantly. In some patients it disappears
completely, whilst in others it remains present even after a year. The lactate in the
acute stage represents anaerobic metabolism (Monsein et al.,1993), which may not
be the case with lactate at the chronic stage. There are several plausible explanations
for persistent lactate: It is possible that there is still some ongoing ischaemia even at
the chronic stage of infarction. In addition, changes in phosphorus metabolites and
alkalosis can cause increased lactate production. Alkalosis has been measured
especially in the hyperaemic stage of the infarction (Syrota et al, 1985). It is possible
that relatively increased cerebral blood flow, associated with a decrease of oxygen
extraction fraction and lower tissue pC02, causes intracellular alkalosis which
selectively stimulates glycolysis (Sappey-Marinier et al.,1992). Lactate can also be
produced by phagocytic glial cells, macrophages or leucocytes in the infarct, as
these cells are known to have a high rate of anaerobic glycolysis (Kely JP 1985).
4.1.3 DWI and MRS in acute stroke
Of the small number of studies that used DWI in combination with MRS, only two
tried to correlate metabolites with diffusion and perfusion parameters. One study
found no correlation whilst the other found correlation between the ADC and NAA
and lactate, expressed as a ratio to the sum of lesion metabolites, but this ratio is
difficult to interpret as none of these metabolites are stable in the acute stroke.
4.1.4 Correlation of metabolites with outcome
Thirteen studies investigated the correlation between the metabolites and clinical
outcome. The results were varied. Half of the studies found that NAA correlated
with outcome, and three studies found that lactate correlated with outcome. Only in
one study, both NAA and lactate correlated with outcome. Finally, two studies
showed no correlation with metabolites. There are important variations in the
baseline characteristics between the studies that may have influenced long term
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outcome. Also, timing of the recruitment of the patients differed between the studies
and the baseline severity of the stroke of the included patients would also have a
major impact on the outcome but has not always been specified.
No studies of MRS in the acute stage and follow up have been big enough to be able
to establish the role of metabolites with certainty in the diagnosis or prognosis of
stroke patients. There is also no clear correlation of metabolites with blood flow or
diffusion imaging.
Larger, carefully designed studies with pre-specified follow up would be necessary
to establish the role of MRS in clinical use and to clarify the pattern of metabolite
change in and around the lesion over time.
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Chapter 3: Methods of patient recruitment, image
acquisition and image processing
Introduction
Previous chapter, the systematic review of MRI spectroscopy, clearly demonstrated
difficulties with drawing conclusions from the studies that were generally small and
used different definitions, methods and analysis.
The aim of this study was to evaluate if proton MRS, by identifying neuronal death
(reduced NAA) and ischemia (raised lactate), could help clarify the relationship
between DWI and PWI parameters and tissue damage in acute ischemic stroke. If
ADC or PWI directly indicate neuronal damage, then ADC and PWI values should
correlate closely with NAA. If they mainly indicate ischemia, then ADC and PWI
values should correlate closely with lactate rather than NAA. Second aim was to
examine temporal variation of NAA and lactate within the ischaemic stroke lesion
over the period of three months and correlate radiological appearances of the
ischaemic lesion with the functional outcome at three months. This was going to be
achieved by following patients up in a structured way and at fixed time points up to
three months following initial stroke.
In this chapter I will describe the study design, patient recruitment, clinical
assessment, data collection, and entry used to gather data for the project. I will also
describe imaging methods, image analysis, data analysis, and clinical follow up.
Statistical tests used will be described in the individual results chapters dealing with
the analysis. The study recruitment and patients' assessment method are both
reported in this chapter whilst demographic data is presented with the results.
3.1. Study design
This study was a prospective observational study in which I recruited patients
within 24 hours of an acute ischaemic stroke and performed imaging and clinical
follow-up for 3 months. I recruited patients with acute stroke who presented and
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could have all initial assessments within 24 hours of the onset of symptoms. The
patients were assessed at 5 time points:
1) 0-24 hours - 1st assessment consisted of full clinical and functional assessment,
magnetic resonance scan (MRI) and carotid Doppler.
2) 5-7 days - MRI
3) 10-14 days - MRI
4) 30 days - MRI
5) 90 days - MRI and functional assessment (modified Rankin scale, Barthel Index,
extended Nottingham ADL scale).
The study was granted ethical approval by the Lothian Research and Ethics
Committee (LREC 2002/4/30). In addition to patient consent we were granted
relative consent, witnessed consent and waiver consent. (For samples of the patient
information leaflet and consent forms see Appendix 3 and 4). All patients who were
enrolled (or their relatives) signed an informed consent form. Only one patient was
enrolled by waiver consent.
3.2 Patient recruitment
3.2.1 Source of patients
I assessed over 300 patients in 24 months that presented at the Western General
Hospital in Edinburgh with symptoms of acute focal neurological deficit. Most
patients were directly seen at the point of entry to the hospital, acute receiving unit
(ARU), but some of them were assessed on a different medical or stroke ward, if
admitted and moved overnight. I carried an "acute stroke bleep" and was therefore




• cortical stroke (Total anterior circulation stroke - TACS or partial anterior
circulation stroke - PACS, Oxfordshire Community Stroke Project (OCSP)
classification (Bamford et al., 1991)
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• symptoms onset less then 24 hours / or able to be scanned within 24 hours
of onset of symptoms. Patient woken up from sleep were also included, but
time "last known to be well" was noted.
• no contraindication to MRI
In the majority of the assessed patients that were thought to have cortical stroke but
were excluded, the main reasons were: late presentation, not able to be scanned
within 24 hours of the onset, or too-ill and unstable to be taken to the MR scanner.
3.2.3 Initial clinical assessment
All patients entered in to the study had detailed clinical assessment which included
presenting history, past medical history and risk factors for stroke, full general
clinical examination including blood pressure, temperature, and blood glucose.
They also had complete neurological examination, including National Institute for
Health Stroke Scale (NIHSS) score, to assess the degree of initial neurological
impairment, (http://unuw.strokecenter.org/trials/scales/). If there was more than a 30
minutes delay between assessment and scanning, NIHSS was repeated and the
assessment closest to scanning used in the analysis. Ideally, patients were assessed
as they came in to the hospital but also if they were admitted through the night and
could have MRI within 24 hours of the onset of symptoms. Out of the 51 patient
with ischaemic stroke, 17 were scanned within 6 hours, 15 between 6-12 hours, and
19 between 12-24 hours.
3.2.4 Follow up of the patients
All patients who entered the study agreed originally to the follow up scans.
However, the follow up varied depending on the clinical condition of the patient
and their experience and tolerance of MRI scanning. 21/50 patients had all 5 scans.
Two patients had 1st and final scan as they found MRI unpleasant and would not
have tolerated it so closely together. Three patients found MRI claustrophobic and
refused further scanning whilst two patients refused to have further MRI beyond
the first one with no further explanation and were discharged from hospital within
a week of stroke, so had very mild stroke. Ten patients died at various time points
during the study (4 patients died after the 1st scan, 2 after the 2nd scan, 2 after the 3rd
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and 2 after the 4th scan). Patients attended follow up initially from the same hospital
but for subsequent scans (especially beyond two weeks), the patient usually
attended either from home or the nearby rehabilitation unit at the Victoria Hospital
Edinburgh. Full details of the number of scans per patient at each time point are in
Table 1.
At 3 months, at the same time as the MRI, each patient had NIHSS as well as
functional assessment including 6 point modified Rankin scale, Barthel Index and
Extended Nottingham ADL scale (see appendix 5 for examples of the scales). For the
patients who had their final scan at three months, the assessment was performed
during their final attendance, soon after or before the MRI scan. For the small
number of patients who refused the scan, the final functional outcome scales were
completed over the phone with a help of the relative if required. It would have been
impossible to be blinded for the patient details, structural, and DWI imaging during
their final functional assessment as I assessed all the patients initially, performed all
TCDs, kept all the notes, and was present during the scanning of all of the patients.
However, both the spectroscopy and perfusion data were processed afterward using
identification numbers rather then names so the analysis was performed blinded to
patient clinical details.
Table 2. Number ofpatients scanned at each time point
1st time point 2nd time point 3rd time point 4th time point 5th time point
51 37 32 26 23
3.2.5 The patient data
The data acquired was recorded on an acute assessment data form, and NIHSS was
recorded on the forms downloaded form the Stroke Centre website
(http://iozvw.strokecenter.org/trials/scales/) (see Appendix 6). This data was then
entered in to a "Foxpro" database designed for the study by the departmental
computer programmer V S. The foxpro database was used for the ease of data entry




3.3.1 Magnetic resonance Imaging
All MR imaging was performed on a GE 1.5 T Signa LX (General Electric,
Milwaukee, WI, USA) scanner situated in the SFC Brain Imaging Research Centre at
the Western General Hospital (Figure 1). After the consent was signed, all patients
(or their relatives), completed the standard MRI safety questionnaire. In some
instances, dysphasic patients required a skull X ray, especially if there was a history
of previous injury to the eyes with metal. If required, patients could be given
oxygen during the scanning and peripheral oxygen concentration was monitored
throughout with pulse oximetry. Each patient required an intravenous cannula for
administration of contrast for perfusion imaging. Once positioned in the scanner,
coordinates of the exact position of the patient's head were recorded for positioning
for the follow up scans. Those coordinates were used to achieve the same patient
position during all subsequent imaging. The minimum time required to acquire all
the sequences was 35 minutes. The length of the scan depended on the patient
degree of cooperation, and dysphasic patients often required someone present in the
scanner with them for reassurance.
Figure 1. Research MRI at the SHEFC Western General Hospital Edinburgh
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3.3.2 MR imaging sequences
The imaging included axial T2-weighted fast spin echo (T2W), axial diffusion tensor
imaging (DTI) based on spin-echo echo-planar imaging (EPI), axial dynamic
susceptibility contrast PWI using gradient-echo EPI, and single slice point resolved
spectroscopy (PRESS) proton MRS chemical shift imaging (CSI).
The imaging parameters for DTI were: field-of-view (FOV) 240 x 240 mm, 15 axial
slices of thickness 5 mm, slice gap 1 mm, acquisition matrix 128 x 128, echo time
(TE) 97.4 ms and repetition time (TR) 10 s. Diffusion sensitising gradients with
scalar b-values of 1000 s/mm2 were applied in six non-collinear directions. The
imaging slices were positioned so as to access the whole brain.
Cerebral brain perfusion was measured from the dynamic signal change following a
bolus injection of a gadolinium-based contrast agent (10 mL of lmmol/mL Gadovist
or 20 mL of 0.5 mmol/mL Omniscan) over a period of 85 seconds. We used an
automated pump connected to the scanner for injecting the contrast (see Figure 1).
We collected thirty-four volumes of 15 axial slices using the same FOV, acquisition
matrix and slice locations as the DTI data, but with a TE of 30 ms and TR of 2.5 s.
Spectroscopy was performed with a chemical shift imaging technique in which a
large volume of interest is divided in to individual grid square (Fig2). The
acquisition volume of interest (VOI) was centred on the diffusion weighted image
(DWI) that showed the maximum extent of the acute stroke lesion. The MRS
acquisition parameters were: FOV 320 mm, slice thickness 10 mm, acquisition
matrix 24x24, TE 145 ms and TR 1000 ms. Automatic shimming and water
suppression were applied. For each phase encoding, 512 complex data points were
acquired with a sampling interval of 1 ms. The VOI typically covered the ischaemic
area and some ipsilateral and contralateral normal brain. A screen capture image
was take to show the slice and VOI position for subsequent scanning. Sequential
imaging was set up with axial slices chosen carefully to be in the same position for
each scanning episode by reference to the "scout" images and the image of the slice
with the spectroscopy grid positioned on it.
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3.3.3 Mapping of the MRS data to the DWI image
The MRS CSI slice was 10 mm thick and the DWI and PWI slices were only 5 mm
thick. During scanning, the CSI slice was positioned so that the DWI/PWI slice
showing the maximum acute stroke lesion extent run through the centre of the CSI
slab with <2.5 mm overlap of the DWI/PWI slice on either side of the CSI slice. The
grid voxel coding was performed on the DWI slice (5mm) that ran through the
centre of the MRS slice, i.e. so that 2.5mm of the 10mm thick MRS slice overlapped
on either side of the DWI/PWI slice, and the coded slice captured the most reliable
(central) MRS information. Because the spectroscopy slice covered the entire
thickness of the DWI and PWI slice that showed the maximum lesion extent, plus
2.5mm on either side, thereby capturing representative spectroscopic information
across a large proportion of the stroke lesion, we tested ways of including the
DWI/PWI slices on either side of the central DWI/PWI slice in the analysis.
However, we found this to introduce more error due to lack of complete overlap of
the additional DWI/PWI slices with the CSI slice and increased risk of partial
volume averaging. During protocol development, we also tested the alternative
placement of the CSI slab with one edge starting with the top edge of a DWI/PWI
slice so that the CSI slab then covered one DWI/PWI slice, plus a slice gap, plus
4mm of the next DWI /PWI slice but this resulted in more problems due to difficulty
in averaging the DWI tissue classification of two adjacent slices except in the very
largest lesions. We have tried various other ways of matching the CSI to the
DWI/PWI by varying slice thickness and gaps but the constraints of slice number
and need for brain coverage mean that there really is no better way of dealing with
this problem. The thickness of the CSI slab is limited by signal to noise - too thin a
slab results in very poor signal to noise. The MRS slab provided much more
information than the single voxel MRS used in most previous studies. Acquisition of
multiple adjacent spectroscopy slices would be too time-consuming to be feasible in
acute stroke.
3.3.4 Image processing
DTI and PWI processing. The images were transferred to a Sun Ultra Sparc Station 10
(SUN Microsystems, Mountain View, CA, USA) and converted to Analyze format
(Mayo Foundation, Rochester, MN, USA). Subsequent processing was performed in
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MATLAB (The MathWorks, Natick, MA, USA). Using FLIRT
(www.fmrib.ox.ac.uklfsi), a three-dimensional computational image alignment
program, bulk patient motion and eddy current induced artefacts were removed
from the DTI data by registering the component EPI volumes to the T2-weighted
volumes acquired as a part of the DTI protocol. Maps of DTI were obtained from the
six DW images acquired for each slice, while ADC maps were calculated from the
diffusion tensor fitted voxel-by-voxel to the DTI data. Cerebral blood volume (CBV,
calculated as area under concentration/time curve), mean transit time (MTT,
calculated as first moment of concentration/time curve) and cerebral blood flow
(CBF, calculated as CBV/MTT) images were calculated from gamma-variate
functions with arterial input function but without deconvolution (Carpenter et al.,
2006). The gamma variate functions were fitted on a voxel-by-voxel basis to PWI
concentration-time curves obtained from the dynamic signal change following
injection of the contrast agent. PWI data were also corregistered to T2/DWI. The
DWI, PWI and CSI data were all registered to the B0T2 image from the baseline DWI
acquisition; all subsequent scans for each patient were also registered to the baseline
B0T2 image.
MRS processing. Spectroscopic data were interpolated to a 32x32 matrix, and 10 mm3
voxels, followed by zero-order phase correction using the residual water signal
(effectively bringing water to a chemical shift of 4.70 ppm) and removal of the
residual water signal using the Hanckel-Lanczos singular value decomposition
(HLSVD) method(van den Boogaart A 1994). Following Fourier transformation, the
resulting spectra were modelled by five Gaussian peaks (corresponding to choline,
creatine, NAA containing compounds and lactate) using the AMARES algorithm
(Vanhamme L 1997) within the MRUI package (van den Boogaart A 1996). Spectra
were automatically discarded if fitted line widths were less than 1 Hz or greater
than 10 Hz, if the metabolite peaks were more than 0.1 ppm offset from their
expected position, if the voxels lay on the edges of the PRESS excitation region, if
the spectra were of poor quality, fell outside brain parenchyma or were >25% CSF.
In addition to automated exclusion of the spectra, I visually inspected all spectra
including raw data and fitted spectra. Spectra were discarded if judged to be of poor
quality eg. having a badly elevated baseline or containing spurious peaks. This also
meant that for some patients there were only a few voxels contributing to some of
the tissue types. Metabolite peak areas (reported in "institutional" units) were
corrected for any drift in scanner performance by reference to monthly spectroscopy
phantom quality assurance data.
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3.4 Spectroscopy data analysis
I approached the data analysis from two different aspects: a) using a voxel based
grid analysis and b) using a region of interest analysis (ROI). The ROI analysis
captures large area of "core" and "normal" tissue but does not allow the analysis of
the complex stroke lesion in great detail for all the parameters of diffusion,
perfusion, and spectroscopy and their associations. It also theoretically can map to
subsequent scans more accurately. The grid classification method and analysis will
be discussed first followed by the region of interest (ROI).
3.4.1 Diffusion grid classification
Classification of the visual appearance of each voxel in the diffusion weighted
image (DWI) was used so as to relate the degree of tissue damage in the diffusion
lesion to the blood flow changes on the perfusion lesion and the metabolite values
derived from spectroscopy on a detailed voxel by voxel basis. It also allowed the
tissue changes on the initial scan to be mapped to changes on subsequent scans to
chart lesion evolution in relation to blood flow and metabolite changes.
Diffusion grid classification is based on the visual inspection of the diffusion lesion
that corresponds to the brain slice with the MRS position (ie. the slice that showed
most extensive stroke lesion on DWI). A program developed in MATLAB® (The
MathWorks, Natick, MA, USA) to perform this sub-regional voxel-based
classification. The voxels were classified according to appearance on the diffusion
image by applying a grid with voxels of dimension 4.7x4.7 mm over the entire DWI
slice corresponding to the MRS slice position (Figure 2). This small voxel grid was
applied to the DWI image because smaller voxels on the DWI image allowed more
precise and reproducible classification of individual voxels than did larger voxels
(equivalent in size to the CSI grid) in pilot testing. The DWI images were all
windowed on the same standard signal intensity to optimize signal contrast
between normal and abnormal tissue. A neuroradiologist, blind to all other data,
classified each voxel as: 'definitely abnormal' (DAL), 'possibly abnormal' (PAL), or
normal 'ipsilateral' (IN) or 'contralateral'(CN) according to the DWI appearance.
The classification also distinguished between the cerebrospinal fluid (CSF), midline,
and voxels that fall outside the brain but still 'within the CSI box'.
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The operational voxel classification(Karaszewski et al., 2006) was used to avoid
introducing bias that might occur by using ADC or PWI thresholds that so far have
not been shown to discriminate between viable and non-viable tissue(Bandera et al.,
2006;Fiehler 2003); DWI signal intensity (not ADC) was the parameter which
correlated most closely with cell death or viability in experimental models in
comparison with histology(Rivers and Wardlaw 2005), and because the DWI
appearance is immediately visible and rapidly assessed in the acute stroke situation
(all other parameters including ADC values require some image processing).
The diffusion grid 'Definitely abnormal' (DAL) voxels contained clearly
hyperintense (bright white) tissue; 'possibly abnormal' (PAL) voxels contained
tissue which appeared subtly hyperintense relative to normal tissue (i.e. in between
background normal tissue and hyperintense 'definitely' abnormal tissue); 'normal'
(N) voxels contained normal-appearing tissue (Figure2). Voxels falling outside brain
parenchyma were excluded. For the longitudinal analysis of choline and creatine
(Chapter 5) we combined DAL and PAL tissue in to the one category labelled
abnormal (Figure 3). Mismatch was defined as voxels which fell within MTT-
abnormal, DWI-normal tissue. The DWI map overlaid on the CSI grid and MTT
map were visually inspected and the voxels that fell in the mismatch tissue
identified. The data was then extracted from the relevant voxels using specifically
designed programme "Brainer" (Figure4).
The inter-rater reliability of classifying voxels was tested by two observers
independently and blindly classifying voxels on 20 scans. The classification based
on DWI compared with the ADC or PWI values (Rivers C.S. 2006) is the most
reproducible. The limits of agreement of the DWI signal values were less than +/-
10% where as variation in ADC and PWI values were much larger (Rivers C.S.2006).
This is in accordance with the experimental literature and probably occurs because
the variation in DWI signal is less, with narrower standard deviations than is the
case with either ADC or PWI values.
The DWI voxel (4.7 x4.7 mm) classification was interpolated to the MRS voxel grid
(size 10x10 mm). The MRS voxels were weighted by the proportion of each DWI-
coded tissue present in each DWI voxel. The DWI voxels interpolated very well to
the MRS voxels as the majority contained tissue of only one classification. In order
to calculate the best proportional representation I used the formula where half of the
'possibly abnormal' tissue was added to 'definitely abnormal' tissue voxel (DWI
137
classification). This meant that all CSI voxels had >75% of the one tissue type.
Majority of voxels however did not change the original classification with this
formula but it did improve the proportional representation in those few CSI voxels
that had mixed tissue within it.
3.4.2 Follow up scans
The same tissue classification was used to extract metabolite concentrations
from the follow-up scans and the subsequent time points were mapped on to the
original coding of the DWI image. We used the interscan registration matrices to
ensure that the spectroscopy voxels from the later time points spatially matched
those on the initial scan. We also assessed changes in infarct extent and swelling
using a previously validated visual rating scale that codes infarct extent according
to typical patterns of involvement in each of the main vascular territories and
swelling according to a validated ordinal 7-point scale (Wardlaw and Sellar 1994).
The scale ranges from 0 (no swelling) to 6 (indicates shift of the midline away from
the side of the infarction with effacement of basal cisterns, thus differentiating
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a) Classification voxel grid (4.7x4.7mm) overlaid on DWI image.
x ipsilateral normal (IN) x contralateral normal (CNL)
x cerebrospinal fluid (CSF) x midline
x definitely abnormal (DAL) x outside
x possibly abnormal (PAL)
b) Fine diffusion grid was transposed over the larger CSI grid. Tissue was classified
according to the maximum percentage of tissue present.
c) Colour CSI map
d) Perfusion map (visually inspected and compared against the diffusion image). Mismatch
region was identified and the data extracted form the area
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Figure 3. A, Classification grid overlaid on the averaged diffusion-weighted image; the
classification in each voxel is indicated by a color cross: Yellow, normal; blue, abnormal;
gray, cerebrospinal fluid or background.
B, MR spectroscopic image of choline levels of the same subject; each 10x10x10 mm3 voxel
is color-coded according to concentration of choline measured. Color bar shows choline
concentration in institutional units.
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3.4.3 Grid analysis of the first time point
Metabolites (in absolute "institutional units"), perfusion (CBF, CBV and MTT,
expressed as "index units" normalised to the contralateral normal hemisphere) and
diffusion (ADC) values (expressed as absolute values) were extracted from each
voxel type in to spreadsheets.
However, to compare different tissue types we required median values of the
metabolites, diffusion and perfusion parameters of all DWI tissue types for each
patient. This was made possible by developing a program, whereby entering tissue
type classification from the MRS slice in to the matching template, mean and
median values for each tissue type were calculated. (Figure 4) This was less labour
intensive but meant that all the data was entered manually and a second quality
check was performed to exclude any voxels that were at the edge of the lesion or
contaminated by the CSF.
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Figure 4. The appearance of the screen of the program for the data entry by tissue type and
calculation ofmean and median values. Tissue types were colour coded as seen on the picture
and if the voxels fell in the diffusion /perfusion mismatch area they were further marked by a
cross.
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1341 373 405 437 469 501 533 565 597 629 661 693
1340 372 404 436 468 500 532 564 596 628 660 692
1339 371 403 435 467 499 531 563 595 627 659 691
338 370 402 434 466 498 530 562 594 626 658 690
1337 369 401 433 465 497 529 561 593 625 657 689
336 368 400 432 464 496 528 560 592 624 656 688
1335 367 399 431 463 495 527 559 591 623 655 687
1334 366 398 430 462 494 526 558 590 622 654 686
333 365 397 429 461 493 525 557 589 621 653 685
332 364 396 428 460 492 524 556 588 620 652 684
331 363 395 427 459 491 523 555 587 619 651 683
1330 362 394 426 458 490 522 554 586 618 650 682
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3.4.4 Regions of interest (ROI)
In addition to the voxel grid analysis, we also used regions of interest (ROI) analysis
to analyse the diffusion lesion, perfusion and metabolite values in the acute stroke.
We outlined the acute ischaemic lesion on the DWI scan, on images with standard
contrast settings, using Analyse™ software, blinded to all other imaging and clinical
data. Images were outlined by an experienced trained rater. The DWI image (not the
ADC map) was used for the reasons already outlined above. A mirror image ROI
was placed in the contralateral hemisphere. The ROI was superimposed on the
ADC, CBF, MTT, and CSI maps and I extracted corresponding lesion and
contralateral normal DWI, PWI values (Figure 5). The DWI ROI covered the whole
of the abnormality, whereas CSI was from the 10-mm slab. Care was taken not to
include CSI voxels lying at the edge of, but mostly outside the ROI, in the ROI
thereby minimizing partial volume effects. Relative metabolites, perfusion and
diffusion values were obtained by dividing the stroke ROI values by those from the
contralateral mirror image region.









Region of interest (ROI) outlined on the DWI and superimposed on the same slice perfusion
maps and spectroscopic imaging inhere each coloured square represents a grid box.
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3.4.5 The metabolites - the rationale for using absolute versus relative
values
The metabolites can be presented in different ways as seen in the systematic review
of the literature, Chapter 2. The majority of the studies in that chapter presented
metabolites in the form of a ratio to either choline, creatine, contralateral normal or
an external standard.
In this study, we have elected to use absolute values of the metabolites in
institutional units as we had regular phantom checks to account for the drift in the
scanner and we have applied an appropriate scaling factor to all the metabolite data.
In order to be able to compare the data to some of the other studies we also
calculated relative values of the metabolites as a ratio to the contralateral side and in
one analysis as a ratio to the sum of the metabolites within the region of interest. As
this study involved multiple tome points we have used the opportunity to look at
the longitudinal change of choline and creatine and therefore their reliability as a
denominator for expressing the metabolite ratio (Chapter 5).
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Chapter 4: Distribution of metabolic changes in the brain
within 24 hours of acute ischaemic stroke and their relation
to diffusion and perfusion parameters
4.1 Introduction
Ischaemic stroke lesions are known to be heterogeneous especially in the early
stages of development of the ischaemia whether imaged by DWI, MRS or SPECT
(Guadagno et ah, 2005; Guadagno et ah, 2006; Nicoli et ah, 2003). At this stage it is
important to know what proportion of the tissue is salvageable if we are to deliver
treatment to the right group of patients and minimise the risk of potentially
dangerous side effects.
This chapter will examine brain metabolites within the first 24 hours of the onset of
stroke and their relationship with diffusion and perfusion parameters, by using
region of interest (ROI) analysis and the CSI grid analysis to determine whether
diffusion or perfusion imaging differentiate penumbra from dead tissue .
4.1.1 The ischaemic penumbra and diffusion/perfusion mismatch
In acute ischemic stroke, the ischemic penumbra is considered to be hypoperfused
tissue where neurons are functionally silent but retain structural integrity and are
potentially salvageable if blood flow can be restored quickly. The mismatch between
magnetic resonance (MR) diffusion-weighted (DWI) and perfusion imaging (PWI)
may be one way of identifying penumbra, but this approach requires
standardisation (Fiehler 2003; Kane et ah, 2007b; Sobesky et ah, 2005). No consistent
perfusion threshold has so far distinguished dead from salvageable tissue reliably
(Bandera et ah, 2006a; Heiss et ah, 2004; Kane et ah, 2007a; Sobesky et ah, 2004).
Several apparent diffusion coefficient (ADC) thresholds have been reported for
salvageable/non-salvageable tissue (Fiehler et ah, 2002; Loh et ah, 2005; Na et ah,
2004), but there is considerable overlap between tissue that had already infarcted,
tissue that was ischemic but viable, and normal but subsequently infracted
(Guadagno et al.,2005; Kidwell et ah, 2000).
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These studies all use the final infarct as shown on T2 or FLAIR imaging at several
days to months after the stroke to determine early tissue viability thresholds.
Flowever many changes occurring in between the acute and late phases could
influence the final tissue fate and may have added to the variability of acute DWI
and PW threshold values.
4.1.2 The role of MRS in understanding metabolic changes in the penumbra
An alternative method of determining early tissue viability would be to use MRS.
This detects N-acetyl aspartate (NAA) which, although its precise function is not
clearly understood, is almost exclusively found in intact functioning neurons in
adults, is present in sufficient quantity to provide a clear measurable signal on MRS,
and loss of NAA indicates neuronal death (Demougeot et al., 2004; Monsein et al.,
1993; Tsai and Coyle 1995). Thus, NAA is reduced in infarcted tissue in patients
(Labelle et al., 2001; Saunders et al., 1995). In a permanent middle cerebral artery
occlusion model, by six hours NAA had fallen to 50% of control with 30% of
neurons appearing viable histologically; by 24 hours, NAA had fallen to 20% of
control with few neurons appearing viable (Sager et al., 1995; Sager et al., 2000). MRS
also detects rapid rises in lactate due to anerobic metabolism in acute ischemic
tissue (Lemesle et al., 2000; Parsons et al., 2000).
4.1.3 The relationship to diffusion and perfusion parameters
If ADC or PWI directly indicate neuronal damage, then ADC and PWI values
should correlate closely with NAA; if they mainly indicate ischemia, then ADC and
PWI values should correlate closely with lactate rather than NAA. However, the
metabolic counterpart of abnormal DWI and PWI is relatively undefined. As
discussed in Chapter 2, there are few studies of MRS and DWI or PWI in acute
ischaemic stroke to date (Labelle et al.,2001; Liu et al., 2003; Nicoli et al.,2003;
Parsons et al.,2000; Parsons et al., 2002; Rumpel et al., 2001; Stengel et al., 2004;
Walker et al., 2004). These studies are small and had a combined total of 190 patients
with average study size around 20 patients. While indicating that NAA fell and
lactate rose in DWI-abnormal areas, these studies did not examine associations
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between metabolites, DWI and PWI parameters in detail across the whole stroke
lesion. Many were unable to profile metabolite, diffusion and/or perfusion values
because they used single voxel spectroscopy (Labelle et al.,2001; Parsons et al.,2000;
Parsons et al.,2002; Rumpel et al.,2001). Many only sampled MRS and diffusion not
perfusion (Labelle et al.,2001; Parsons et al.,2000; Parsons et al.,2002; Rumpel et
al.,2001; Stengel et al.,2004; Walker et al.,2004). Only one small study compared
NAA with both DWI and PWI simultaneously in the DWI-visible lesion, but found
very heterogeneous ADC values (Nicoli et al.,2003) (see Chapter 2 for further
details).
As DWI and PWI values change immediately with the onset of ischemia, whereas
neuronal death occurs after a period of ischemia, one explanation for the variability
in reported DWI and PWI thresholds of viability, and in the range of NAA values
for a given apparent diffusion coefficient (ADC) value in previous studies, could be
that DWI and PWI values mainly indicate the presence of ischemia but are only
indirect markers of neuronal loss. Clarification of the association between the DWI
(or PWI) abnormality and the amount of neuronal injury at the time of imaging
could improve the interpretation of DWI and PWI.
Here, I describe using proton MR spectroscopic imaging to map NAA, lactate, DWI
and PWI values across the acute ischaemic lesion and normal brain.
4.1.4 Region of interest (ROI) analysis versus voxel based
We examined the metabolites across the lesion in two different ways; ROI analysis
and voxel based analysis, as discussed in methods Chapter 3; The ROI analysis
provides a summary estimate of the average change in a parameter within the lesion
and in some circumstances has shown better correlation with final infarct size and
infarct growth then voxel-based analysis (Na et al.,2004). Voxel based analysis
allows more detailed analysis of the lesion by anatomical subregion. In this study
the lesion was divided according to DWI appearance.
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4.2 Methods for the ROI and grid analysis
Detailed description of methods can be found in Chapter 3.
4.2.1 Statistical analysis
All statistical tests were performed in SPSS 14.0 for Windows (SPSS Inc, Chicago, 111,
USA)for both ROI and grid analysis. The imaging data were not normally
distributed (Kolmogorov-Smirnov test, p>0.01), so we used non-parametric
Wilcoxon Signed Rank Sum Test to compare the metabolite concentrations, ADC
and PWI parameters between different voxel classes and ROIs from the ipsilateral
and contralateral side. We compared metabolites, DWI and PWI parameters within
each voxel class and ROI using the Spearman Rank Correlation coefficient (p), and
setting significance at the 0.05 level (2-tailed). We examined the relationship
between imaging parameters, stroke severity (NIHSS score) and time from stroke to
imaging on a per patient basis. We examined the subgroup of patients imaged
within six hours of stroke.
We tested for independent associations between metabolites and
diffusion/ perfusion parameters using general linear modelling in the ROI analysis.
In the grid analysis we combined 'definitely' and 'possibly abnormal' tissue to
create an 'abnormal' category and performed general linear regression to test for
independent associations between metabolites, diffusion and perfusion parameters
in the DWI normal versus abnormal appearing tissue. Bonferoni correction was
applied by considering p<0.01 as significant for multiple comparisons.
In the ROIs, we used lesion metabolite and ADC values in the primary analyses, but
repeated the comparison using the lesion/contralateral region ratio as a secondary
outcome (for comparison with previous studies). We also calculated lesion





43 patients in total were used between the two types of analysis. One patient was
not included in the ROI analysis which had 42 patients with traceable regions of
interest. The age, time from onset and OCSP classification are given in the Table 1.
14 (32%) patients were scanned within six hours, 14 (32%) between six and 12 hours,
and 15 (36%) patients between 12 and 24 hours after stroke. 22/43 patients (51%)
had DWI/PWI mismatch on MTT. No patients received thrombolysis or
investigational treatment and none had carotid stenosis of more than 50%.
Table 1. Age, time from onset, severity and OCSP classification
a /
, / Time from onset OCSP classificationAge (range+/- , .
SD) hours ^meanj TACS PACS NIHSS
76+/- 11 (37-95) 8+/-6.6 (1.5-24) 19(44%) 24(56%) 9+/-7.8 (1-29)
The demographic detail of all individual patients including their risk factors for
ischaemic stroke is listed in Table 2.
Table 2. Demographic characteristics of the 43 patients included in the grid and ROI
analysis
Sex of the patients 23 male
Side of the lesion 23 left hemisphere
Smoking history 32 non smokers (13 ex smoker)
Cognitive impairment 3 / 43
Ischaemic heart disease 21 / 43
Hypertension 27 / 43
Diabetes mellitus 1 / 43
Peripheral vascular disease 2 / 43
Atrial fibrillation 12 / 43
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4.3.2 Region of interest analysis
Metabolites in the DWI lesion
NAA and choline levels were significantly lower in the diffusion lesion than in
contralateral normal brain (ipsilateral versus contralateral: NAA 96.0 versus 122.4,
R=0.0001; choline 63.6 versus 70.1, R=0.015 Wilcoxon Rank Sum; Figure 1). Lactate
was detected in all but one diffusion lesion (lactate ipsi versus contralateral: 12.5
versus 42.5, P=0.0001) (see Table 3, Figurel). Some lactate was detected in 10
patients in the contralateral region; in all cases this was less than in the diffusion
lesion and all patients had large diffusion lesions and generalized cerebral atrophy.
Creatine did not differ significantly between the lesion and contralateral normal
brain.
Table 3. Median metabolite concentrations in the diffusion lesion and mirror image
contralateral brain: absolute values in institutional units corrected for the scanner drift.
Metabolites
Ischaemic lesion (ROI)





(Wilcoxon Rank Sum test)
NAA 96.0 (37-178,+/-33) 122.4 (44-175,+/-32) p=0.0001*
Lactate 42 (0-93,+/-26) 12.5 (0-59,+/-12) p=0.0001*
Choline 63.6 (28-118,+/-21) 70.1 (24-119,+/-23) p=0.015*
Creatine 70.0 (26-98,+/-19) 71.5 (21-107,+/-19) <NOIIOh
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Figure 1. Box plots of absolute median values of the metabolites in the acute ischemic lesion
ROI on diffusion imaging (ipsilateral) and in contralateral normal brain.
Legend: Box indicates interquartile range; middle bar, median with numeric value; whiskers
represent maximum and minimum values; circles above represent outliers
Relationship between metabolites, DWI and PWI parameters
The diffusion and perfusion values in the ROI of the lesion are given in the Table 4.
There was no correlation between lesion NAA and ADC (p = 0.15, p=0.34), MTT (p =
0.16, p=0.31) or CBF (p = -0.11, p=0.48)(Table 5). Higher lesion lactate was associated
with lower lesion ADC (Spearman p= -0.32, P=0.039) and prolonged MTT
(Spearman p= 0.31 P=0.04). There were no associations between choline or creatine
and DWI or PWI values. These results did not change when we repeated these
analyses using metabolite and ADC ratios (Table 5) (ie, relative values) instead of
absolute values. Restricting the analyses to those patients imaged within 6 hours did
not show any correlation between NAA and ADC, MTT, and CBF (Table 6). Lactate
correlated strongly with MTT (Spearman p=0.74, P=0.003) and CBF (Spearman p= -
0.78, P=0.001) but not ADC (Spearman p= -0.495, P=0.07). There was an association
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between [lesion NAA]/[lesion NAA+choline+creatine](Nicoli et ah,2003) and
reduced ADC (Spearman p=0.434, P=0.005), but this composite ratio is difficult to
interpret given that neither NAA nor choline are constant in acute stroke.
Table 4. The relative values ofperfusion and diffusion parameters in the ROI
ADC Median (range +/-SD)
perfusion Relative to contralateral
"5^ 0.7 (0.5-1.5,+/-0.3)
MTT 1-3 (0.3 - 3.4,+/-0.3)
ADC 0.8 (05 - 1.0,+/-0.5)
ADC, absolute apparent diffusion coefficient; MTT, mean transit time; CBF, cerebral blood
flow.





ADC p = 0.15, p=0.34 p = 0.17, p=0.29 p =-0.32, p=0.039
CBF p = -0.11, p=0.48 p = -0.01, p=0.93 p = -0.10, p=0.52
MTT p = 0.16, p=0.31 p = 0.005, p=0.97 p = 0.31, p=0.043
Table 6 Spearman's Rank Correlation Coefficient (p) Between Metabolites and Diffusion and




ADC p = 0.28, p=0.36 p = -0.40, p=0.15
CBF p = 0.12, p=0.70 p = -0.78, p=0.001
MTT p =-0.13, p=0.64 p = 0.75, p=0.002
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Metabolites, stroke severity, lesion volume, time from stroke
There was no association between any of the metabolites and the initial NIHSS
score. Larger DWI lesion volume was associated with reduced NAA (Spearman's p
= -0.42, p=0.006) and increased lactate (Spearman's p = 0.49, p=0.001) but not with
choline or creatine. Longer times to scanning were associated with lower NAA
(Spearman's p = -0.33, p=0.03) and larger lesion volumes (Spearman's p = 0.35,
p=0.023) but not with lactate, choline, creatine or ADC (Figure2).
Linear regression analysis
We tested for independent associations between NAA, lactate and
diffusion /perfusion parameters, time to scan and stroke severity using linear
regression (Table 7). MTT (p=0.02) and DWI lesion volume (p=0.005) were
significant predictors in the lactate model and time from onset to scan (p=0.034) in
the NAA model.
Table 7. Linear regression analysis with lactate and NAA as constants and DWI, PWI
parameters, lesion volume, time to scan (hours), and stroke severity as variables in the model
Coefficients Coefficients
of the regression line of the regression line
Model B Std. Error Sig. B Std. Error Sig.
(Constant) -1.514 37.162 0.968 91.377 49.283 0.072
CBF 16.725 16.908 0.329 2.160 22.423 0.924
MTT 24.988 10.354 0.021 12.793 13.731 0.351
Volume 2.636 0.889 0.005 -2.176 1.179 0.073
ADC -4.776 28.967 0.870 10.329 38.415 0.790
Onset-scan (hrs) -0.153 0.607 0.802 -1.772 0.805 0.034
NIHSS -0.696 0.550 0.214 -0.134 0.729 0.854
Dependent variable: lesion lactate Dependent variable: lesion NAA
ADC indicates absolute apparent diffusion coefficient; MTT, mean transit time; CBF, cerebral
blood flow; NIHSS, National Institutes of Health Stroke Scale Score.
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Summary of the results from the ROI analysis
We found no direct association between NAA as an index of neuronal loss and ADC,
CBF, or MTT in the acute diffusion lesion, on either absolute or relative measures.
However we did find associations between elevated lactate, reduced ADC, and
prolonged MTT, which all indicate the presence of ischemia. The results did not
change when the analysis was restricted to patients imaged within 6 hours of stroke.
The larger diffusion lesions were associated with lower NAA and higher lactate
values which is consistent with findings of previous studies showing that large
lesions on T2 weighted imaging had lower NAA and higher lactate than small
lesions (Lanfermann et al., 1995; Lemesle et al.,2000; Parsons et al.,2002; Pereira et al.,
1999; Wardlaw et al., 1998).
These results also confirm the observations made in previous small MRS studies:
there was no correlation between NAA and ADC (Labelle et al.,2001) because the
range of NAA values for a given ADC value was very wide (Nicoli et al.,2003).
Therefore ADC and perfusion values are useful markers of the presence of ischemia.
The lack of correlation with neuronal damage would explain the absence of
agreement between previous studies on reported thresholds for salvageable/non
salvageable tissue. The heterogeneity of ADC and PWI values (Bandera et al., 2006;
Guadagno et al.,2005) within and around the acute stroke lesion, together with
recovery of DWI-abnormal tissue in some cases (Davis and Donnan 2005; Kidwell et
al.,2000), means that it is unlikely that any single DWI or PWI parameters will
reliably indicate the amount of permanent tissue damage.
Further discussion of the results, strength, and weaknesses of the study will be
presented together with the results of the grid analysis at the end of this chapter.
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4.3.2 Results - MRS grid analysis
Association between metabolites and with tissue appearance on DWI
NAA was lowest in the DWI 'definitely abnormal' voxels (Table 8), and lower in
'definitely' than in 'possibly abnormal' voxels. (97.9 vs 113.3, p=0.01), It was also
lower in 'possibly abnormal' than in 'mismatch' and 'normal' voxels (Table 9; Figure
3). There was no difference in NAA between mismatch (DWI/MTT) and normal
tissue. That is, NAA was reduced only in tissue that appeared in any way abnormal
on DWI; the more abnormal the tissue appeared, the lower the NAA, and therefore
the greater the neuronal loss.
Lactate was highest in 'definitely abnormal' voxels (Table 8), and successively lower
in 'possibly abnormal', 'mismatch', 'ipsilateraT and 'contralateral normal' tissue (all
comparisons p<0.01).
There was no difference in ADC between 'definitely' and 'possibly abnormal' voxels,
but ADC was reduced in any DWI abnormal ('definitely' or 'possibly') compared
with 'mismatch' and 'normal' voxels (Table 8; Figure 3).
There was no difference in CBF or MTT values between 'definitely' and 'possibly
abnormal' voxels. CBF was reduced and MTT prolonged in any DWI abnormal
('definitely' or 'possibly') compared to 'mismatch' and 'ipsilateral normal' voxels,
and MTT was prolonged in ipsilateral compared to 'contralateral normal' voxels.
When the analysis was restricted to the 15 patients imaged within six hours of stroke,
the significant associations all became non-significant, probably due to the small
number of patients.
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Table 8 Median values by tissue type for metabolites, ADC and PWI parameters.
Median ADC, PWI and metabolite values
Tissue type ADC CBF CBV MTT NAA LACT
DAL 804.3 0.7 0.9 1.1 97.9 89.8
PAL 857.9 0.8 0.9 1.2 113.3 52.0
INL 1098.5 0.9 1.1 1.1 124.6 21.2
MM 1050.8 1.0 1.6 1.8 124.9 30.7
CNL 1126.6 1.0 1.0 1.0 131.9 16.4
Legend: Tissue Type: DAL-'definitely abnormal', PAL- 'possibly abnormal', INL-'ipsilateral
normal', MM-'mismatch', CNL- 'contralateral normal'. CBF, CBV and MTT expressed as
Index Units ( normalised to the contralateral normal hemisphere), ADC xlO"6 mm2/sec, and
NAA and lactate as absolute values in institutional units
Table 9. Significance of differences between metabolites, DWI and PWI parameters between
different voxels classified according to the DWI appearance.
Tissue voxel type Wilcoxon signed rank sum test comparing tissue types (p values)
ADC CBF CBV MTT NAA LACT
DAL vs PAL 0.758 0.68 0.636 0.85 0.01 0.001
PAL vs INL 0.001 0.003 0.06 0.006 0.007 0.0001
INL vs CNL 0.57 0.32 0.05 0.0001 0.01 0.006
MM vs DAL 0.136 0.435 0.86 0.177 0.004 0.002
MM vs PAL 0.088 0.095 0.263 0.291 0.039 0.011
MM vs CNL 0.178 0.005 0.158 0.0001 0.178 0.003
Wilcoxon signed rank test. (* bold - statistically significant vaue)
Legend: Tissue Type: DAL-'definitely abnormal', PAL- 'possibly abnormal', INL-'ipsilateral
normal', MM-'mismatch', CNL- 'contralateral normal'. CBF,CBV and MTT expressed as
Index Units ( normalised to the contralateral normal hemisphere), ADC xlO"6 mm2/sec, and
NAA and lactate as absolute values in institutional units
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Figure 3: Box plots ofmedian absolute metabolite (in institutional units), ADC and
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Figure 3 legend: The box represents the interquartile range; the middle bar represents the
median; whiskers represent maximum and minimum values; circles above represent outliers.
D, 'definitely' abnormal; P, 'possibly' abnormal; iN, ipsilateral normal; cN,contralateral
normal; M, mismatch voxels
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Associations with time to imaging and stroke severity
NAA was lower in patients scanned at later times after stroke in 'definitely' and
'possibly abnormal' voxels (p= -0.4, p=0.03 and p = -0.44, p=0.04 in 'definitely' and
'possibly abnormal' tissue respectively) (Table 10). Lactate, ADC and MTT were not
associated with time to scanning in any voxel type. Higher CBF and CBV values
were associated with increasing time from onset to scanning only in possibly
abnormal tissue (p =0.52, p=0.0001, p =0.4, p=0.008 respectively) (Table 10). When
restricted to the 15 patients imaged within six hours, the significant associations
became non-significant, probably due to the small sample size. There was no
association between NAA or lactate and stroke severity (NIHSS) in any of the voxel
types. More severe stroke was associated only with lower ADC and CBF in 'possibly'
abnormal voxels (p = -0.5, p=0.003, p = -0.32, p=0.04 for ADC and CBF respectively)
and with prolonged MTT in 'ipsilateral normal' voxels (p =0.6, p=0.001) (Table 10).
When restricted to the 15 patients imaged within six hours, the association between
NAA, lactate and stroke severity remained non-significant; ADC and CBF in
'possibly abnormal' tissue lost the significant association with NIHSS; and the
association between CBF, CBV, MTT and NIHSS in 'ipsilateral normal' tissue became
significant. These results should be interpreted with caution due to the small number
of patients in this subgroup analysis.
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Associations between metabolites and diffusion and perfusion parameters
Univariate analyses showed no association between NAA and ADC or PWI
parameters in DWI 'definitely' (NAA vs. ADC, p = -0.16, p=0.4; and vs. MTT p =0.33,
p=0.054) or 'possibly' (NAA vs. ADC, p = -0.24, p=0.1; and vs. MTT p =0.172, p=0.28)
abnormal voxels. Elevated lactate was associated with reduced ADC and prolonged
MTT in 'definitely' (lactate vs. ADC, p = -0.41, p=0.02; and vs. MTT p =0.42, p=0.02)
and 'possibly' (lactate vs ADC p =-0.32, p=0.04 and vs. MTT p =0.37, p=0.02)
abnormal voxels. We repeated the analysis in the 15 patients imaged within six
hours. The association between NAA, ADC and PI parameters remained negative
and the associations between elevated lactate and reduced ADC/prolonged MTT
were also unchanged. Multivariate modelling confirmed the association between
reduced NAA and increasing time to scanning in the whole patient group
(Coefficient B -2.4, p=0.001), and between high lactate and reduced ADC (Coefficient
B -0.07, p=0.001), but not between any other variables (Table 11). Restricting the
analysis to the 15 patients imaged within six hours did not change these results.
Table 11. Multivariate analysis: Models with NAA and lactate as dependent variable to test
for independent association with diffusion and perfusion variables in voxel based analysis.
Unstandardized Unstandardized
Coefficients Coefficients
Model B StdError Significance B StdError Significance
(Constant) 107351 31.958 0.002 102387 35.427 0.006
NIHSS -1.733 0.644 0.11 0.084 0.714 0.907
Onset_MRl -2.363 0.665 0.001 0.576 0.737 0.439
MTT 0.055 0.025 0.38 0.008 0.028 0.784
ADC -0.004 0.018 0.820 -0.074 0.020 0.001
CBF 0.029 0.023 0212 -0.020 -0.026 0262
CBV -0.046 0.024 0.063 0.030 0.026 0262
Dependent variable:NAA Dependentvariable: lactate
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4.4 Discussion
Summary of the results and main conclusions
This study demonstrates several important points concerning characterisation of
tissue damage with imaging in acute ischemic stroke. Firstly, the ADC, PWI and
lactate values are sensitive to the presence of ischemia (significant differences
between DWI abnormal, mismatch and normal tissue) but the absence of any
correlation with NAA indicates that they are less specific for cumulative permanent
neuronal damage. A similar conclusion was drawn from the ROI analysis. Secondly,
the elevated lactate but normal NAA in 'mismatch' tissue is consistent with the
hypothesis that mismatch tissue is ischemic but still viable. Thirdly, the NAA
temporal profile was different to that of ADC, PWI and lactate values - NAA
declined with time after stroke, consistent with experimental models (Sager et
al.,2000), whereas ADC, PWI and lactate values showed no clear temporal profile.
Fourthly, the acute ischemic lesion appearance on DWI (the "whiteness"), but not the
ADC value, corresponded with the degree of neuronal damage, consistent with
experimental data where DWI signal intensity but not ADC level was associated
with histologically-determined neuronal damage (Rivers and Wardlaw 2005). Thus
in the acute ischemic lesion, the lack of association between NAA and ADC, MTT
and lactate, may explain the lack of any consistent ADC or PWI threshold identified
to date to distinguish salvageable from non-salvageable tissue(Bandera et al.,2006;
Fiehler2003). The findings of the ROI analysis are in agreement with the grid
analysis.
The strengths of the study
These include the large sample size (for a complex stroke imaging study), careful
patient assessment, careful image registration and detailed voxel-based analysis. The
use of DWI appearance in the image analysis means that the results are independent
of any threshold values and also directly translatable to clinical practice, fast and
immediate to apply - the brighter the DWI signal, the greater the neuronal damage,
and presumably the less likely that the tissue will be salvageable (but this would
require further testing). We could have used an ADC or PWI threshold to delineate
the acute stroke lesion, but no consistent threshold has yet been found that reliably
identifies salvageable/non-salvageable tissue (Bandera et al.,2006). Both ROI analysis
and voxel-based analysis (although much more detailed than region-of-interest
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approaches), may suffer from partial volume effects at lesion edges particularly for
CSI. I was very careful to exclude poorly fitted or noise contaminated spectra and all
CSF-contaminated voxels. I included patients imaged up to 24 hours after stroke (in
pre-specified time windows) so as to be able to examine the temporal profile and
because there is evidence of substantial amounts of ischemic but viable tissue (50% of
lesion) up to at least 24 hours after stroke (Markus et al., 2004). Whether or not this
apparently viable tissue is salvageable with revascularisation therapies beyond six
hours is currently uncertain and the subject of ongoing trials. When we restricted
analysis to just those patients imaged within six hours of stroke, the results in general
did not change although many of the significant associations lost their significance,
most likely due to the small sample size (applies to both analyses). We did not use
metabolite ratios because their use is questionable as there is no reliable denominator
that does not change in acute ischaemic stroke: both choline and creatine are altered
by the ischaemic process (discussed in Chapter 5) (Munoz et al., 2008). Some
variations in alternative metabolite ratio denominators may be interesting, for
example the lactate/NAA ratio which is a sensitive metabolic index of acute
ischaemia which was used to demonstrate the wide metabolic heterogeneity inside
the abnormal area delineated by ADC map (Nicoli et al.,2003). Indeed, the increasing
lactate level combined with the simultaneous decreasing NAA level may enhance the
diagnostic value of this metabolic ratio and avoid potential problems due to
increased water content from cellular oedema (Nicoli et al.,2003). It is difficult to
perform absolute MRS quantification of brain metabolites due to variations in water
content arising from brain pathology. The additional sequences (absolute T1
quantification) required to overcome this would make the scan times intolerable for
acutely ill patients and as the tissue water increase in the first 24 hours of stroke is
less than 6% it would seem reasonable to use standardised individual metabolite
values (Dzialowski et al., 2004).
The limitations of the study
Lack of out-of-hours scanner availability hampered recruitment (although there is no
evidence that patients admitted during the night are different to those seen during
the day). Not all patients were able to complete the scanning protocol, particularly
those with severe stroke, so some patients that started imaging did not contribute to
the analysis and patients with very severe stroke may be underrepresented in this
study. We used a single thick spectroscopic imaging slab centred on the DWI slice
that showed the acute stroke lesion at its most extensive; the spectroscopy slice
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covered the entire thickness of the DWI and PWI slice that showed the maximum
lesion extent, plus 2.5mm on either side, thereby capturing representative
spectroscopic information across a large proportion of the stroke lesion. This has
been discussed in some detail in the methods chapter 3. The correlations of
metabolites with time after stroke should be interpreted cautiously because these
data come from different patients imaged at different times after stroke, not the same
patients imaged serially. However, it would have been unethical and impractical to
image patients every few hours soon after admission with stroke. The time of onset
may have been estimated as earlier than it actually was in those who awoke from
sleep with stroke (I used the time last known to be normal to the best of my ability),
as there is some evidence that the stroke most often occurs shortly before awaking
rather than just after falling asleep, but I aimed to be conservative. The multivariate
analysis does adjust for some confounding factors, but not all and multiple
comparisons should therefore be cautiously interpreted. Thus, associations between
time and ADC, NAA, or PWI values may still be confounded by stroke severity or
other factors, and these data should be regarded as exploratory. Larger studies with
more patients imaged sequentially early after stroke would be required to be certain
of overcoming these confounders reliably, although would be practically difficult
and may suffer from other sources of bias. The data on patients imaged within six
hours should also be interpreted cautiously as the sample size (15 patients) is small.
One previous study of six patients found a strong correlation between lesion ADC
and NAA and lactate (Nicoli et al.,2003) using a region of interest rather than voxel
based approach. The region of interest analysis in the same patient population, found
an association between the ratio [lesion NAA]/[lesion NAA+choline+creatine] and
reduced ADC (Spearman p= 0.434, p=0.005) but it is important to note that this
composite ratio is difficult to interpret given that neither NAA nor choline are
constant in acute stroke.
Therefore we did not repeat the analysis with that ratio using the grid-based
analysis. Also in agreement with Nicoli et al, in both the grid analysis and the ROI
analysis, we have shown an association between rising lactate and falling ADC.
Nicoli et al (Nicoli et al.,2003) also commented on the pronounced heterogeneity of
ADC within the lesion which we have also found. The association of elevated lactate
with both falling ADC and prolonged MTT in the present study means that we
would most likely have found a similar association to that of Nicoli (Nicoli et
al.,2003) for the ratio of lactate/NAA with ADC and MTT. Another study (14
patients) found no correlation between ADC and NAA in the first 24 hours (Labelle
et al.,2001). The lack of association between ADC and NAA could be explained by
165
different rates of change. ADC falls immediately after stroke (Kucinski et alv 2002)
before rising, at different rates in different patients, to supra normal values, whilst
NAA represents cumulative neuronal death and levels decline more gradually (Sager
et al.,1995; Sager et ah,2000; Saunders et al.,1995).
The presence of lactate in normal appearing tissue on T2-weighted imaging has been
reported previously in 11 patients between 2-24 hours after stroke. However, as T2-
weighted imaging is less sensitive to ischemic change than DWI, it is possible that
some of the normal appearing tissue on T2-weighted imaging was actually ischemic
(Gillard et al., 1996). Another study found lactate outside the diffusion (ADC) lesion
(Stengel et ah,2004). In both studies the lactate could have been in mismatch tissue.
Some lactate in DWI normal tissue ipsilateral to the stroke could be accounted for by
partial volume effects from adjacent mismatch voxels but we also found lactate in
contralateral normal brain. This could be an artefact of fitting lipids, or
contamination from lactate entering CSF from ischemic brain in patients with
significant cerebral atrophy. However, the most likely reason is that lactate can be
found in healthy brain tissue in older people or that MRS may be a better indicator of
future pathology (and/or asymptomatic present pathology) than MRI (Sijens et al.,
2001).
What do the present findings mean?
NAA is found exclusively in functioning neurons (Demougeot et al.,2004; Tsai and
Coylel995). Several ischemia models demonstrated an initial rapid decrease of NAA
following induction of ischemia, then a further slower decline (Monsein et al.,1993),
that correlated closely with histological evidence of neuronal death (Sager et al.,1995;
Sager et al.,2000). The NAA had fallen to 50% of normal by 6 hours and to 20% of
normal by 24 hours, corresponding with similar proportions of non-viable neurons
identified histologically (Sager et al.,2000). Although accumulation of oedema fluid
in the ischaemic lesion could "dilute" the NAA and account for some of the apparent
reduction in NAA, generally within the first 24 hours the increase in water content is
around 6% as judged by experimental and patient data (Dzialowski et al.,2004),
which would not be enough to account for the magnitude of metabolite changes that
we have detected. Thus it is reasonable to regard NAA reduction as specific for
neuronal loss in acute ischemia. In contrast, at subacute times, there is some
uncertainty about whether any residual NAA detected spectroscopically represents a
few still viable neurons, neuronal debris, infiltrating microglia, or possibly migrating
neural stem cells (Demougeot et al.,2004). This pattern of early NAA loss has been
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confirmed in patients (Gideon et al., 1994; Saunders et al.,1995). In contrast, in animal
models, the ADC value falls as neuronal and glial swelling develops, and then either
remains low in persistent occlusion models until dead cells of all types are lysed, or
rises in transient ischemia models due primarily to resolution of glial swelling
(Rivers and Wardlaw 2005). Indeed histological comparisons suggest that the ADC is
a better marker of glial cell status than of neuronal viability, with the DWI signal
("whiteness") being a better marker of neuronal death than the ADC (Rivers and
Wardlaw 2005), which is why we used the DWI lesion brightness to classify the
voxels and placed the ROI around the DWI- visible lesion. The lack of specificity of
ADC values for neuronal death is also suggested by the wide range of values found
in definite infarcts (Hand et al., 2006). From any one "snapshot" in time, it is not
possible to say whether the ADC is falling, at the nadir, or rising. Tissue with very
low ADC values may recover in patients (Fiehler et al.,2002) and animal models
(Rivers and Wardlaw 2005) providing further evidence that no single ADC threshold
is likely to discriminate salvageable from unsalvageable tissue. PWI values are also
heterogeneous in stroke lesions (Wu et al., 2006) with no clear threshold for
salvageable tissue (Bandera et al.,2006). Therefore it would be difficult for a single
"snapshot" of ADC or PWI values to indicate, directly, neuronal loss or tissue
salvageability and may explain the lack of any clear ADC or PWI threshold for
reliably differentiation of permanently damaged from viable ischemic tissue.
MRS is still not suitable for routine assessment of acute stroke patients though is
useful in research. From a clinical perspective, only NIHSS (not metabolites or
PWI/DWI parameters) predicted 3-month outcome. This exploratory work suggests
that more information is needed to determine whether, and how, imaging metrics of
tissue damage can be used to assess tissue salvageability and guide patient
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Chapter 5: Longitudinal changes over three months of NAA,
lactate, choline, and creatine
Previous chapters dealt with distribution of the metabolites during the first 24 hours
of onset of stroke and their relationship with diffusion and perfusion parameters. In
this chapter I will report changes in metabolites over three months period at five
fixed time points (see Chapter 3, Methods). I have looked at the longitudinal profile
of NAA and lactate as well as choline and creatine. The data will be reported in two
sections in this chapter.
5.1 Introduction
5.1.1 The changes in NAA and lactate over three months
Much research in ischemic stroke has been devoted to limiting tissue damage by
identifying ischemic tissue that could be salvaged before death, and establishing the
duration of ongoing tissue injury. Most work has focused on diffusion and
perfusion MRI, but proton MR spectroscopy (MRS) is also a valuable tool for
identifying metabolic changes occurring during brain ischaemia. NAA appears
almost exclusively in normal neurons and has been used to detect neuronal damage
in various neurological disorders including stroke (Saunders 2000). This has been
extensively discussed in the Introduction. Experimental data confirm the close
relationship between NAA detected spectroscopically and the proportion of normal
neurons (Rigotti et ah, 2007). Lactate appears in ischemic brain and in the acute stage
indicates a change from oxidative metabolism to anaerobic glycolysis (Graham et ah,
1992; Saunders et al., 1995). Although much of the total tissue damage probably
occurs in the first few hours after stroke, the longest duration of survival of ischemic
but viable tissue, and the period over which further damage might accumulate from
secondary factors, is unknown. There is evidence that damage may continue
subacutely (Rivers et ah, 2004), offering possible targets for delayed therapeutic
interventions if the causes can be identified. Therefore, determining the prolonged
time course of changes in NAA and lactate after stroke could identify the period of
cumulative tissue damage.
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Previous studies of NAA and lactate after stroke, as discussed in chapter 2,
unanimously confirm an acute decrease in NAA in the centre of ischemic lesions
consistent with neuronal loss, and high concentrations of lactate. However, these
studies provided little reliable data on the duration or pattern of metabolite changes
as they were generally small, imaged different patients at different times
(confounding temporal variation with between-patient differences (Ford et al., 1992;
Lanfermann et al., 1995; Walker et al., 2004), used ratios to other metabolites
(assuming that these do not change after stroke (Lemesle et al., 2000; Parsons et al.,
2000); or only provided data from a single voxel in the lesion (Federico et al., 1998;
Gideon et al., 1994; Kamada et al., 1997; Saunders et al.,1995) rather than
simultaneous data across normal and abnormal brain. The findings for the duration
of detection of lactate were particularly inconsistent, from rapid reduction to
undetectable levels (Gideon et al.,1994; Saunders et al.,1995), to persistence weeks or
months after stroke (Graham et al.,1992; Sappey-Marinier et al., 1992).
To examine the time course of tissue damage following ischemia, NAA and lactate
were measured with proton MRSI, across ischemic and normal brain, in a large
group of patients at five fixed time points. I extracted metabolite data from voxels
classified according to the appearance of the initial DWI to avoid using thresholds
for the reasons extensively discussed in the previous chapters (3 and 4).
5.1.2 Evolution of choline and creatine over three months
Previous studies of ischemic stroke used choline and creatine to calculate ratios of
NAA or lactate to compare affected and healthy tissue in individuals or between
different subjects (Ford et al.,1992; Kim et al., 2001; Parsons et al.,2000). This is based
on the assumption that the concentrations of choline or creatine do not change
significantly during ischemia (Fenstermacher and Narayana 1990). Many
subsequent studies have used choline or creatine as denominators to measure the
ratio of NAA or lactate, assuming that neither choline nor creatine change in
ischaemia. I have used data obtained in my research to establish whether choline
and creatine could be used as reliable denominators for other brain metabolites in




Patient recruitment and imaging techniques have been described in chapter 3.
5.2.1 Data analysis
We used the "grid method" of classifying tissue into normal and abnormal areas on
the basis of the lesion appearance on the DWI sequence as described in Chapter 3.
For each patient, median values of NAA and lactate concentration for each tissue
class were calculated. Data from all patients were normally distributed
(Kolmogorov- Smirnov tests) and were combined to obtain mean NAA and lactate
concentrations for each tissue class at the five time points. The differences in the
NAA and lactate concentration time profiles of different tissue classes: definitely
(DAB) and possibly abnormal (PAB), ipsi-(INL) and contralateral normal (CNL)
voxels in individual patients were assessed using linear mixed model analysis
(Brown and Prescott 2006) performed in SAS 9.1 (SAS Institute Inc., Cary, NC). This
analysis shares similarities with ordinary linear regression, but allows for missing
data and therefore includes data from all patients, independently of the number of
time points available. In simple linear regression, if an observation has missing data
for any of the explanatory variables, the entire observation cannot be used in the
analysis. Another potential drawback of simple linear regression is that it cannot
allow for certain structures within the data, for example those that occur when
repeated measurements are taken from the same patient, such as is the case here.
The current analysis aimed to predict NAA or lactate using four brain tissue types:
DAB, PAB, INL and CNL. In a simple linear regression, if a patient had been
missing data on any one of these tissue types, the data from the other tissue types
would have been discarded. For example, a patient with a missing PAB would be
dropped entirely from the analysis. However, in a linear mixed model, the data
from the other tissue types are still used to estimate of the relationship of those
tissue types with NAA or lactate, the patient with the missing PAB measurement
would still contribute to the estimates for CNL, INL, and DAB.
This also avoids bias due to including only patients who were well enough to
complete the five time points. With this method the effect of tissue type and time
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after stroke on NAA and lactate concentration could be tested, and also whether the
change over time varied between tissue types, while allowing for the differences in
NAA and lactate between patients. Lactate values were log-transformed to better fit
the linear mixed model.
The levels of choline and creatine were measured in the abnormal tissue (part of
grid analysis (see chapter 3), longitudinally at 5 fixed time points up to 3 months
after onset. For this analysis more simplified classification was used categorising
tissue as normal and abnormal (for details, see chapter 3). Average values of choline
and creatine concentrations were calculated for each tissue type in each patient at
each time point (Figure2). A general linear model repeated measures regression
analysis was used to compare changes over time in the concentrations of choline
and creatine in normal and abnormal tissue. General linear model analyses were
performed in SPSS 14.
5.3 Results
5.3.1 Patient characteristics
For this analysis, all 51 patients were included, of mean (±SD) age 75 ±15 years
(range 37-95), and mean NIHSS 11 ±8 (range 1-29) (for full demographic detail see
Table 1). Of these 51, 21 had a total anterior circulation stroke syndrome and 30 had
a partial anterior circulation stroke syndrome. Seventeen patients were first imaged
within 6 hours after stroke (33%), 15 at 6-12 hours (30%), and 19 at 12-24 hours
(37%), giving mean (+/-SD) scanning times of 11 + 7 hours for the first, and 5 ±1, 12
±2, 31 ±2, and 95 ±6 days for each of the subsequent scans. Follow-up scanning was
not possible in all cases; some patients died or were too ill, while others declined
further scanning. From the 51 initial patients, 26 (51%) were scanned up to 1 month
and 23 (45%) at 3 months. For a full number of scans at each time point please see
Table 1 Chapter 3.
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Table 1. Demographic characteristic of the study population (total 51 patients)
Sex of the patients
















5.3.2 Results -Temporal evolution of NAA and lactate
In definitely and possibly abnormal and ipsilateral normal voxels, NAA
concentration fell over the first two weeks with some increase thereafter, but still
remained lower than baseline at three months (Figure 1A). The nadir appeared at
about 12 days. For individual tissue classes, both the plot of mean NAA and the
linear mixed model showed that NAA concentration was significantly reduced at all
time points for definitely and possibly abnormal voxels versus normal brain (p
<0.01) (Table 2). Assessment of infarct extent and swelling was possible in 34
patients who had follow up scans, of which 47% presented with swelling in the
admission scan. Swelling increased by one or more points in most of these patients
at five days (for methods see chapter 3); however, in most (94%) cases the increase
was of two points or less in the seven-point swelling scale. Therefore, the changes in
swelling were small and cannot explain the altered NAA signal of definitely and
possibly abnormal voxels. NAA was not significantly reduced in ipsilateral normal
voxels when considering all time points, but its temporal evolution was different
from that of contralateral normal voxels, with ipsilateral normal being reduced at
two weeks and at three months (p=0.01 in both cases), possibly due to infarct
growth into tissue which was normal initially. The NAA concentration time curve
for possibly abnormal voxels differed from that of definitely abnormal, with
possibly abnormal being higher (p= 0.02). NAA did not change significantly in
contralateral normal voxels at any time.
Lactate levels were initially elevated in both definitely and possibly abnormal
voxels, falling sharply thereafter (Figure IB). Although lactate appeared to
normalize at two weeks, some lactate was still present at one and three months in
both definitely and possibly abnormal voxels (Figure IB). The linear mixed model
showed elevated lactate in definitely and possibly abnormal and ipsilateral normal
voxels, with p < 0.01 for both definitely and possibly abnormal and p = 0.02 for
ipsilateral normal voxels (Table 2). There were no differences between definitely
and possibly abnormal voxels (p= 0.35). Some lactate was detected at low levels in
contralateral normal tissue at all time points, but these did not change over time.
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Table 2. Results from the linear mixed model analysis of the time-concentration curves ofN-
acetylaspartate (NAA) and lactate in each tissue class
95%CI
Difference
Tissue estimate t Value P Lower Upper
NAA
DAB vs CNL -38.2 -5.0 <0.01 -53.4 -23.0
PAB vs CNL -22.5 -3.0 <0.01 -37.4 -7.6
INL vs CNL -11.0 -1.5 0.13 -25.4 4.4
PAB vs DAB 15.4 2.4 0.02 2.6 28.2
Log (lactate)
DAB vs CNL 1.7 11.6 <0.01 1.4 1.9
PAB vs CNL 1.3 9.6 <0.01 1.1 1.6
INL vs CNL 0.3 2.5 0.02 0.1 0.6
PAB vs DAB -0.1 -0.9 0.35 -0.3 0.1
NAA and lactate are in institutional units. DAB = definitely abnormal; CNL = contralateral
normal; PAB = probably abnormal; INL = ipsilateral normal
Figure 1. Temporal evolution of mean N-acetylaspartate (NAA) (A) and lactate (B)
concentrations for all patients in standardized institutional units as a function of time
foreach tissue class. The error bars indicate standard errors.
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5.3.3 Results - Choline and creatine
Data from 51 patients was used for this analysis (see patients characteristics in the
above section); Figure 2 shows the change with time of mean choline (2A) and
creatine (2B) concentrations in abnormal and normal tissue regions for all patients at
all time points. The general linear model regression analysis did not show any
overall difference in the temporal evolution of choline concentration between
abnormal and normal tissue over the three months of study, possibly due to
sigmoid shape of the recovery curve of abnormal voxels values after two weeks
(Table 3; Figure 2A). A further analysis including only data from the first three scans
showed that the concentration of choline in abnormal tissue was in fact significantly
lower than normal over the first two weeks after stroke (general linear model
regression P=0.034). The general linear model regression analysis showed that
creatine concentration was significantly reduced in abnormal tissue after the first
scan up to 3 months after stroke (P=0.011)(Table 3)
Figure 2. Temporal evolution of mean (A) choline and (B) creatine concentrations in
institutional units. The error bars indicate SD. Note: graphs include data from all patients
imaged at each time point.
Days Days
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Table 3. Summary of Tests ofBetzoeen-Subject Effects for General Linear Model
Repeated Measurements Analysis ofCholine and Creatine Time Evolution*
Test Source
Type III Sum
of Squares df F P
Choline over 3 months Intercept 10 901 109.4 1 994.8 <0.001
Tissue type 1026.4 1 0.937 0.341
Error 30 682.1 28
Choline over 2 weeks Intercept 1 041 281.7 1 1900.5 <0.001
Tissue type 2586.3 1 4.720 0.034
Error 29 038.6 53
Creatine over 3 months Intercept 971 633.0 1 732.8 <0.001
Tissue type 9704.2 1 7.319 0.011
Error 41 103.6 31
5.4 Discussion
This analysis of longitudinal data of NAA and lactate in acute ischemic stroke
provides robust data on the time course of neuronal loss and tissue damage. This
data shows that permanent neuronal loss (NAA reduction) is accumulated over the
first 12 days. This confirms NAA reductions found in smaller studies (Federico et
al.,1998; Ford et al.,1992; Gideon et al.,1994; Graham et al.,1992; Lanfermann et
al.,1995; Parsons et al.,2000; Saunders et al.,1995; Wardlaw et al., 1998) but, by
including all patients, provides much more reliable time-course data. The very
slight rebound in NAA values for definitely, possibly abnormal, and ipsilateral
normal voxels at 12 days suggests that the neuronal damage was, on average,
maximal at this time. As neurons are not considered to regenerate (Monsein et al.,
1993), this minor rebound could be caused by resolving tissue oedema within the
lesion and partial volume averaging with normal brain at the edge of the lesion as
any mass effect receded. Neuronal damage is considered to occur within the first
few hours of stroke. The further decreases in NAA up to 12 days could be caused by
increased tissue oedema or changes in metabolite relaxation times (Walker et
al.,2004). However, a previous study (Saunders et al.,1995), which corrected for
changes in water concentration within the infarct and relaxation times, observed
similar NAA changes. Furthermore, in this analysis of longitudinal data an oedema
rating scale suggested that increase in oedema at 5 days was minimal in most
patients; since infarct mass effect from oedema is maximal at 5-7 days and declines
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thereafter (Wardlaw et al., 1993), usually being substantially resolved by 10-14 days,
dilution effects of oedema cannot wholly account for the subacute NAA changes.
Therefore, the progressive fall in NAA to 12 days cannot only be attributed to
changes in metabolite relaxation times or tissue swelling, and it is best accounted for
by accumulating neuronal damage.
This interpretation is supported by the return of lactate to normal levels at this time.
Hence, the evolution observed for both metabolites suggests that permanent
damage continues to accumulate until about 12 days. The initial reduction of NAA
concentration in ipsilateral normal tissue could be accounted for by partial volume
effects in voxels coded normal but just at the edge of the stroke lesion, thus possibly
including some abnormal tissue. The later fall in NAA in ipsilateral normal at
subacute times is probably due to infarct growth with "recruitment" of normal
voxels into the stroke lesion since in 14% of subjects the lesion grew beyond the
initial ischemic area according to the rating scale (Wardlaw and Sellar 1994). The
lactate in ipsilateral normal tissue may be due to ischemia beyond the edges of the
DWI-visible lesion, e.g., within areas of reduced perfusion, or to partial volume
averaging at the edge of the lesion. Lactate rose at 1 and 3 months in both definitely
and possibly abnormal voxels. This recurrent lactate elevation after 2 weeks has
been noted previously (Federico et al.,1998; Ford et al.,1992; Gideon et al.,1994;
Graham et al.,1992; Sappey-Marinier et al.,1992) and attributed to tissue infiltration
by inflammatory cells with a high rate of anaerobic glycolysis, such as macrophages.
Histologically, these begin to appear three days after infarction and disappear
gradually over several months (Petroff et al., 1992). However, as in previous studies,
lactate was still detected in the ischemic lesion in some patients beyond the time
that most phagocytosis of necrotic cells would be expected to be completed
(Federico et al.,1998; Gideon et al.,1994; Graham et al.,1992) suggesting that the
processes involved in resolution of tissue damage may continue for much longer
than current knowledge suggests.
The lactate in contralateral normal tissue was not anticipated as lactate is generally
associated with the presence of pathology. However, lactate appears to be intrinsic
to healthy aging, as has been detected in 10% of apparently normal men aged 60 and
25% aged 90 (Sijens et al., 2001)(Chapter 4). The average age in our patients (75+/-
15) could therefore explain the low lactate concentration found in contralateral
apparently normal tissue.
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It is interesting that although reduced, NAA was still clearly detectable in even the
most abnormal appearing tissue on DWI where the most damage would be
expected, suggesting that in some patients a substantial proportion of neurons were
still viable in the core of the stroke lesion even at 12 days. NAA concentration
mirrored the "brightness" of the lesion on DWI as NAA was lower in definitely (the
whitest) than in possibly abnormal voxels. This suggests that the diffusion lesion
appearance reflects the severity of the underlying neuronal damage. The substantial
reductions in NAA secondary to ischemia seen in this and other stroke studies are a
reasonably reliable indicator of loss of viable neurons. Although animal models
have suggested that low levels of NAA (<20%) could be attributable to NAA
trapped in cell debris (Sager et al., 2000), evidence to date indicates that the majority
of NAA signal is lost at the point of neuronal death (Monsein et al.,1993). Minor
reductions in NAA which later recovered (thereby suggesting that the neuronal
damage was only transient) have been observed in animal models of HIV infection
(Greco et al., 2004) and multiple sclerosis (MS) plaques (Tsai and Coyle 1995), in
both cases probably attributable to tissue fluid changes secondary to inflammation.
NAA reduction in MS plaques may also be permanent (Tsai and Coylel995) and
correlated with gliosis, consistent with it being a marker of permanent neuronal
loss. One small study with monkeys infected with simian immunodeficiency virus
suggested that minor (7.7%) reductions in NAA might be attributable to non-
permanent neuronal damage (Lentz et al., 2005), but longer studies would be
needed to determine what proportion, if any, of NAA reduction could be accepted
as transient and what proportion permanent neuronal loss.
Early studies reported no significant changes in choline concentrations in the
ischemic lesion (Fenstermacher and Narayana 1990), which prompted the use of
choline as a denominator to assess changes in other metabolites in stroke (Parsons et
al.,2000). However, other studies found either an increase (Graham et al.,1992;
Sappey-Marinier et al.,1992) or a decrease in choline levels (Duijn et al., 1992;
Lanfermann et al.,1995) in stroke lesions. Discrepancies might be related to
individual variability, the small sample sizes of 10 patients or less in some studies
(Duijn et al.,1992; Sappey-Marinier et al.,1992), or to the use of different patients
scanned at different time points rather than the same patients scanned at similar
times (Lanfermann et al.,1995). The current study is the largest to date following the
same group of patients with stroke longitudinally using proton MR spectroscopic
imaging at fixed time points to reduce this variability. The choline levels were
significantly reduced in stroke compared with healthy tissue during the first two
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weeks. Thus, using choline measured within the lesion as a denominator for
metabolic ratios would overestimate other metabolites' concentrations. This would
introduce ambiguity to the conclusions drawn from MR spectroscopic studies of
acute stroke using these ratios, because reported values would be subjected to
changes in two metabolites instead of one. For example, it was previously reported
that the ratio of lactate/choline in acute stroke is a better predictor of clinical
outcome than the ratio NAA/ choline (Parsons et al.,2000). This could result from
the decrease of choline in the lesion, which makes the NAA/choline ratio less
sensitive to reductions in NAA, whereas it enhances the increase of lactate in
lactate/choline ratios. Creatine has been used less often than choline to calculate
metabolite ratios in stroke. In events such as ischemia, creatine cannot be used as an
internal reference because its concentration varies with the anaerobic tissue
conditions and, as in the current study, other authors have consistently found a
general decrease in the concentration of creatine in the ischemic lesion (Duijn et
al.,1992; Lanfermann et al.,1995). Although metabolite ratios are still used because of
the simplicity of their calculation, methods for quantifying individual metabolites
are now well established. In vivo measurement of metabolite concentrations can be
achieved, for example, by calibrating the measured spectral resonance area with the
known concentration of a reference solution and using the appropriate corrections
for volume normalization, coil loading, and differential T2 attenuation (Michaelis et
al., 1993). Future MR spectroscopic studies of ischemic stroke should be aware of
temporal changes in choline and creatine within the lesion, particularly choline. If
ratios of other metabolites to choline or creatine are to be used during the analysis,
the potential ambiguity introduced into the ratios by the variation of these
metabolites should be carefully considered.
The strengths of the study
As discussed in Chapter 4 with the first time point analysis, this study has a large
sample size for a complex imaging study. The spectroscopy data were acquired
using multi-voxel rather than single voxel technique. The patients were scanned at
five standard time points, whereas previous studies of ischemic stroke used data
from different patients at different times or the same patients but at variable times.
All patient data was included and not just those scanned at all times, by using a
mixed modelling approach. Extreme care was taken to match the position of voxels
on all scans and as discussed earlier I was very careful to exclude all CSF
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contaminated voxels as well as ones at the edge of the lesion. The concentrations
were expressed as standardized metabolite values (discussed in methods chapter),
in the individually examined tissues determined according to the DWI appearance
(the implication of using thresholds is discussed in the previous chapter). Previous
studies were unable to provide information on metabolite changes in abnormal and
normal tissue simultaneously and frequently reported changes in NAA and lactate
as ratios to choline or creatine, assuming that these do not change. The changes in
the choline and creatine levels are discussed below.
The weaknesses of the study
I was unable to image all patients at all times, since some died, were too unwell, or
refused further scanning. Also, regional tissue distortion on follow-up scans due to
changes in mass effect of the infarct could not be adjusted for. Finally, partial
volume averaging will be present since spectroscopy voxels were 1 cm3, so some
inclusion of two tissue classes in some voxels is inevitable, particularly at the edge
of the lesion. However, I did account for partial volume averaging by adjusting the
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Chapter 6: Relationship of metabolites, diffusion and
perfusion parameters with outcome
In the previous two chapters, I explored correlations between diffusion and
perfusion parameters and metabolites at various time points from stroke onset and
how it helps us in assessing viable brain tissue. In this chapter I will explore the
correlation of metabolites, diffusion and perfusion parameters with clinical outcome
as measured by the modified Rankin scale (Chapter 3).
6.1 Introduction
Predicting a patient's outcome more accurately when they first present, and using
that information to guide the treatment would be of great clinical benefit. The
factors that influence the outcome are numerous. Severity of stroke on presentation
is well known to predict outcome; the more severe the stroke at onset, the worse the
clinical outcome (Derex et al., 2004 ;Wardlaw et al., 1998). However, some of the
patients with severe stroke still make a good recovery, and identifying them early
would help to improve selection of patients for potentially dangerous treatments.
In recent years, numerous studies have looked at perfusion (PWI) and diffusion
imaging (DWI) in acute stroke, and diffusion perfusion mismatch as a way of
identifying early on, which patients would potentially benefit from treatment. The
diffusion perfusion concept has been discussed in the introduction (Chapter 1.2.4).
Numerous studies investigated diffusion perfusion mismatch, but only a few
reported the functional outcome of the patients (Kane et al., 2007b). The randomised
trial which measured mismatch in thrombolysed and non thrombolysed patients
did not show attenuation of infarct growth, but more importantly did not show a
better clinical outcome in the thrombolysis group, than in the placebo group (Davis
et al., 2008).
In the literature review on spectroscopy in stroke (Chapter 2) I found thirteen
studies that investigated the relationship of metabolites to the stroke outcome. None
of the studies measured metabolites within 24 hours. There was no consensus
among the studies, although, half of the studies found that NAA correlated with
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outcome, and only a quarter found that lactate correlated with the outcome. Two
studies found that neither of the metabolites correlated with the outcome.
In the analysis of the patients from this study, I investigated the correlation between
the initial level of metabolites and diffusion and perfusion parameters, first in the
region of interest (ROI) and then using CSI grid analysis. I also investigated
diffusion perfusion mismatch lesion, and the correlation of the parameters within
the mismatch with an outcome.
6.2 Methods
Detailed description of methods can be found in Chapter 3.
6.2.1 Statistical analysis
All statistical tests were performed in SPSS 14.0 for Windows (SPSS Inc, Chicago, 111,
USA) for both ROI, grid, and mismatch analysis. The imaging data were not
normally distributed (Kolmogorov-Smirnov test, p>0.01), so the Spearman Rank
Correlation coefficient (p) was used to examine the correlation between the severity
(NIHSS), metabolites, diffusion and perfusion parameters and the outcome
measure, setting significance at the 0.05 level (2-tailed). I used linear regression
analysis in both the ROI and grid analysis to find out if either the metabolites or
DWI and PWI parameters would fit the model predicting the outcome, as measured
by modified Rankin scale. I limited the model to a maximum of 5 variables to
minimise false positive results.
6.3 Results
6.3.1 Patient characteristics
The age range of the 43 patients that were used for this analysis was (median + /- SD
and range) 76 +/-11 (37-95). All patients were scanned within 24 hours 8+/-6.6 (1.5-
24) of which, 14 (32%) patients were scanned within six hours, 14 (32%) between six
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and 12 hours, and 15 (36%) patients between 12 and 24 hours after stroke. 22/43
patients (51%) had a DWI/PWI mismatch on the MTT perfusion parameter. None of
the patients received thrombolysis or investigational treatment, and none had
carotid stenosis of more than 50%. These were mostly moderately severe strokes
with NIHSS of 9+/-7.8 (1-29), and according to OCSP classification 19 (44%) were
TACS and 24 (56%) PACS. In the "perfusion diffusion mismatch" group 15/22
(68%) patients were TACS whilst in "no mismatch group" 4/21 (19%) were TACS.
6.3.2 Region of interest (ROI) analysis and outcome
Metabolites, stroke severity, lesion volume, time from stroke, and 3 month
functional outcome
There was no association between any of the metabolites and the NIHSS score.
Larger DWI lesion volume was associated with reduced NAA (Spearman's p= -0.42,
p=0.006) and increased lactate (Spearman's p= 0.49, p=0.001) but not with choline or
creatine. Longer times to scanning were associated with lower NAA (Spearman's p=
-0.33, p=0.03) and larger lesion volumes (Spearman's p= 0.35, p=0.023) but not with
lactate, choline, creatine or ADC. There was no correlation between the metabolites,
ADC, MTT or CBF and three month Rankin score. However, the clinical parameter
of NIHSS (measured at baseline) was associated with the three month Rankin score
(Spearman's p= 0.665, p=0.0001), in keeping with the known strong association
between stroke severity and functional outcome.
Linear regression analysis
I used linear regression analysis (Tables 1 and 2) to test whether metabolites, or
diffusion and perfusion parameters predict functional outcome. In the model with
metabolite values and the volume as variables (Tablel), both volume of the lesion
(p= 0.027), and lactate (p= 0.029) were statistically significant. In the model with
lesion volume, and diffusion and perfusion parameters (Table 2), no parameters
reached statistical significance.
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Table 1. Linear regression analysis with metabolites and lesion volume as independent




Model B Std. Error Beta t Sig.
1 (Constant) 3.183 1.356 2.347 .025
Volume 1.88E-005 .000 .398 2.305 .027
Choline .015 .021 .153 .731 .470
Creatine .008 .026 .077 .328 .745
NAA -.009 .015 -.151 -.639 .527
Lactate -.031 .014 -.372 -2.272 .029
a Dependent Variable: modrank
Table 2. Linear regression analysis with diffusion perfusion parameters and lesion volume as





Model B Std. Error Beta t Sig.
1 (Constant) 8.848 3.170 2.792 .008
CBFi -2.592 1.377 -.353 -1.882 .068
MTTi -.844 .887 -.179 -.952 .347
volume 7.49E-006 .000 .159 .985 .331
ADC -3.498 2.818 -.205 -1.241 .222
a Dependent Variable: modrank
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6.3.3 Grid analysis and outcome
Correlations of metabolites, diffusion and perfusion parameters from the
abnormal tissue, and NIHSS with outcome
None of the metabolites correlated with the outcome as measured by the Rankin
scale. MTT correlated significantly with the Rankin scale (Spearman p= 0.6,
p<0.0001), but not CBF, CBV, or ADC. NIHSS was also significantly correlated with
the outcome (p= 0.7, p<0.0001) (Table 3). Both, the MTT and NIHSS were
significantly correlated with the outcome when measured in "definitely abnormal"
and "possibly abnormal" tissue.
Correlations of metabolites, diffusion and perfusion parameters from the
mismatch tissue, and NIHSS with outcome
The PWI parameters from the mismatch tissue (for the definitions of tissue types see
Chapter 3) did not correlate with the outcome, but ADC (Spearman p= 0.4, p=0.046)
was significantly correlated with mRS but not negatively as expected. NAA also
correlated with the outcome (Spearman p= -0.4, p=0.04), whilst NIHSS was strongly
correlated (Spearman p= 0.6, p=0.0006) (Table 3).
Tnble 3. Correlation (Spearman p) between metabolites, ADC and PWI values, and NIHSS
with outcome (modified Rankin scale) in the grid analysis.
Abnormal tissue Mismatch tissue
Spearman p
ADC p =0.219 p=0.158 p =0.429 p=0.046
CBF p =-0.274 p=0.075 p =-0.172 p=0.445
CBV p =0.295 p= 0.055 p =0.319 p=0.148
MTT p =0.596 p= 0.0001 p =0.411 p=0.058
Choline p =0.110 p= 0.482 p =-0.076 p=0.738
Creatine p =-0.113 p = 0.470 p =0.-280 p=0.207
NAA p =-0.108 p = 0.489 p =-0.442 p=0.039
Lactate p =0.023 p= 0.885 p =-0.192 p=0.393
NIHSS p =0.709 p= 0.0001 p =0.569 p=0.006
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Linear regression analysis
In the linear regression analysis model with the DWI, PWI parameters (abnormal
tissue) and NIHSS as independent variables, and modified Rankin at three months
as a dependent variable, it was only NIHSS that reached statistical significance
(p=0.0001)(Table 4). In the model with the metabolites as independent variables
(abnormal tissue), none of them reached statistical significance (Table 5).
Table 4. Linear regression analysis DWI, PWI parameters from the abnormal tissue, and
NIHSS as independent variables, and modified Rankin score at 3 months as dependent




Model B Std. Error Beta t Sig.
1 (Constant) 1.400 1.765 .793 .433
ADC .000 .001 .013 .116 .908
CBFI -.001 .001 -.306 -1.180 .246
CBVI .001 .001 .343 1.030 .310
MTTI .000 .001 -.038 -.121 .904
nihss .162 .036 .607 4.537 .000
a Dependent Variable: modrank
Table 5. Linear regression analysis with metabolites from the abnormal tissue as independent




Model B Std. Error Beta t Sig.
1 (Constant) 3.542 1.768 2.003 .052
Cho .035 .021 .303 1.651 .107
Cr -.017 .019 -.168 -.918 .365
NAA -.014 .014 -.204 -1.001 .323
Lact -.003 .011 -.053 -.316 .753
a Dependent Variable: modrank
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6.4 Discussion
The results of this analysis show that MTT and NIHSS are correlated with outcome
as measured by the modified Rankin scale (mRS). The metabolites had no
correlation with the outcome, except for the correlation of NAA from mismatch
tissue and mRS. MTT from the abnormal looking tissue on DWI is correlated with
the mRS, but is less significant when taken from the diffusion perfusion mismatch
area (Spearman p= 0.4, p=0.058), with the trend in the right direction. This confirms
the observation from previous studies that MTT in the acute stage is correlated
with functional outcome (Beaulieu et ah, 1999; Kane et ah, 2007a; Parsons et ah, 2002).
The MTT lesion area tends to be large and overestimates the lesion size in
comparison with other perfusion parameters such as CBF (Parsons et al.,2002;
Rivers et al., 2006; Sorensen et ah, 1999). Therefore, MTT values from the mismatch
region would also include a considerable proportion of the oligaemic, but not "at
risk" tissue.
NIHSS was strongly correlated with the outcome, whether measured in patients
with mismatch or just with the abnormal looking tissue. This is consistent with
previous studies where the initial clinical severity was an independent predictor of
the outcome (Derex et al.,2004; Lemesle et ah, 2000; Pereira et ah, 1999; Rother et ah,
2002; Wardlaw et al.,1998). ADC from the mismatch tissue positively correlated with
the mRS which is not an expected correlation. When analysed across the whole
lesion (chapter 4), ADC did not significantly differ between mismatch and normal
tissue. The stroke cohort in this study was elderly and age may be an independent
factor in conversion of ischaemic tissue in to infarction (Ay et ah, 2005). In addition
older patients may have higher number of white matter lesions and increased ADC
values (Bugalho et al 2007, Shenkin et al 2005), all of which may contribute toward
the correlation between ADC and the outcome. However, this has not been
specifically looked at in our or any other studies, and the numbers in this mismatch
analysis (23 patients) are rather small and therefore the result should be interpreted
with caution.
The metabolites in the diffusion lesion did not show any correlation with the
outcome, either independently or as a part of the linear model. This is in agreement
with 2 previous studies that measured metabolites in the stroke lesion within the
first four days from stroke onset (Gideon et ah, 1994; Wardlaw et al.,1998). Studies
which found NAA to be a good predictor of the outcome recruited patients either
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subacutely (within the first week of stroke), or more chronic, from one to several
months (Federico et al., 1996; Federico et al., 1998; Ford et al., 1992; Lemesle et
al.,2000; Pendlebury et al., 1999; Pereira et al.,1999). Studies which found lactate to
be predictive of outcome also did not recruit patients within 24 hours, but up to 22
days (Graham et al., 1995; Parsons et al., 2000).
Reduction in NAA and persistence of increased lactate beyond 24 hours may be
better predictors of outcome than when measured acutely. In the acute stage (within
24 hours) NAA levels have possibly not fallen far enough, as it takes around 10 - 15
days for NAA to reach a nadir (also demonstrated in this data, see previous
chapter)(Saunders et al., 1995). Lactate, although a marker of acute ischaemia does
not seem to predict tissue fate at this acute stage. NAA, when measured in
mismatch tissue, only just reached statistical significance. This would have to be
confirmed in the larger sample as this is based only on the data from the 23 patients
who had mismatch present.
The strength and weaknesses of the study have been discussed extensively in
chapters 4 and 5.
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Conclusion
Implications for clinical practice
Magnetic resonance imaging is increasingly used in every day practice in the
assessment of stroke but spectroscopy remains largely a research tool. Despite the
improvement in the acquisition time, the processing of the data is still very lengthy
and one that could not be used in every day clinical practice. The development of
new software that would allow processing of the data immediately, preferably on
the MRI console, could change how MR spectroscopy (MRS) is utilised in the future.
However, MRS is a unique tool for assessing metabolites in vivo, and in this study
we confirmed that N Acetyl aspartate (NAA) represents cumulative permanent
neuronal damage whilst lactate is a marker of presence of ischaemia together with
perfusion (PWI) and diffusion (DWI) parameters.
What does this mean for acute stroke diagnosis? By correlating DWI with NAA and
lactate across the ischaemic lesion (the tissue that looks definitely abnormal,
possibly abnormal, and surrounding normal tissue) we could show that the acute
ischaemic lesion appearance on DWI (the "whiteness"), but not the ADC value,
corresponds with the degree of neuronal damage. This is an important finding, as
visual inspection of the lesion is the fastest way of assessment (in comparison to
measuring thresholds) and potentially could be very important as speed is crucial
when assessing eligibility for the acute stroke treatment.
On the other hand, for the patients that do not present early enough to be
considered for acute stroke treatment, there is evidence from the metabolite
measurement that NAA levels reduce gradually, reaching its lowest point around 12
days. Studies of diffusion and perfusion imaging and with PET imaging have also
found existence of potentially salvageable tissue up to 48 hours following stroke.
Furthermore, studies with serial diffusion and perfusion imaging have shown that
features of tissue damage, consistent with microvascular blockage and tissue
swelling, continue to be present in some patients for weeks after the stroke. No
treatments, including neuroprotective agents, are available at present at this late
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stage in stroke but these imaging studies show that there is a potentially salvageable
tissue beyond conventional time limit of four and half hours, and that other
processes may continue to increase tissue damage for days to weeks after stroke that
could be amenable to treatment, once the underlying mechanisms are better
understood. The focus on the hyperacute phase has deflected attention away from
these later stages which might offer additional opportunities to limit the ultimate
tissue damage and so improve the chances of recovery.
Previous studies have frequently used choline and creatine as denominators to
express the concentration of NAA or lactate. The ratios are still used for simplicity
of their calculation, but methods for quantifying individual metabolites are now
well established. We showed that choline is significantly reduced in the first two
weeks after stroke onset and creatine levels remained significantly low during
whole of the three months of the study period. When the ratio of NAA or lactate to
choline and /or creatine is used to express the metabolite concentration, the
potential large ambiguity introduced in to the metabolite quantification should be
carefully considered when interpreting the results. Ratios should be avoided
wherever possible.
Implications for research
I would hope that there is a place for MRS to be used in the future clinical research,
especially when trying to establish the metabolic state of the infarcted tissue and
correlates of the metabolites with other imaging parameters that would help predict
the fate of the tissue and, potentially, the clinical outcome. Sequences are now faster
and image processing (though not to the refined degree used in this thesis) is
available on scanner consoles, making spectroscopy a more accessible tool.
I would encourage studies with larger sample sizes, that include patients without as
well as with mismatch, that aim to collect data in such a way that they could be
combined into large individual patient data meta analyses in future. It would be
important that studies use carefully co registered multisequence image data so as to
ensure that the tissue being studied is geographically the same, and to avoid using
thresholds to define tissue based on imaging parameters like ADC or perfusion
values because they are too variable and probably don't work!!! Also spectroscopy
could be valuable tool to study the effects of thrombolysis on changes in metabolite
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levels especially whether NAA might actually recover and with the advancement of
the spectroscopy techniques in future studies could try to include more slices
through the lesion which would give better metabolic reflection of what is going on
within the lesion. Also, the elderly population represents the majority of the stroke
population but is underrepresented in the studies, especially the very elderly.
Metabolites during normal ageing processes have not been studied to any detail. It
would be important to know if lactate in the normal ageing brain is a feature of the




Appendix 1a: Medline search strategy
MEDLINE spectroscopy
1. Cerebrovascular disorders/
2. exp Brain ischemia/
3. Carotid artery diseases/ or Carotid artery thrombosis/
4. stroke/
5. exp brain infarction/
6. Cerebral arterial diseases/ or Intracranial arterial diseases/
7. exp "Intracranial embolism and thrombosis"/
8. (stroke$ or apoplex$ or cerebral vasc$ or cerebrovasc$ or cva or transient isch?emic
attack$ or tia$).tw.
9. (brain or cerebr$ or cerebellS or vertebrobasil$ or hemispher$ or intracran$ or
intracerebral or infratentorial or supratentorial or middle cerebr$ or mca$ or anterior
circulation).tw.
10. (isch?emi$ or infarcts or thromboS or emboli$ or occlusS or hypoxi$).tw.
11. 9 and 10
12.1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 11
13. spectrum analysis/ or exp magnetic resonance spectroscopy/
14. (magnetic resonance adj5 spectroscopy).tw.
15. (mrs or h mrs or h-mrs or mr spectroscopy).tw.
16. ((chemical shift adjlO imaging) or csi).tw.
17. (n-acetylaspartate or NAA or aspartic acid).tw.
18. aspartic acid/
19. 13 or 14 or 15 or 16 or 17 or 18
20. 12 and 19
21. limit 20 to humans





4. exp carotid artery disease/
5. brain infarction/ or brain stem infarction/ or cerebellum infarction/
6. brain ischemia/ or transient ischemic attack/
7. exp occlusive cerebrovascular disease/
8. (stroke$ or apoplexS or cerebral vasc$ or cerebrovascS or cva or transient isch?emic
attacks or tia$).tw.
9. (brain or cerebr$ or cerebell$ or vertebrobasil$ or hemispher$ or intracran$ or
intracerebral or infratentorial or supratentorial or middle cerebr$ or mca$ or anterior
circulation).tw.
10. (isch?emi$ or infarcts or thromboS or emboli$ or occlusS or hypoxi$).tw.
11. 9 and 10
12. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 11
13. spectroscopy/ or nuclear magnetic resonance spectroscopy/
14. (magnetic resonance adj5 spectroscopy).tw.
15. (mrs or h mrs or h-mrs or mr spectroscopy).tw.
16. proton nuclear magnetic resonance/
17. ((chemical shift adjlO imag$) or csi).tw.
18. n acetylaspartic acid / or aspartic acid/
19. (n-acetylaspartate or NAA or aspartic acid).tw.
20. or/13-19
21. 12 and 20
22. limit 21 to human
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Main purpose of the study: (To predict outcome, development new technique, comparative)
QUALITY RATING:
1 Prospective □_
2 Blinded to image analysis □_
3 Blinded to final outcome
4 Systematic follow-up □_
5 Stroke physician/neurologist initial assessment □
6 Validated spectroscopy technique □_




Total No of Subjects:
No actually included in the analysis:
Reason for the exclusion from the analysis:
Age Range:




Did patient receive any acute experimental treatment?:




Who made the diagnosis: (stroke physician, neurologist, duty medical doctor, A&E doctor,
GP or not stated)
Indication of stroke severity/subtype:
Were any outcome data collected and what time after the stroke: (was there a systematic





Data Acquisition & Processing Method:




If not quantified, method of data reporting (ratio to Cr, etc):
Data interpretation:
Was a reader blinded to clinical details?
Was a reader blinded to other imaging?
Was a reader blinded to clinical outcome?
Comparison to DWI/PI or any other imaging:
Overall conclusion of the study:
Additional comments on paper quality or result:
Appendix 3
THE MAGNETIC RESONANCE IMAGING AND
ULTRASOUND IN ACUTE STROKE
Sample letter to patient's general practitioner about the study
Dear Dr ,
Re: (patient's name, dob, address)
Your patient, Mr X, has agreed to participate in the study of imaging in acute stroke,
"Magnetic Resonance Imaging and Ultrasound in Acute Stroke". MrX had a MRI
scan and Carotid Doppler scan which has been used as part of his management and
the results will be enclosed in his discharge summary. Mr X will be invited for further
scan at one and three months after his initial stroke.
If you require any further information please do not hesitate to contact us.
Yours sincerely
Dr Vera Cvoro Dr Joanna Wardlaw
Clinical Research Fellow Professor of Neuroradiology and
Honorary Consultant Neuroradiologist
Tel 0131 537 1000 bleep 5699 Tel 0131 537 2943
MAGNETIC RESONANCE IMAGING AND ULTRASOUND
STUDIES IN ACUTE STROKE
PATIENT'S CONSENT FORM
T
he Magnetic Resonance and Ultrasound Imaging Studies in Acute
Stroke has been explained to me and I have read the information leaflet
about it. I have had time to consider the study and have had all my
questions about it answered.
I understand that I am free to withdraw at any time from any part of the
study, without giving a reason, and without it adversely affecting my future
medical care.







(signature of the investigator)
(name of the investigator)
MAGNETIC RESONANCE IMAGING AND ULTRASOUND
STUDIES IN ACUTE STROKE
RELATIVE'S ASSENT FORM
On behalf of my relative, (patient's name),
the Magnetic Resonance Imaging and Ultrasound Studies in Acute Stroke
has been explained to me and I have read the information leaflet about it.
I have had time to consider the study and have had all my questions
about it answered.
I understand that my relative is free to withdraw at any time from any part
of the study, without giving a reason, and without it adversely affecting their
future medical care.
I give my assent for their participation in the study and magnetic resonance







(signature of the investigator)




THE MAGNETIC RESONANCE IMAGING AND
ULTRASOUND IN ACUTE STROKE
You have been admitted to the Western General Hospital because you may have
had a stroke. We would like you to consider being a part of a study on Magnetic
Resonance Imaging (MRI) and Ultrasound scanning of the arteries in patients who
have had a stroke. It will provide valuable information about what exactly is
happening in the brain when people have a stroke and therefore help us give the
right kind of treatment.
You will first be seen by the doctor who will ask you questions about the symptoms
that brought you to hospital, then you will have full examination.
As soon as possible after the examination we will organise for you to have an MRI.
This scan uses magnetism but will not cause any harm to you. Many other hospitals
around the world use the magnetic scan routinely. We do ask you to lie still for
around 30 minutes. The machine is slightly noisy so you will have earplugs to protect
your ears. You will be able to communicate with us during the scanning. If you feel
uncomfortable or claustrophobic, the scan can be stopped at any time. If you
know you are
claustrophobic, please tell us and we will not do the MR scan.
This scan is important because it gives us much more detailed pictures of the
brain, including what sort of damage may have happened to cause your
stroke. We think that in the future, this more detailed information will help us
decide what sort of treatment is best for patients like you. In order to record
blood flow in your brain you will need a small injection into a vein in your arm
through the needle, which usually gets put in, while you are in the admission
unit. You will not require a CT (computed tomography) scan of your brain
which is a routine treatment in this hospital and gives less information.
You will also have an ultrasound scan of the blood vessels to your head. This
does not involve any injections. We simply place a small amount of jelly on
your neck and just in front of your ears and look for the blood flow with the
small camera. It lasts around 5 to 10 minutes.
In order to monitor what happens to your stroke over the next few
weeks, we would like to repeat the magnetic and ultrasound scans in
about five days, two weeks, one and three months after your stroke. At
three months time you would also have a full examination by the
doctor to assess how well have you recovered from the stroke.
You may decide to withdraw from the study at any time. This will make no difference
to the care you receive from the stroke team in the hospital and outpatients. If you
decide to take part in this study you will be asked to sign a consent form. Even when
you sign a consent form you are still free to withdraw from the study at any time
without having to give a reason and without affecting your future care.
Your GP will receive information about your involvement in the study and the results
of your scans.
Any information that you give us as well as the results of the scans will be treated as
confidential and will only be available to the doctors looking after you and research
staff involved in this project.
This study has been funded by the Stroke Association and has been approved by the
Lothian Research and Ethics Committee.
If you would like to obtain further information about the study from somebody who is
not directly involved you
could speak to Dr Zeman who can be contacted through the Western General
switchboard No 0131 537 1000.
If you have any questions about the study even after you leave the hospital,
please feel free to contact Dr Cvoro at the Western General Hospital
(switchboard no 0131 537 1000, bleep 5699).
Appendix 5: assessment scales




0 No symptoms at all
1 No significant disability despite symptoms; able to carry out
all usual duties and activities
2 Slight disability; unable to carry out all previous activities, but
able to look after own affairs without assistance
3 Moderate disability; requiring some help, but able to walk
without assistance
4 Moderately severe disability; unable to walk without
assistance and unable to attend to own bodily needs without
assistance
5 Severe disability; bedridden, incontinent, and requiring
constant nursing care and attention
6 Dead
TOTAL (0-6):








5 = independent (or in shower)
GROOMING
0 = needs to help with personal care
5 = independent face/hair/teeth/shaving (implements provided)
DRESSING
0 = dependent
5 = needs help but can do about half unaided
10 = independent (including buttons, zips, laces, etc.)
BOWELS
0 = incontinent (or needs to be given enemas)
5 = occasional accident
10 = continent
BLADDER
0 = incontinent, or catheterized and unable to manage alone




5 = needs some help, but can do something alone
10 = independent (on and off, dressing, wiping)
TRANSFERS (BED TO CHAIR AND BACK)
0 = unable, no sitting balance
5 = major help (one or two people, physical), can sit
10 = minor help (verbal or physical)
15 = independent
MOBILITY (ON LEVEL SURFACES)
0 = immobile or < 50 yards
5 = wheelchair independent, including corners, > 50 yards
10 = walks with help of one person (verbal or physical) > 50 yards
15 = independent (but may use any aid; for example, stick) > 50 yards
STAIRS
0 = unable










0 as Not ut all
1 as With help
2 » Alone with difiiculty





- walk around outside?
- climb stairs?
- get in and out of the car?
- walk over uneven ground?
- cross roads?




- manage to feed yourself?
- make yourself a hot drink?
- take hot drinks from one room to another?
-do the washing up?
- make yourself a hot snack?
TOTAL
DOMESTIC TASKS
- manage your own money when out?
- wash small items ofclothing?
- do your own shopping?
- do a full clothes wash?
TOTAL
LEISURE ACTIVITIES
- read newspapers and books?
- use the telephone?
- write letters?
- go out socially?












Alert - keenly responsive
Drowsy - arousable by minor stimulation to obey, answer, or respond
Stuporous - requires repeated stimulation to attend, or is obtunded and requires strong or painful
stimulation to make movements (not stereotyped)
























Partial gaze palsy - gaze is abnormal in one or both eyes, no forced deviation/total gaze paresis
















Minor - flattened nasolabial fold, asymmetry on smiling
Partial - total or near total paralysis of lower face









No drift - holds limb at 90 degrees for full 10 seconds
Drift - drifts down but does not hit bed
Some effort against gravity











No drift - holds limb at 90 degrees for full 10 seconds
Drift - drifts down but does not hit bed
Some effort against gravity











No drift - holds limb at 45 degrees for full 5 seconds
Drift - drifts down but does not hit bed
Some effort against gravity











No drift - holds limb at 45 degrees for full 5 seconds
Drift - drifts down but does not hit bed
Some effort against gravity








Present in 1 limb






Partial loss - patient feels pinprick is less sharp or is dull on affected side








Mild - moderate dysphasia obvious loss of fluency or comprehension, without significant limitation on ideas
expressed or form of expression. Makes conversation about provided material difficult or impossible, e.g.
examiner can identify picture or naming card from patient's response.
Severe dysphasia - all communication is through fragmentary expression; great need for inference,
questioning, and guessing by the listener who carries burden of communication. Examiner cannot identify
materials provided from patient response







Mild - moderate dysarthria - patient slurs some words, can be understood with some difficulty.
Unintelligible or worse - speech is so slurred as to be unintelligible (absence of or out ofproportion to







Partial neglect - Visual, tactile, auditory, spatial, or personal inattention or extinction to bilateral simultaneous
stimulation in one of the sensory modalities
Complete neglect - Profound hemi-inattention or hemi-inattention to more than one modality. Does not
recognise own hand or orients to only one side of space
Notes for completion of NIHSS:
Administer stroke scale items in the order listed. Record performance in each category after each subscale exam. Do
not go back and change scores. Follow directions provided for each exam technique. Scores should reflect what the
patient does, not what the clinician thinks the patient can do. The clinician should record answers while administering
the exam and work quickly. Except where indicated, the patient should not be coached (i.e., repeated requests to patient
to make a special effort).
1a. Level of Consciousness: The investigator must choose a response, even if a full evaluation is prevented by such
obstacles as an endotracheal tube, language barrier, orotracheal trauma/bandages. A 3 is scored only if the patient
makes no movement (other than reflexive posturing) in response to noxious stimulation.
1b. LOC Questions: The patient is asked the month and his/her age. The answer must be correct - there is no partial
credit for being close. Aphasic and stuporous patients who do not comprehend the questions will score 2. Patients
unable to speak because of endotracheal intubation, orotracheal trauma, severe dysarthria from any cause, language
barrier or any other problem not secondary to aphasia are given a 1. It is important that only the initial answer be graded
and that the examiner not "help" the patient with verbal or non-verbal cues.
1c. LOC Commands: The patient is asked to open and close the eyes and then to grip and release the non-paretic
hand. Substitute another one step command if the hands cannot be used. Credit is given if an unequivocal attempt is
made but not completed due to weakness. If the patient does not respond to command, the task should be
demonstrated to them (pantomime) and score the result (i.e., follows none, one or two commands). Patients with
trauma, amputation, or other physical impediments should be given suitable one-step commands. Only the first attempt
is scored.
2. Best Gaze: Only horizontal eye movements will be tested. Voluntary or reflexive (oculocephalic) eye movements
will be scored but caloric testing is not done. If the patient has a conjugate deviation of the eyes that can be overcome
by voluntary or reflexive activity, the score will be 1. If a patient has an isolated peripheral nerve paresis (CN III, IV or VI)
score a 1. Gaze is testable in all aphasic patients. Patients with ocular trauma, bandages, pre-existing blindness or
other disorder of visual acuity or fields should be tested with reflexive movements and a choice made by the investigator.
Establishing eye contact and then moving about the patient from side to side will occasionally clarify the presence of a
partial gaze palsy.
3. Visual: Visual fields (upper and lower quadrants) are tested by confrontation, using finger counting or visual threat as
appropriate. Patient must be encouraged, but if they look at the side of the moving fingers appropriately, this can be
scored as normal. If there is unilateral blindness or enucleation, visual fields in the remaining eye are scored. Score 1
only if a clear-cut asymmetry, including quadrantanopia is found. If patient is blind from any cause score 3. Double
simultaneous stimulation is performed at this point. If there is extinction patient receives a 1 and the results are used to
answer question 11
4. Facial Palsy: Ask, or use pantomime to encourage the patient to show teeth or raise eyebrows and close eyes.
Score symmetry of grimace in response to noxious stimuli in the poorly responsive or non-comprehending patient. If
facial trauma/bandages, orotracheal tube, tape or other physical barrier obscures the face, these should be removed to
the extent possible.
5-8. Motor Arm and Leg: The limb is placed in the appropriate position: extend the arms (palms down) 90 degrees (if
sitting) or 45 degrees (if supine) and the leg 30 degrees (always tested supine). Drift is scored if the arm falls before 10
seconds or the leg before 5 seconds. The aphasic patient is encouraged using urgency in the voice and pantomime but
not noxious stimulation. Each limb is tested in turn, beginning with the non-paretic arm. Only in the case of amputation
or joint fusion at the shoulder or hip may the score be "x" and the examiner must clearly write the explanation for scoring
as an "x."
9. Limb Ataxia: This item is aimed at finding evidence of a unilateral cerebellar lesion. Test with eyes open. In case of
visual defect, insure testing is done in intact visual field. The finger-nose-finger and heel-shin tests are performed on
both sides, and ataxia is scored only if present out of proportion to weakness. Ataxia is absent in the patient who cannot
understand or is paralyzed. Only in the case of amputation or joint fusion may the item be scored "9", and the examiner
must clearly write the explanation for not scoring. In case of blindness test by touching nose from extended arm
position.
10. Sensory: Sensation or grimace to pin prick when tested, or withdrawal from noxious stimulus in the obtunded or
aphasic patient. Only sensory loss attributed to stroke is scored as abnormal and the examiner should test as many
body areas [arms (not hands), legs, trunk, face] as needed to accurately check for hemisensory loss. A score of 2,
"severe or total," should only be given when a severe or total loss of sensation can be clearly demonstrated. Stuporous
and aphasic patients will therefore probably score 1 or 0. The patient with brain stem stroke who has bilateral loss of
sensation is scored 2. If the patient does not respond and is quadriplegic score 2. Patients in coma (item 1 a=3) are
arbitrarily given a 2 on this item.
11. Best Language: A great deal of information about comprehension will be obtained during the preceding sections of
the examination. The patient is asked to describe what is happening in the attached picture, to name the items on the
attached naming sheet, and to read from the attached list of sentences. Comprehension is judged from responses here
as well as to all of the commands in the preceding general neurological exam. If visual loss interferes with the tests, ask
the patient to identify objects placed in the hand, repeat, and produce speech. The intubated patient should be asked to
write. The patient in coma (question 1a=3) will arbitrarily score 3 on this item. The examiner must choose a score in the
patient with stupor or limited cooperation but a score of 3 should be used only if the patient is mute and follows no one
step commands.
12. Dysarthria: If patient is thought to be normal an adequate sample of speech must be obtained by asking patient to
read or repeat words from the attached list. If the patient has severe aphasia, the clarity of articulation of spontaneous
speech can be rated. Only if the patient is intubated or has other physical barrier to producing speech, may the item be
scored "9", and the examiner must clearly write an explanation for not scoring. Do not tell the patient why he/she is
being tested.
13. Extinction and Inattention (formerly Neglect): Sufficient information to identify neglect may be obtained during
the prior testing. If the patient has a severe visual loss preventing visual double simultaneous stimulation, and the
cutaneous stimuli are normal, the score is normal. If the patient has aphasia but does appear to attend to both sides, the
score is normal. The presence of visual spatial neglect or anosagnosia may also be taken as evidence of abnormality.
Since the abnormality is scored only if present, the item is never untestab
